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Chapter 1  
I n t r o d u c t i o n  a n d  o b j e c t i v e s  o f  
t h e  t h e s i s  
1 Introduction 
1.1 Challenges of protein drug formulation 
The chemical and physical properties of protein drugs result in unique challenges in the 
separation, purification, formulation, storage and delivery of these macromolecules, deviating 
from the difficulties typically occurring during the development of small organic molecule 
therapeutics [1, 2]. Based on the underlying mechanism, protein degradation can be separated 
into two pathways, namely chemical and physical instability [1-3]. Chemical instability describes 
any process that comprises covalent protein modification via bond formation or cleavage 
generating a new chemical entity [1, 2]. In contrast, physical instability involves changes in the 
secondary, tertiary or quaternary protein structure in the absence of covalent modifications [1, 
2]. These include denaturation, aggregation, precipitation and adsorption to surfaces, whereas 
processes such as deamidation, racemization, hydrolysis, oxidation, disulfide exchange and β-
elimination are examples of chemical instability [1-3]. Protein stabilization against both 
chemical and physical degradation can be addressed by various formulation strategies, 
including e.g. chemical modification of the protein and choice of appropriate additives, 
excipients and formulation pH [1-6]. Specifically the formulation development of high 
concentration protein injectables is frequently associated with enhanced protein aggregation 
due to increased molecular interaction and specific hurdles such as high viscosity [7, 8]. 
The susceptibility of proteins to degradation is generally lower in the dried state than in 
aqueous solution [2, 9]. The protein´s mobility is reduced, impeding protein-protein 
interactions that are especially prerequisite for aggregation [10, 11]. Besides the conventional 
application by injection after reconstitution, the development of solid protein formulations 
allows for additional routes of administration, such as inhalation, modification of the release 
profile due to embedding in matrices as well as incorporation of proteins into tissue 
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engineering scaffolds and medical devices [12]. Lyophilization represents the process of choice 
for the preparation of dry protein powders [5, 6, 13]. However, the interest towards the 
development of alternative drying methods has steadily increased in recent years because 
freeze-drying, although successful for many proteins, has certain disadvantages, such as long 
processing times, batch operation and high capital equipment costs [14-16]. Other drying 
techniques for proteins, currently being evaluated, comprise spray-drying [17, 18], spray-freeze 
drying [17], supercritical fluid drying [19-23] and vacuum drying [14, 24, 25]. Furthermore, 
particle generating techniques, such as crystallization [8, 26-28] and precipitation [29], in 
combination with subsequent drying are suitable for manufacturing of dry protein powder. 
The protein-coated microcrystals (PCMC) technology represents an alternative technique to 
stabilize the protein in the solid state and also allows for the development of nonstandard 
dosage forms, for example protein suspensions for subcutaneous application. This therapeutic 
dosage form could for instance be beneficial when high concentration protein solutions are not 
feasible due to reduced protein solubility, poor stability or high viscosity. Moreover, PCMC 
powder may be used for the development of drug delivery systems e.g. in the case of sustained 
release matrix material employed as co-precipitating excipients. 
1.2 The protein-coated microcrystals technology 
1.2.1 Definition of protein-coated microcrystals 
The protein-coated microcrystals technology represents an alternative method of protein 
stabilization in the solid state. It is based on the coprecipitation of an aqueous solution of 
protein and carrier material induced by a rapid addition of a surplus of organic water-miscible 
solvent in which the PCMC components are not or hardly soluble, e.g. isopropanol or 
isobutanol. The immediate dehydration of the protein and the carrier components, comprising 
physiological acceptable substances such as buffer species, amino acids, sugars and inorganic 
salts, results in the formation of a suspension that is concentrated and subsequently dried via 
supercritical fluid extraction with carbon dioxide. The powder harvested consists of water-
soluble particles in the lower micrometer range, typically less than 50 µm. 
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1.2.2 Development and application of the PCMC technology 
The PCMC technology, mainly as a batch process, was foremost described in the patent 
‘WO 00/69887 – Rapid dehydration of proteins’ by Moore et al. [30]. Herein, the authors 
pointed out that biomolecules keep a native-like conformation after particle formation due to 
the rapid dehydration step. The term ‘biomolecule’ comprised not only proteins, peptides or 
polypeptides, but nucleic acids such as DNA and RNA as well. Figures attached to the patent 
application demonstrate the formation of crystals with planar surfaces covered by amorphous 
protein, a structure that was confirmed in several subsequent studies [31, 32]. The process 
leading to this type of particles was termed crystal lattice mediated self-assembly (CLAMS) by a 
group of chemists from the University of Strathclyde [33]. Additionally, it was shown that 
precipitated PCMCs can be stored in the organic solvent and that the protein retains its activity 
and stability throughout the process [30]. The patent described that applications of this 
technology include preparation of enzymes for biocatalysis, formulation of pharmaceutical drug 
products and purification processes. 
Early applications of this technology mainly focused on enzyme PCMC suspensions for 
biocatalysis in organic solvents. Kreiner et al. were the first to prove that the preparation of 
subtilisin Carlsberg protease PCMCs and several lipase PCMCs with potassium sulfate as co-
precipitant results in particles with higher catalytic activities than lyophilized enzyme products 
[31]. They further showed that storage of the PCMC suspension in propan-1-ol for up to 
14 months leads to only negligible loss in activity [34]. The superiority of lipase K2SO4 PCMCs 
over the free enzyme concerning bioactivity rates in non-aqueous media is acknowledged by 
several authors [32, 35, 36]. Raita et al. investigated the applicability and operational stability of 
lipase PCMCs during biodiesel production [37]. Kreiner et al. extended the idea of PCMCs as 
biocatalysts to oxidoreductases [38]. 
However, not only enzymes for biocatalysis can be addressed with the PCMC technology. Vos 
successfully co-precipitated proteins like trypsin, pepsin, adenosine deaminase and myoglobin 
with several carrier materials during his studies on the formation mechanism of PCMCs [39]. 
The PCMC technology also allows for co-immobilization of two proteins onto the same carrier 
crystals [40]. 
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Khosravani et al. used the PCMC technology for the formulation of adenylate cyclase toxin 
(CyaA) of Bordetella pertussis, a potential candidate for vaccination against pertussis [41], 
which is usually stored in highly concentrated urea solutions for stability reasons. The authors 
showed that urea could be removed during the PCMC co-precipitation process with DL-valine as 
carrier due to its high solubility in the precipitating solvent ethanol. Furthermore, CyaA PCMCs 
that included calmodulin alone or in combination with bovine serum albumin (BSA) elicited full 
adenylate cyclase and cell invasive activities when reconstituted in aqueous buffer. Murdan et 
al. found that PCMCs of diphtheria toxoid stabilized the vaccine even at elevated temperatures 
[42]. Partridge et al. as well as König extended the PCMC technology to antibody (IgG) coated 
microcrystals [43, 44]. The pharmaceutical PCMC powders may be applied to the patient 
parenterally after reconstitution in aqueous media or as a suspension. Furthermore, as the 
resulting powders are usually very fine and free-flowing due to the supercritical fluid drying 
process, they can be used for pulmonary drug delivery if their particle size is between 0.5 and 
5 µm. 
For the production of PCMCs, essentially, only one carrier component and a biomolecule are 
required, as shown in early studies [31, 35, 36, 38, 45]. According to WO 2004/062560, carriers 
can be nearly any compound that crystallizes rapidly and that can be used as a saturated 
solution. Most commonly an inorganic salt, an amino acid or a sugar was employed [46]. 
Potassium sulfate was the carrier of choice. Amongst the amino acids, especially DL-valine [41, 
47], glycine [44] and L-glutamine [39, 48] proved to be suitable carrier components. Mannitol 
has been utilized as carrier by Vos [39]. Kreiner et al. extended the choice of immobilization 
matrix to both inorganic and zwitterionic compounds acting as solid-state buffers [45]. These 
substances, e.g. Na-AMPSO (3-((1,1-dimethyl-2-hydroxyethyl)amino)-2-hydroxypropanesulfonic 
acid), Na2CO3 and NaHCO3, can provide in situ ionization-state control which has been shown to 
be beneficial for the catalytic activities of two serine proteases [28]. It was pointed out by 
Moore et al. that certain biomolecules, like antibodies, need further stabilization during the 
PCMC production since exposure to polar solvent and immobilization on a surface means 
serious stress to the protein [49]. The authors recommended using a neutral co-precipitant, e.g. 
glycine, in combination with a basic and/or an acidic additive, especially the amino acids 
L-arginine and L-glutamic acid, and optionally further excipients like a neutral non-polymeric 
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additive, for instance sugars like trehalose, polysorbates and inorganic salts, such as NaCl. 
These precipitation-protective additives were suggested to form associates with the protein on 
the surface of the crystalline PCMC core [29]. The necessity of a rather complex carrier 
composition for sufficient stabilization was recently acknowledged during PCMC formulation 
development of an IgG at Boehringer Ingelheim [48]. 
These exemplary PCMC applications especially in the pharmaceutical field indicate that the 
PCMC technology represents a promising new method of stabilization of therapeutic 
biomolecules as dry powders. Therefore, this technology was introduced and further 
investigated at Boehringer Ingelheim in Biberach/Riss (D), initially in cooperation with XStalBio 
Limited (Glasgow, UK). 
1.2.3 PCMC production at Boehringer Ingelheim 
The first PCMC-related patent WO 00/69887 and most of the published work described the 
production of PCMCs in a batch mode where an aqueous solution of the protein and the carrier 
(protein-carrier solution) was added dropwise to the anti-solvent under stirring [30]. In 
‘WO 2004/062560 - Pharmaceutical composition’, however, the idea of producing PCMCs with 
a two-line continuous process for large-scale batches was introduced [46]. The authors stated 
that the use of a flow-co-precipitator could not only lead to PCMCs with higher uniformity, but 
also with increased bioactivity and stability compared to samples prepared by the batch 
process. These advantages were ascribed to the reduction of stress induced by the air-solvent 
interface or shear forces during mixing. Considering these aspects, a continuous PCMC 
production process was implemented at Boehringer Ingelheim [48].  
In general, after preparation of the aqueous protein-carrier solution, the PCMC production at 
Boehringer Ingelheim encompasses the following three steps which are visualized in Figure 1-1: 
 A. Mixing / PCMC precipitation 
A pre-blended aqueous solution of protein and carrier material (protein-carrier solution) is 
rapidly mixed with an excess of a water-miscible organic solvent saturated with all carrier 
excipients. Hence, the PCMCs co-precipitate immediately. The modular mixing platform 
(Figure 1-1A), established by König, comprised a static double or quadruple jet impingement 
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mixing module as well as pressure sensors, temperature sensors and mass flow meters to 
monitor and control the precipitation step [48]. In the double jet impingement mixer, usually 
chosen for the manufacturing of PCMCs, two independent anti-solvent streams delivered by 
micro gear pumps are merged with the protein-carrier solution. According to fluid dynamic 
computations [44], the design of the mixer as well as an appropriate pumping speed ensures 
homogenous mixing of the different phases. The resulting PCMC suspension is collected in an 
external vessel. 
 B. Concentration of the PCMC suspension / solvent exchange 
The concentration step of the PCMC suspension is necessary in order to avoid excessive drying 
times and costs. For this purpose, a modified pressure filtration unit has been developed [44]. 
In the context of this thesis, the products were concentrated simply by sedimentation and 
subsequent decantation of the supernatant to avoid shear stress inevitable during pressure 
filtration. In order to reduce the water content, the sediment was resuspended in fresh, 
saturated solvent and allowed to settle again (Figure 1-1B). 
 C. Drying of the concentrated PCMC suspension 
Supercritical fluid (SCF) drying with carbon dioxide (CO2) was chosen as a very effective and 
gentle way of removing the anti-solvent from PCMC suspensions [19]. CO2 exists as a SCF above 
its critical point at 31.0 °C and 73.8 bar [50]. SCFs have diffusive and viscosity properties similar 
to gases and can dissolve other compounds due to liquid-like densities [51]. The nonpolar 
supercritical CO2 is conducted through the PCMC suspension and dissolves the anti-solvent 
which is then carried out of the drying chamber and collected in a separator (Figure 1-1C). Polar 
water molecules show insufficient solubility in supercritical CO2 and are not removed 
effectively. Consequently, the initial water content of the suspension has to be minimal to 
obtain powders of acceptable residual moisture. The PCMCs are left behind as a powder with 
low bulk density, low residual solvent content and increased fine particle fraction [46]. To 
further decrease the residual water content, a vacuum drying step follows SCF drying. 
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Figure 1-1: Visualization of the PCMC production process at Boehringer Ingelheim; 
(A): precipitation step; (1) three micro gear pumps for the delivery of solvent and protein-
carrier solution, (2) mass flow meters, (3) Ehrfeld platform equipped with the double jet 
impingement mixer, pressure and temperature sensors, (4) glass bottles for harvesting of the 
PCMC suspension; (B) concentrating and solvent exchange step; left: freshly precipitated 
PCMC suspension, right: PCMC suspension 18 h after precipitation with (5) supernatant and 
(6) sediment; (C) supercritical drying with CO2 which dissolves and removes the anti-solvent 
leaving behind the dry PCMC powder; (7) gas bottles with CO2, (8) pump for CO2 delivery, 
(9) stainless steel basket filled with PCMC suspension and powder, respectively. 
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Production parameters like mixing speed and water-to-solvent ratio are known to significantly 
influence PCMC properties. Therefore, optimized values for these parameters were kept 
constant for reasons of comparability. A mixing speed of 1000 mL/min for pure isobutanol and 
1:1 (v/v) isopropanol/2-methyl-2,4-pentanediol mixtures ensured turbulent (Reynolds number 
≥ 2300) and efficient mixing. According to König et al., the mixing intensity not only affects the 
PCMC particle size and its distribution, but also the binding strength of the protein on the 
carrier material [44, 48]. 
In agreement with previous studies, the water-to-solvent ratio was set to 5:95 (v/v) [44]. On the 
one hand, an excess of solvent is crucial for rapid precipitation of PCMCs, on the other hand, a 
certain water content seems to be important for protein stability. Studying trypsin PCMCs, Vos 
found that the bioactivity of the enzyme decreased with declining water content [39], being 
consistent with the observations made on subtilisin Carlsberg by Partridge et al. [52]. The 
authors stated that water was essential for maintaining the enzymatic activity of trypsin as all 
proteins typically need key structural water molecules for stability [39]. 
2 Objectives of the thesis 
This thesis aimed to evaluate pharmaceutical applications of the protein-coated microcrystals 
technology. Besides formulation considerations, the focus was on the development of a 
potential final dosage form for PCMC powder as high concentration suspension allowing for 
subcutaneous administration as well as on mechanistic questions. 
The first objective of the thesis was to apply the PCMC technology that has successfully been 
used for the formulation of various protein drugs, including mAbs [43, 44], adenylate cyclase 
toxin of Bordetella pertussis [41] and diphtheria toxin [42],  to a non-glycosylated cytokine. This 
hydrophobic protein is commercially formulated as lyophilisate with a large amount of human 
serum albumin (HSA), but the PCMC formulation may allow for stabilizing the cytokine in the 
absence of this excipient. Therefore, a formulation screening had to be conducted, aiming at 
developing an optimal carrier composition that provided high process stability to the cytokine. 
The most promising formulation should subsequently be studied during a long-term stability 
study over 52 weeks and analyzed in detailed for biological activity. 
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In the following study, a previously developed mAb PCMC formulation was intended to be 
applied to another IgG (mAb2). Furthermore, the formulation screening aimed to reduce the 
number of carrier components and thus the overall complexity of the protein-coated 
microcrystals. Thus, the influence of each carrier component on the PCMC powder properties 
had to be investigated. The optimized formulation should further be studied during an 
accelerated short-term stability study to identify the maximal protein load enabling high 
antibody storage stability, additionally in comparison to a corresponding liquid formulation. 
Apart from formulation development, the second major objective of this thesis was to develop 
PCMC suspensions for subcutaneous administration as alternative dosage form to protein 
solutions because specifically for mAbs high concentration s.c. formulations are of high 
practical relevance. This requires physiologically acceptable solvents as dispersing agent which 
are compatible with both the protein itself and the protein carrier powder particles. Organic 
water-miscible solvents selected for the according study comprised glycerol, 
N-methylpyrrolidone (NMP), propylene glycol and PEG 400, whereas sesame oil, benzyl 
benzoate and medium-chain triglycerides (MCT) were chosen as oily resuspension media. As 
opposed to the organic water-miscible vehicles, the evaluation of the oils additionally had to 
include detailed investigations of the release process of the protein from the oily PCMC 
suspensions. Furthermore, injectability of the formulations was to be demonstrated. 
Despite widespread studies on the PCMC technology, the mechanism underlying the particles` 
formation and the protein stabilization are still not fully understood. Therefore, mechanistic 
questions, such as the characterization of the crystallinity/amorphicity and the morphology of 
the particles in dependence of the formulation composition, should finally be addressed to gain 
insights in the assembly of protein-coated microcrystals taking place during the rapid 
dehydration. Moreover, precipitation of protein on separately prepared carrier crystals was 
planned to advance the understanding of the PCMC formation process. 
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H S A - f r e e  f o r m u l a t i o n  o f  a  
h y d r o p h o b i c  c y t o k i n e  a s  p r o t e i n -
c o a t e d  m i c r o c r y s t a l s  
This chapter is intended for publication: 
K. Berkenhoff, K. Bechtold-Peters, V. Christ, S. Bassarab, W. Friess, HSA-free formulation of a 
hydrophobic cytokine as protein-coated microcrystals; in preparation. 
Abstract 
The development of liquid injectables for hydrophobic cytokines bears particular challenges 
because the proteins’ hydrophobicity may result in low solubility, a high aggregation tendency 
and marked adsorption phenomena. Therefore, various formulations contain HSA as stabilizing 
agent. Our study aimed to develop a stable HSA-free formulation of a hydrophobic cytokine as 
protein-coated microcrystals (PCMCs). Based on coprecipitation, the PCMC technology offers 
the possibility to stabilize protein in the solid state. For the optimization of the PCMC 
composition with respect to amino acid, sugar and salt, we performed a formulation screening 
that focused on protein process stability as well as on PCMC formation and particle structure. 
The investigation revealed only minor differences in protein process stability between the 
excipient combinations selected. One promising formulation based on valine and sucrose was 
chosen for further detailed investigation of protein bioactivity and long-term stability over one 
year at 5 ± 3 °C and 22 ± 3 °C. Bioactivity was completely preserved during the PCMC 
production process. Moreover, the level of aggregation detected via HP-SEC and SDS-PAGE as 
well as the amount of oxidized species increased only slightly over storage time depending on 
the storage temperature. Storage at 5 ± 3 °C provided good stability of the cytokine coated 
microcrystals over one year. Compared to long-term stability studies with commercialized 
lyophilized cytokine formulations, the overall stability as PCMCs turned out to be improved. 
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Therefore, the PCMCs represent a very encouraging technology for the formulation of the 
hydrophobic cytokine as well as potentially various other protein drugs. 
1 Introduction 
Research is progressing fast in the area of cytokines that are widely used in the treatment of 
cancer, autoimmune disorders and related diseases [1]. In the formulation development of a 
number of cytokines, some specific challenges have to be overcome, originating from the 
hydrophobicity of these proteins [2]. Cytokines frequently are of a limited solubility [3, 4] and 
can show pronounced aggregation and adsorption tendencies [5, 6]. Therefore, in various cases 
human serum albumin (HSA) is added, e.g. to beta-interferons, because it provides stabilizing 
effects, increases solubility and reduces the unspecific adsorption to surfaces [7]. Extavia®, 
Betaferon®/Betaseron®, and Avonex® (lyophilisate) represent some marketed products that 
contain a large surplus of HSA (e.g. for Betaferon® 50-fold by weight) [8]. Nevertheless, the use 
of HSA in the formulation development of proteins gives rise to various concerns. First, HSA 
used in these formulations is generally obtained from human plasma and thus is tainted with 
the peril of blood derived pathogens. This problem would be cured by the use of recombinant 
HSA which has become available at larger quantities [9]. Furthermore, it can be speculated 
about the potential risk of mixed HSA/cytokine aggregates which may lead to severe immune 
responses [10]. Finally, the presence of the large HSA excess precludes or at least complicates 
the various analytics which would allow to demonstrate the cytokine´s integrity in the 
formulation [2]. In consequence of these disadvantages, significant efforts are made to avoid 
the use of HSA in the development of cytokines as exemplarily realized in Avonex® (liquid) and 
Rebif® [8] or studied by Hawe and Friess [5]. These HSA-free formulations are classical liquid or 
lyophilized dosage forms. 
The protein-coated microcrystals technology represents an alternative method of protein 
stabilization in the solid state. It is based on the coprecipitation of an aqueous solution of 
protein and carrier material which is induced by a rapid addition of a surplus of organic 
water-miscible solvent, e.g. isopropanol or isobutanol [11]. The immediate dehydration of the 
protein and the carrier components, comprising physiological acceptable substances such as 
buffer species, amino acids, sugars and inorganic salts [12], results in the formation of a 
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suspension that is concentrated and subsequently dried via supercritical fluid extraction with 
carbon dioxide. The powder harvested consists of water-soluble particles in the lower 
micrometer range. The idea of the PCMC technology goes back to a patent of Moore et al. [11]. 
The applications described by various researchers include not only proteins, peptides and 
polypeptides, such as e.g. subtilisin Carlsberg protease [13], lipase [14, 15], trypsin [16, 17], BSA 
[16, 18], IgGs [16, 19], but also DNA and RNA [20]. König established a pilot-scale production 
process for PCMCs that enables a continuous production of up to 120 L suspension per hour 
[16]. Thus, this technology has become an attractive method in protein formulation e.g. as 
highly concentrated suspension for subcutaneous injection or powder for pulmonary delivery. 
The objective of our study was to develop a HSA-free formulation of a hydrophobic cytokine as 
PCMCs. Therefore, a formulation screening had to be conducted to optimize the carrier 
composition. The focus of the protein analytics was on monomer content, turbidity, protein 
recovery and bioactivity upon reconstitution of the powder. Subsequently, one promising 
formulation was to be chosen to investigate the bioactivity in comparison to a marketed 
lyophilized product of the cytokine. Moreover, a long-term stability study over 52 weeks was 
carried out considering the integrity (HP-SEC, RP-HPLC, SDS-PAGE) and the structure 
(2nd-derivative UV, intrinsic fluorescence, FT-IR spectroscopy) of the cytokine as well as the 
PCMC morphology (x-ray diffractometry, SEM). 
2 Materials and methods 
2.1 Materials 
L-Phenylalanine, L-aspartic acid, DL-dithiothreitol, acetonitrile, Water CHROMASOLV® for HPLC 
and trifluoracetic acid were purchased from Sigma-Aldrich, Steinheim, D, L-2-methyl-
2,4-pentanediol and disodium EDTA dihydrate from Merck, Darmstadt, D. Sodium dodecyl 
sulfate was procured from Serva, Heidelberg, D, L-glutamic acid and D/L-valine were from 
Fluka, Buchs, CH. L-Arginine and glycine were obtained from Ajinomoto Omnichem, Louvain-la-
Neuve, B, trisodium citrate dihydrate and citric acid monohydrate from Jungbunzlauer, 
Ladenburg, D. Sodium dihydrogen phosphate dihydrate was delivered by Dr. Paul Lohmann, 
Hungen, D, sodium chloride by Akzo Nobel, Hengelo, NL, and trehalose dihydrate by Ferro 
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Pfanstiehl, Waukegan, IL, USA. MOPS (3-(N-Morpholino)-1-propanesulfonic acid sodium salt) 
was acquired from Carl Roth, Karlsruhe, D, sucrose from Südzucker, Mannheim, D. 
SilverXpress® Silver Staining Kit originated from Invitrogen, Darmstadt, D, and isopropanol from 
Hedinger, Stuttgart, D. All chemicals were utilized without further purification. 
The protein bulk drug substance provided by Boehringer Ingelheim was composed of 
1.5 mg/mL hydrophobic cytokine, 50 mM sodium acetate trihydrate, 1 mM disodium EDTA 
dihydrate and 0.1 % sodium dodecyl sulfate (SDS). The buffer of the bulk drug substance was 
exchanged via ultra- and diafiltration resulting in a protein solution that consisted of 11-
21 mg/mL protein, 22 mM citrate and 0 or 52 mM NaCl (crossflow buffer exchange and 
concentration unit, Boehringer Ingelheim, Biberach/Riss, D; membrane cassette Sartocon Slice, 
Hydrosart, 5 kd, Sartorius, Göttingen, D; Quattroflow 150 S membrane pump, Quattroflow Fluid 
Systems, Hardegsen, D). Furthermore SDS was present in the protein solution because it cannot 
be removed via ultra- and diafiltration, as similarly reported by Mahler at al. for polysorbate 20 
[21]. 
2.2 Methods 
2.2.1 PCMC production process 
The PCMC production process is divided into four main steps: preparation of protein-carrier 
solution, precipitation, concentration/solvent exchange, and drying. For the preparation of the 
protein-carrier solution the carrier material was dissolved in water and the solution pH value 
was adjusted to 5.5 (3.0 for formulation Asp3.0) prior to the addition of the protein solution. 
The composition of the protein-carrier solutions is presented in Table 2-1. Their solid content 
amounted to 45 mg/mL except for formulations Asp5.5 and Asp3.0 which had a solid content of 
7 mg/mL due to the low solubility of aspartic acid of 4 g/L [22]. 
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Table 2-1: Composition of protein-carrier solutions [% w/w]. 
Formulation Val +NaCl 
ValSuc
+NaCl 
ValSuc
-NaCl 
GlyPhe
Tre 
GlyGlu
Arg ValArg Asp5.5 Asp3.0 
Trisodium citrate 
dihydrate 8.6 8.6 8.6 8.6 8.6 8.6 8.6 8.6 
Citric acid 
monohydrate 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 
Sodium chloride 5.1 5.1 -- 5.1 5.1 5.1 5.1 5.1 
Cytokine 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 
Glycine -- -- -- 40.0 46.2 -- -- -- 
L-Glutamic acid -- -- -- -- 4.6 -- -- -- 
L-Arginine -- -- -- -- 6.3 37.6 -- -- 
DL-Valine 75.1 74.1 79.2 -- -- 37.6 -- -- 
Sucrose -- 1.0 1.0 -- -- -- -- -- 
L-Phenylalanine -- -- -- 5.7 -- -- -- -- 
L-Aspartic acid -- -- -- -- -- -- 57.1 57.1 
MOPS -- -- -- 11.4 -- -- -- -- 
Trehalose 
dihydrate -- -- -- 18.0 18.0 -- 18.0 18.0 
Final pH  5.6 5.6 5.7 5.6 5.5 5.4 5.6 3.1 
Solid content 
[mg/mL] 45 45 45 45 45 45 7 7 
 
The precipitation was carried out as described in detail by König [23]. Briefly, two equal streams 
of precipitating agent were mixed with one stream of protein-carrier solution in a small double 
jet impingement mixer of an inner diameter of 1.5 mm (Boehringer Ingelheim Pharma GmbH 
Co. KG, Biberach/Riss, D). The precipitating agent was a 1:1 mixture of isopropanol and 
2-methyl-2,4-pentanediol based on volume saturated with all carrier components. The mixing 
ratio of the precipitating agent and the protein-carrier solution was set to 95 : 5 (v/v). The 
modular mixing platform from Ehrfeld (Bayer Technology, Wendelsheim, D) encompassed three 
micro gear pumps (HNP pumps mzr 11507 and 7255, Hydraulik Nord Fluidtechnik, Parchim, D), 
pressure sensors and temperature sensors to monitor the precipitation step. The total flow rate 
of 1000 mL/min was controlled by the software LabView (National Instruments, Munich, D) and 
Coriflow mass flow meters (Bronkhorst, Kamen, D). The final suspension volume after 
precipitation was 1 L for the formulation screening (2 L for the formulations based on aspartic 
acid) and 5 L for the subsequent bioactivity and long-term stability study. Based on macroscopic 
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evaluation the precipitation behavior was ranked into three groups: (1) significantly 
decelerated, (2) slightly decelerated, (3) rapid. 
For the formulation screening the PCMCs were gained by vacuum filtration of the suspension 
through a 0.45 µm membrane filter (Durapore Membrane Filter 0.45 µm HV 47 mm, Millipore, 
Schwalbach, D) and drying in the glove box flushed with dry air. For the bioactivity and long-
term stability study this simplified procedure was replaced by the detailed PCMC production 
process as described by König et al. [23]. For concentration of the PCMC suspension the 
supernatant was decanted 18 h after the precipitating step and the concentrated suspension 
was filtered through a 0.45 µm membrane filter (Stericup 47 mm, Sartorius, Göttingen, D). After 
two washing steps with isopropanol saturated with the excipients the filter cake was 
resuspended in this solvent. For the final supercritical drying process (Thar SFE-500, Thar 
Technologies, Pittsburgh, PA, USA) carbon dioxide at 100 bar and a flow rate of 25 g/min was 
utilized at 45 °C, after drying for 130 min the pressure was decreased by 3 bar/min. 
2.2.2 Storage stability study 
For the stability study 10, 50 (analysis of protein structure), or 100 mg (x-ray diffractometry) of 
the PCMC powder based on formulation ValSuc-NaCl was filled into 2 R glass vials (Fiolax®, 
Schott, Mühlheim, D). Half of the vials was stoppered (Gusto C 1503 6720 GC grau 6 TP, Stelmi, 
Roissy Charles De Gaulle Cedex, F) under lab atmosphere in the glove box, the other half in a 
freeze-dryer flooded with nitrogen (Epsilon 2-12 D, Martin Christ, Osterode, D) at 20 °C, 
760 mbar. Samples were stored at 5 ± 3 °C or 22 ± 3 °C. Analysis of the PCMC powder was 
performed directly after PCMC production (t0), after two (t2wk), four (t4wk), eight (t8wk) and 
52 weeks (t52wk) of storage. Investigations by x-ray diffractometry, scanning electron 
microscopy, SDS-PAGE as well as spectroscopic methods were limited to t0, t8wk and t52wk. 
2.2.3 Analysis of PCMCs 
2.2.3.1 Reconstitution of PCMC powder 
During the formulation screening 22 mM citrate buffer with 52 mM sodium chloride pH 2.0 was 
used to dissolve the powder. For formulation ValSuc-NaCl this buffer was prepared without 
sodium chloride. For the stability study samples were reconstituted with 11.5 mM NaCl, pH 2.0. 
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2.2.3.2 Turbidity 
Turbidity was measured at a protein concentration of 1 mg/mL except for the formulations 
Asp5.5 and Asp3.0 which required double the volume of reconstitution medium due to low 
solubility of aspartic acid and which were thus analyzed at 0.5 mg/mL. During the formulation 
screening, turbidity was investigated by 90 ° light scattering at λ = 400-600 nm (Turbidimeter 
2100 AN, Hach Lange, Düsseldorf, D) expressed in formazine nephelometric units (FNU) 30 min 
after reconstitution (n=3). For the stability study, turbidity was determined by 90 ° light 
scattering at λ = 633 nm 90 min after the addition of the reconstitution medium.  
The turbidity values were compared to the reference solutions I-IV of the Ph. Eur. (method 
2.2.1 clarity and degree of opalescence of liquids) [24], as shown in Table 2-2. According to the 
Ph.Eur., FNUs are equivalent to NTUs (Nephelometric Turbidity Unit) in regions up to 40 NTUs. 
Table 2-2: Turbidity of the opalescence reference solutions according to Ph. Eur.. 
Reference solution Turbidity [NTU] Degree of opalescence 
I 3 Clear (≤ Ref. I) 
II 6 Slightly opalescent (≤ Ref. II) 
III 18 Opalescent (≤ Ref. III) 
IV 30 Very opalescent (≤ Ref. IV) 
 
2.2.3.3 Theoretical protein recovery 
For the evaluation of protein recovery 30 mg of PCMC powder were dissolved and filtered 
through a 0.45 µm syringe filter (Rotilabo-Spritzenfilter steril 0.45 µm PVDF, Carl Roth, 
Karlsruhe, D) 30 min after reconstitution. UV measurement (UV/VIS Spectrometer Lambda 20, 
PerkinElmer, Rodgau-Jügesheim, D) in Halfmicro Plastibrand® cuvettes (Brand, Wertheim, D) 
was carried out at 280 nm, corrected against buffer, based on an extinction coefficient of 1.70 
(n=3) [5, 25]. Theoretical protein recovery was calculated as the quotient of the cytokine 
fraction in the PCMCS to the cytokine fraction in the total solid mass of the protein-carrier 
solution. 
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2.2.3.4 Protein integrity 
2.2.3.4.1 HP-SEC 
For HP-SEC method A a TSKgel G3000SW column (7.8 mm ID x 60.0 cm L) and a TSKgel SWXL 
Guardcol precolumn (Tosoh Bioscience, Stuttgart, D) were used on an Äkta micro (GE 
Healthcare, Uppsala, Sweden) with 200 mM sodium dihydrogen phosphate and 0.1 % SDS. 25 µl 
samples of 0.6 mg/mL protein were injected in duplicate and protein elution was monitored via 
UV-detection at 210 nm. Aggregation in percent was calculated based on the ratio of the area 
under the curve (AUC) of soluble aggregates to the total AUC of aggregates and monomer 
(n=2). Method A was used in the formulation screening as well as in the stability study, 
representing the standard HP-SEC method for the cytokine [5]. 
Additionally, method B, as developed by BI, was used as orthogonal method in the stability 
study to assess cytokine aggregation. It was performed on a TSKgel G3000SWXL column 
(7.8 mm ID x 30.0 cm L) and a TSKgel SWXL Guardcol precolumn (Tosoh Bioscience, Stuttgart, 
D). The mobile phase was composed of 60 % acetonitrile, 40 % water and 0.1 % TFA. Peaks 
were detected via UV at 214 nm. 
2.2.3.4.2 SDS-PAGE 
SDS-PAGE was conducted at 200 V with Power Ease 500 and XCell Sure Lock in combination 
with 12 % Bis-Tris gels (NuPAGE®, 1 mm, 10 wells, Invitrogen, Darmstadt, D) and NuPAGE® 
MOPS SDS running buffer. Samples were mixed 8:2 with NuPAGE® LDS sample buffer, and 7:2:1 
with NuPAGE® LDS sample buffer and 0.5 M dithiothreitol for the reducing SDS-PAGE. After 
heating up to 95 °C for 5 min, 5 µl of the samples and the marker (Precision Plus Protein 
Standard), representing 1 µg protein, were loaded to each well. Furthermore, 2 ng BSA were 
loaded to one well for the purpose of sensitivity control. The gels were stained with 
SilverXpress® Silver Staining Kit. 
2.2.3.5 Particle size 
The particle size was determined in suspension by laser diffractometry (OASIS equipped with 
HELOS/BF, CUVETTE CUV-50ML/US, SUCELL/M, SVA, Sympatec, Clausthal-Zellerfeld, D). 
Suspension was added until an optical concentration of about 5 % was reached in the cuvette 
that contained 50 mL of the precipitating solvent at a stirring speed of 500 rpm. Based on 
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Fraunhofer model the particle size distribution was calculated and expressed as volume 
distribution (Q3). The mean value and the span 90 as (x90-x10)/x50 were used for powder 
characterization (n=3). 
2.2.3.6 Particle morphology 
Particle morphology of PCMC suspensions was analyzed by the use of a light optical microscope 
(Olympus BX50 F4, Olympus, Tokyo, Japan) equipped with a digital camera (HVC 20, Hitachi, 
Maidenhead, GB). Additionally, for scanning electron microscopy (Zeiss SUPRA 55 VP, Zeiss, 
Oberkochen, D), powder samples on an aluminum stub and coated with gold/palladium 
(SCD 500, BAL-TEC, Witten, D) were prepared.  
2.2.3.7 Bioactivity 
The bioassay was based on lung cancer indicator cells A549 [26]. Briefly, preincubated with 
different concentrations of the cytokine, the cells were infected with encephalomyocarditis 
virus and thus a cytopathic effect was evoked leading to cell lysis. The number of viable cells 
was analyzed by an MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. 
The concentration of the cytokine that led to the lysis of 50 % of the cells (ED50) was referred to 
cytokine standard. The biological activity of the samples was determined based on three 
independent batches of each sample. Each batch consisted of two plates with the sample in 
triplicates. 
2.2.3.8 Oxidized species 
The amount of oxidized cytokine was analyzed by RP-HPLC (Alliance 2695, Waters, Milford, MA, 
USA) with a Zorbax 300SB-CN column (4.6 x 150 mm, Agilent, Böblingen, D) as stationary phase. 
The mobile phase was composed of phase A (100 % water with 0.1 % trifluoroacetic acid (TFA)) 
and phase B (84 % acetonitrile, 16 % water, 0.084 % TFA). The volume fraction of phase B was 
increased from 40 % to 55 % (9 min), 60 % (15 min) and 80 % (20 min) and finally reduced back 
to 40 % (21 min). A duplicate of 50 µl samples with 0.25 mg/mL protein was injected at a flow 
rate of 0.7 mL/min and detected at 214 nm (UV). The fraction of oxidized protein was 
calculated as percentage of the AUC of the peak caused by oxidized cytokine to the total AUC 
(n=2). 
HSA-free formulation of a hydrophobic cytokine as protein-coated microcrystals 
24 
2.2.3.9 Protein structure 
Conformational changes of the protein were analyzed via intrinsic fluorescence spectroscopy, 
UV spectroscopy and Fourier transform infrared spectroscopy. As valine which was used as 
main carrier component interferes with the FT-IR analysis, a special form of sample preparation 
was required prior to measurement [27, 28]. For the separation of protein from the carrier 
components in the PCMC powder, differences in solubility of the constituents were utilized. 
50 mg of PCMC powder was suspended in 10 mL Water For Injection (WFI), stirred for 10 min 
and centrifuged at 3000 g for 10 min. The supernatant containing the water soluble 
components, including valine, was removed and fresh WFI was added. After four repetitions 
the lasting sediment that only consisted of protein was finally dissolved in 1.5 mL 0.25 % SDS 
solution and the solution was filtered through a 0.45 µm syringe filter for further analysis. The 
absence of valine in the solution was controlled via thin layer chromatography based on 
ninhydrine detection. 
2.2.3.9.1 Intrinsic fluorescence spectroscopy 
Samples of 0.1 mg/mL protein in SUPRASIL® 114-QS precision cuvettes (10 mm, Hellma, 
Mühlheim, D) were excited at 295 nm and 25 °C and the emission was scanned from 305 nm 
to 400 nm with a step size of 1 nm and 1 s integration time (Fluorimeter QM-4-CW, PTI, 
Birmingham, NJ, USA). The evaluation was based on normalized spectra. 
2.2.3.9.2 UV spectroscopy 
Samples of 0.3 mg/mL protein were scanned from 240 to 350 nm (UV/VIS Spectrometer 
Lambda 20, PerkinElmer, Rodgau-Jügesheim, D). The second derivative of the absorption was 
used. 
2.2.3.9.3 Fourier transform infrared spectroscopy 
FT-IR spectroscopy was performed using a Tensor 37 and a Confocheck measuring cell (Bruker, 
Ettlingen, D). Spectra were recorded from 4000 to 900 cm-1 with 120 scans and a resolution of 
2 cm-1 at 25° C. Atmospheric compensation was done and buffer spectrum served as reference. 
Spectra were processed by vector normalization prior to calculating the average spectrum 
based on three measurements. Second derivative was built applying 17 smoothing points 
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(Savitzky-Golay algorithm). The protein concentration of the samples ranged from 
3 to 8 mg/mL. 
2.2.3.10 X-ray powder diffraction 
The crystallinity of cytokine PCMCs was analyzed with XRD in transmission mode from 
3 °- 40 ° 2 Θ, 0.5 ° steps and 20 s/step based on 1.5406 Å CuKα-radiation at 40 kV and 
40 mA (Stoe, Darmstadt, D). Samples were fixed in the sample holder between two Ultraphan 
foils (cellulose diacetate) with a thickness of 0.014 mm (Stoe, Darmstadt, D). 
3 Results 
3.1 Formulation screening 
3.1.1 Particle formation and characterization 
Based on their precipitation behavior, the formulations were divided into three groups 
(Table 2-3). The formulations GlyPheTre, GlyGluArg and ValArg precipitated rapidly. The 
product that left the mixing unit already represented a white suspension. All formulations that 
contained valine as main carrier component (Val+NaCl, ValSuc+NaCl, ValSuc-NaCl) as well as the 
sample Asp5.5 showed a slightly decelerated precipitation behavior and the product was not 
yet turbid at the outlet of the mixer, but turbidity immediately built up in the container used for 
harvesting. In contrast, formulation Asp3.0 became turbid after 1 h. 
The formulations clearly differed in their particle size that was analyzed via laser diffractometry 
(Table 2-3). ValArg, GlyGluArg and Asp5.5 formed rather small particles with x50 values ranging 
from 4 µm to 16 µm. Precipitation of the formulations Asp3.0, ValSuc-NaCl and Val+NaCl 
resulted in considerably larger particles in suspension with x50 values of 35, 37 and 58 µm, 
respectively. GlyPheTre and ValSuc+NaCl particles were of medium size (x50 values of 22 and 
27 µm). As the algorithm is based on spherical shaped particles, the x50 values do not represent 
an absolute particle size, but can serve for comparison. As exemplarily presented in Figure 2-1, 
the particle morphology was not spherical for any formulation. The formulations which were 
based on valine as only main carrier component (Val+NaCl, ValSuc+NaCl, ValSuc-NaCl) were 
characterized by a platelet-like shape (Figure 2-1a). A similar shape was found for the 
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formulation Asp5.5. The presence of arginine as additional carrier component apart from valine 
resulted in a fine and less defined particle morphology (Figure 2-1e). Needle-shaped PCMCs 
were found in the formulations that were based on glycine (Figure 2-1b, d) as well as for the 
sample Asp3.0 (Figure 2-1c). Additionally, as it can be seen in Figure 2-1a, b, d, smaller and 
more transparent particles were present besides the crystalline structures. This observation is 
underlined by the particle size distributions that were found to be bimodal (Table 2-3) except 
for the formulations GlyGluArg, Asp5.5 and Asp3.0, whose distributions were left-skewed 
monomodal. In the majority of cases, the bimodality of the particle size distributions was 
reflected by a higher span 90 value. 
a  b  
c  d  
e  
Figure 2-1: Particle morphology of cytokine PCMCs in suspension (light microscopy): 
a: ValSuc+NaCl, b: GlyGluArg, c: Asp3.0 d: GlyPheTre, e: ValArg. 
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3.1.2 Protein process stability 
After dissolution of the PCMCs the turbidity of most of the samples did not significantly differ 
(Table 2-3), except for the formulations GlyPheTre and ValArg which showed higher turbidity 
values than reference sample II of the Ph. Eur. (6 NTU) [24]. For formulation GlyPheTre a 
slightly increased turbidity of 7.9 FNU was detected, whereas the sample ValArg could not be 
successfully dissolved and consequently was not analyzed further. 
With respect to theoretical protein recovery calculated as the quotient of the cytokine fraction 
in the PCMCS to the cytokine fraction in the total solid mass of the starting solution, the 
samples differed significantly and could be classified into three groups. In the samples 
ValSuc-NaCl and GlyGluArg a 100 % protein recovery was found (Table 2-3). The formulations 
ValSuc+NaCl, GlyPheTre and Asp3.0 showed a protein recovery of about 130 %, whereas for 
Val+NaCl, ValArg and Asp5.5 recovery was considerably decreased to approx. 70-90 %. 
The analysis of soluble aggregates via HP-SEC method A revealed some minor differences 
between the samples. The formulations ValSuc+NaCl, ValSuc-NaCl, GlyPheTre and GlyGluArg 
contained approx. 4 % of soluble aggregates (Table 2-3). The aggregate content of the 
formulations Val+NaCl, ValArg, Asp5.5 and Asp3.0 was 5-6 %. Only marginal amounts (< 0.3 %) 
of soluble fragments were found in some samples. 
In the bioactivity test, the sample ValSuc-NaCl achieved the highest relative activity and was set 
as 1.00 for comparison and ranking of the formulations. The typically used bioactivity reference 
sample was not taken into consideration due to impact of the complex dissolution and sampling 
procedure at this stage. ValArg and Asp 5.5 revealed a bioactivity of > 0.90, whereas all other 
formulations exhibited significantly reduced values between 0.45 and 0.70. 
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Table 2-3: Results of the formulation screening; precipitation behavior: (1) significantly 
decelerated, (2) slightly decelerated, (3) rapid; turbidity: n.m. = not measurable; theoretical 
protein recovery; HP-SEC: bulk drug substance: 2.0 % ± < 0.1 aggregates, 97.9 % ± < 0.1 
monomers, 0.1 % ± < 0.02 fragments; particle-size distribution (PSD): location of maxima, 
main peak printed in bold [µm]; bioactivity: related to bioactivity of sample ValSuc-NaCl  = 1. 
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3.2 Long-term stability study 
Based on the results of the formulation screening, the formulation ValSuc-NaCl was selected for 
a storage stability study. Its bioactivity was 103 % referred to the standard lyophilized 
formulation of the hydrophobic cytokine. The biological activity did not significantly differ 
among the intermediate products of the PCMC process (powder harvested from the suspension 
after precipitation, powder harvested from the suspension after solvent exchange and 
concentration, powder harvested after supercritical drying). Samples were stored up to 
52 weeks at 5 ± 3 °C and 22 ± 3 °C with air or nitrogen headspace. 
Turbidity values for all samples investigated were in general low, between 0.2 and 1.7 FNU 
(Figure 2-2). Thus, turbidity was significantly lower than that of reference suspension I of the 
European Pharmacopoeia which exhibits a value of 3 NTU [24]. No significant increase or trend 
with storage could be detected for any storage conditions. 
 
Figure 2-2: Turbidity of ValSuc-NaCl PCMCs in long-term stability study. 
HP-SEC analysis via method A did not reveal significant changes in the amount of soluble 
aggregates within eight weeks and the monomer content of all samples was the same as for the 
initial material (Figure 2-3) (p > 0.05). After 52 weeks the monomer content was reduced by 
approx. 1 % for the samples stored at 22 ± 3 °C. A slight but significant decrease of monomer 
was also detected upon 52 week storage in the refrigerator (p < 0.05), with air in the headspace 
as opposed to nitrogen. The HP-SEC results obtained by method A were confirmed by the 
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orthogonal method B which essentially rendered the same monomer content for all samples 
(± 0.2 %). 
 
Figure 2-3: Monomer content (HP-SEC, method A) of ValSuc-NaCl PCMCs in long-term stability 
study. 
In SDS-PAGE the main bands occurred in the range between 17 and 19 (monomer), and 30 and 
36 kDa (dimer), respectively. Furthermore, minimal bands were seen at about the BSA band for 
the non-reduced gel and around 70 kDa and 15 kDa for the reduced gel. Evaluating the band 
patterns of all samples, SDS-PAGE gels both reduced and non-reduced showed slightly more 
intense covalent dimer bands for the samples stored at room temperature for 52 weeks in 
comparison to the initial material and PCMCs stored in the refrigerator (Figure 2-4). This minor 
increase in soluble aggregates was in line with the results obtained by HP-SEC analysis. Due to 
silver stain no quantification was feasible, but the SDS-PAGE indicated the covalent nature of 
some of the dimers. At least some of the covalent dimers were likely not linked via disulfide 
bridge because the corresponding band persisted under reducing conditions. 
In RP-HPLC analysis no significant increase (p > 0.05) in the amount of oxidized cytokine was 
observed for the samples stored under different conditions for 2 and 4 weeks (Figure 2-5). A 
slight, but not yet significant trend to more oxidized species was found after 8 weeks. After 
52 weeks a significantly higher percentage of oxidized protein was detected for all samples. The 
change depended on the storage conditions as PCMCs stored at room temperature showed an 
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increase in oxidation level by 2.1 % (air) and 1.6 % (N2), whereas the amount of oxidized 
cytokine increased by 0.9 % (air) and 0.8 % (N2) in the refrigerator. 
(a) 
 
(b) 
 
Figure 2-4: SDS-PAGE of ValSuc-NaCl PCMCs in long-term stability study: (a) non-reduced 
samples; (b) reduced samples; lane assignment: I: BSA control; II: Precision Plus Protein 
Standard [kDa]; III: t0 sample; IV: 52 wk. air, 22 ± 3 °C; V: 52 wk. air, 5 ± 3 °C; VI: 52 wk. N2, 
22 ± 3 °C; VII: 52 wk. N2, 5 ± 3 °C; VIII: Precision Plus Protein Standard. 
Analysis of cytokine’s secondary structure via FT-IR measurement did not reveal any significant 
differences between the initial PCMCs at t0 and the samples stored under various conditions for 
52 weeks (Figure 2-6). The spectra showed a distinctive band at approx. 1650 cm-1 indicating 
the dominance of an α-helical structure for the cytokine. No signs occurred at approx. 
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1620 cm-1 or 1685 cm-1, typical of intermolecular β-sheet often appearing in aggregated 
material due to unfolding [29]. Hence, protein secondary structure did not change over storage 
time independent of the headspace and the temperature. This outcome was underlined by 
intrinsic fluorescence spectroscopy and 2nd-derivative UV spectroscopy of PCMCs stored for 
52 weeks (Figure 2-9 and Figure 2-10 supplementary material). All samples rendered identical 
spectra independent of storage. 
 
Figure 2-5: Oxidized cytokine of ValSuc-NaCl PCMCs analyzed by RP-HPLC in long-term 
stability study. 
 
Figure 2-6: FT-IR spectra of ValSuc-NaCl PCMCs after separation from carrier components in 
long-term stability study. 
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The pattern recorded by x-ray diffractometry demonstrated that cytokine coated microcrystals 
were of crystalline character (Figure 2-7). A comparison to the spectra of the raw materials 
indicated that the ValSuc-NaCl PCMC spectrum was dominated by the signals originating from 
the main carrier valine. Important peaks of the other carrier components, sodium citrate, citric 
acid and sucrose, were not detected in the PCMC spectrum. The absence of those signal 
patterns was most evident at 2 theta of 8-17 ° because the PCMC spectrum did not show any 
significant signal in this range. Moreover, no spectral differences of the cytokine PCMCs were 
detected independent of the storage conditions as well as of the duration of the stability study. 
 
Figure 2-7: X-ray analysis of ValSuc-NaCl PCMCs in long-term stability study; spectrum 
assignment: I: 52 wk. air, 22 ±3 °C; II: PCMCs t0; III: D/L-valine; IV: trisodium citrate dihydrate; 
V: citric acid monohydrate; VI: sucrose; arbitrary offset for better comparison. 
In SEM, most PCMCs showed a more or less spherical shape with a crystalline core coated with 
crumbly material (Figure 2-8a, b) and particles of the small, crumbly, less compact coating were 
found separated from the large spherical particles. Placebo particles without protein were 
rosette shaped and of crystalline appearance (Figure 2-8c). In contrast to the cytokine PCMCs, 
this powder lacked of the less compact, smaller particles. No changes in particle morphology 
were seen in stored samples at all storage temperatures, storage time points and independent 
of the headspace (Figure 8d). 
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a  b  
c  d  
Figure 2-8: SEM of ValSuc-NaCl PCMCs: a, b, c: cytokine coated ValSuc-NaCl PCMCs at t0 (a 
and b) and stored for 52 weeks at 22 ± 3 °C with ambient air headspace (c); d: placebo 
ValSuc-NaCl PCMCs (i.e. precipitated from an aqueous carrier solution without cytokine). 
4 Discussion 
The idea of the PCMC technology is to stabilize protein in the solid state. The particle formation 
is based on a coprecipitation of protein and water-soluble carrier components which is realized 
by the addition of an excess of organic water-miscible solvent. The focus of the paper was on 
the applicability of the PCMC technology to formulate a hydrophobic cytokine with respect to 
process and storage stability of the protein. In the formulation screening, different carrier 
components were combined including amino acids (arginine, aspartic acid, glycine, glutamic 
acid, phenylalanine, valine), sugars (sucrose, trehalose) and the inorganic salt NaCl. Particle 
formation and morphology were investigated as well as protein stability in terms of turbidity, 
protein recovery, monomer content and bioactivity. The most promising formulation 
ValSuc-NaCl was subsequently chosen for a long-term stability study over 52 weeks. Protein 
activity, integrity (HP-SEC, RP-HPLC, SDS-PAGE) and structure (2nd-derivative UV, intrinsic 
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fluorescence, FT-IR spectroscopy) as well as PCMC morphology (x-ray diffractometry, SEM) 
were analyzed in detail. 
4.1 Particle formation and characterization 
According to their precipitation behavior, being rapid, slightly or significantly decelerated, the 
PCMC formulations of the screening were classified into three groups. The precipitation of the 
formulations that contained valine as main carrier component, Val+NaCl, ValSuc+NaCl, 
ValSuc-NaCl, was slightly decelerated. The presence or absence of NaCl and sucrose did not 
influence the precipitation rate. Replacing 50 % of valine by arginine, however, significantly 
accelerated the precipitation process. As arginine is considerably more hydrophilic than valine 
at the precipitation pH of 5.5, it is assumed to exhibit a reduced solubility in the hydrophobic 
solvent leading to the formation of crystallization nuclei that trigger the PCMC precipitation. 
The formulations with glycine as main carrier, GlyPheTre and GlyGluArg, precipitated rapidly. 
The dominance of highly water soluble components, such as glycine and trehalose, acting as 
nucleation starter in a rather hydrophobic surrounding probably enhanced the precipitation 
tendency. For two formulations which only differed in the exchange of glycine against valine, 
fast crystallization of glycine PCMCs compared to slow precipitation of valine containing carriers 
was observed [23]. With respect to the formulations Asp5.5 and Asp 3.0 that were based on 
aspartic acid, the precipitation behavior was slightly and significantly decelerated, respectively. 
This could be attributed to the reduced solid content of 7 mg/mL in the protein-carrier 
solutions as opposed to 45 mg/mL for all other formulations. 
Furthermore, the particle morphology in the suspensions harvested after the precipitation step 
depended on the carrier composition of the formulations. The particles of glycine containing 
formulations (GlyPheTre and GlyGluArg) were needle-shaped, as previously described [16]. The 
use of valine as main carrier component resulted in platelet-like shaped particles as detected 
for Val+NaCl, ValSuc+NaCl and ValSuc-NaCl PCMCs via light microscopy. Platelet-like PCMCs 
were also found by Kreiner et al. who investigated DNA-coated microcrystals made of valine as 
well as by König for valine PCMCs coated with trypsin or trypsinogen [16, 20]. Moreover, Lahav 
and Leiserowitz reported on a plate-like shape of valine grown from aqueous solution [30]. 
They further argue that the platelet-like shape is caused by the hydrophobic side chains 
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providing increased layer energy and reduced water binding concentration at the sides of the 
bilayers, compared to α-glycine. The formulation ValArg that contained valine and arginine in 
equal parts resulted in fine and less defined particles. In dependence of the precipitation pH, 
aspartic acid PCMCs were needle-shaped (pH 3) and platelet-shaped (pH 5.5).  
Apart from larger crystalline structures, smaller and more transparent particles were found in 
the suspensions. This observation was in line with the bimodal particle size distributions and 
the consequently higher span 90 values that were detected for most of the formulations. SEM 
analysis of ValSuc-NaCl PCMCs confirmed the coexistence of two different particle fractions, 
namely larger crystalline particles and smaller, less compact material, in the powder. Parts of 
the less compact material were coated onto the larger crystals and a second fraction did exist 
separately. In contrast, ValSuc-NaCl placebo PCMCs were of a rosette-like crystalline structure 
composed of numerous platelets, but the smaller, crumbly particles, which were found in the 
cytokine PCMCs, were missing. Consequently, the crystalline core of the spherical particles can 
be assumed to consist of carrier components, primarily of valine. The less compact structure 
was likely made of protein and amorphous carrier of unknown ratio. The x-ray diffractogram of 
ValSuc-NaCl PCMCs showed the main signals of crystalline valine which corresponds to König 
who proposed a crystalline state for PCMCs with a protein load of ≤ 10 % [23]. However, typical 
peaks of trisodium citrate, sucrose and citric acid did not appear in the PCMC diffractogram. 
This finding could be ascribed to the low amount of sucrose and citric acid (1.0 and 1.2 % w/w) 
present in the PCMCs, being below the detection limit of the method, or to an amorphous state 
as found for sodium citrate (8.6 % w/w). Assuming a fully crystalline state of valine and an 
amorphous state of sodium citrate/citric acid and sucrose, the latter two can stabilize the 
protein via formation of a glassy amorphous matrix as described in the literature. Izutsu et al. 
found that sodium citrate formed a glassy state after lyophilization, which prevented BSA and 
bovine IgG from alterations in secondary structure induced by freeze-drying [31]. The 
stabilization of proteins by sucrose, via amorphous matrix and/or hydrogen bonding, is 
frequently described for the manufacturing of solid protein formulations, such as lyophilization 
[32], spray drying [33, 34] and supercritical fluid drying [35].  
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With respect to the composition of the precipitated particles, the theoretical protein recovery 
reflects the ratio of protein to carrier. A value of 100 % indicated that the ratio of protein to 
carrier in the PCMC powder, initially originating from the composition of the protein-carrier 
solutions, did not change during the manufacturing process. A value of more than 100 % as 
detected for the formulations ValSuc+NaCl (135 %), GlyPheTre (128 %) and Asp3.0 (127 %) 
represented an augmented loss of carrier material. With respect to Asp3.0, the incomplete 
crystallization of aspartic acid was linked to a significantly reduced precipitation behavior. For 
ValSuc+NaCl and GlyPheTre, however, the high values must be attributed to incomplete 
precipitation of main carrier components, namely valine and glycine and/or trehalose, but 
could not further be explained. On the contrary, the samples ValArg and Asp5.5 contained less 
protein than theoretically expected (69 %). For ValArg PCMCs, the presence of the basic amino 
acid arginine resulted in an increased pH of the reconstituted PCMC powder. As the solubility of 
the cytokine is known to be reduced with increasing pH, the theoretical recovery does not 
reflect a protein loss during the manufacturing process, but the protein was not completely 
dissolved as indicated by a sediment formed in the sample [5]. In contrast, the reduced amount 
of protein in Asp5.5 PCMCs, which completely dissolved upon reconstitution, can be referred to 
an incomplete coprecipitation of the cytokine with the carrier component at pH 5.5. 
4.2 Influence of carrier combination on protein process stability 
The influence of the carrier combination on protein process stability was studied via turbidity 
measurement, bioassay and HP-SEC. Quantitatively, amino acids are the most important 
excipient for the formulation of proteins as PCMCs. The present study included formulations 
that were based on a single amino acid, such as valine or glycine, as well as formulations made 
up of up to three amino acids (GlyGluArg). Glycine and valine were the main amino acids in the 
formulations because they had successfully been used for the PCMC stabilization of various 
molecules, such as albumin, lysozyme and trypsin, as well as during the development of the 
continuous PCMC manufacturing process [14, 17, 23, 36]. Amongst other things, the influence 
of NaCl and sucrose on the protein process stability of valine PCMCs was investigated. With 
respect to NaCl, a striking difference in turbidity was seen between the formulations 
ValSuc+NaCl and ValSuc-NaCl. NaCl did not influence the aggregation tendency of the cytokine 
formulated as PCMCs as the aggregation level in HP-SEC was 3.7 % (ValSuc+NaCl) and 3.9 % 
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(ValSuc-NaCl), but the absence of NaCl reduced the turbidity upon reconstitution of the PCMCs 
by about 50 % (3.5 FNU  1.7 FNU). According to Hawe and Friess an increasing NaCl 
concentration and consequently growing ionic strength was found to result in a turbidity 
increase of the cytokine, independent of the pH value [5]. This finding was explained by a poor 
and strongly pH and ionic strength depended solubility of the cytokine. NaCl was subsequently 
assumed not to be a suitable excipient for isotonicity adjustment. The negative effect of NaCl 
on the solubility of the cytokine formulation was also seen in the bioactivity assay. ValSuc-NaCl 
PCMCs provided the highest cytokine activity, whereas ValSuc+NaCl showed significantly 
reduced bioactivity (0.47). In contrast, NaCl had previously been considered as indispensable 
for the precipitation of PCMCs [16]. Consequently, the stabilizing or destabilizing impact of NaCl 
depends on the protein formulation and cannot be generalized. Hawe and Friess, for example, 
described that, in contrast to the HSA-free cytokine formulation, the presence of HSA required 
the addition of NaCl to create a stable protein solution [5, 62]. This might by the reason, 
besides isotonicity adjustment, why some marketed HSA containing lyophilisates of the 
cytokine are reconstituted with NaCl solution, such as Betaferon® and Extavia® [8]. Also 
according to Zhang et al. NaCl decreased the aggregation rate of recombinant keratinocyte 
growth factor upon reconstitution of the lyophilisate [37].  
Moreover, the formulations Val+NaCl and ValSuc+NaCl were selected to investigate the impact 
of sucrose on cytokine process stability. In comparison to Val+NaCl, the addition of sucrose 
slightly reduced the aggregate level in HP-SEC (4.5  3.7 %), whereas turbidity marginally 
increased (2.8  3.5 FNU). A stabilizing effect of sucrose against aggregation was also reported 
by Hawe and Friess for a liquid cytokine formulation [5]. Several patents claim sucrose as 
stabilizer in aqueous interferon formulations as well as diluent for the reconstitution of 
corresponding lyophilisates [38-41]. The stabilization of proteins by sucrose in solid protein 
formulations, as discussed above, is ascribed to the formation of a glassy state, hydrogen bonds 
or a combination thereof.  
In formulation ValArg 50 % of valine was replaced by arginine whose properties to suppress 
protein unfolding and aggregation are particularly discussed in literature [27, 42-45]. The 
presence of arginine in the PCMC formulation of the cytokine resulted in an increase of 
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aggregates detected via HP-SEC (4.5  5.3 %). The turbidity of the formulation could not be 
measured due to incomplete dissolution and consequently sedimentation of the PCMC powder. 
Thus, the effect of arginine did not correspond with the solubility and stability enhancing effect 
as described by Shirley et al. as well as by Samaritani and Del Rio for liquid interferon 
formulations [46, 47]. However, the authors neither specified the concentration of arginine nor 
the pH value of the formulations and did not postulate any stabilizing mechanism that is 
apparently not yet sufficiently understood [42]. In the case of cytokine PCMCs, incomplete 
dissolution behavior was associated with reduced cytokine solubility in the presence of the 
basic amino acid arginine shifting the pH to a higher value. 
Apart from valine, two formulations (GlyPheTre, GlyGluArg) were based on glycine as main 
carrier component. The bioactivity of the glycine based PCMCs was clearly reduced (0.47 and 
0.53). Despite the typically high standard deviations and wide acceptance levels of cell-based 
bioactivity assays, this result at least reflects a clear trend. The turbidity values of the 
formulation GlyPheTre (7.8 FNU) were slightly higher compared to the values of the other 
samples (1.6-3.8 FNU), but the aggregate level was low (3.7 %). Thus, this carrier combination 
provided good cytokine process stability with respect to aggregate formation, but the overall 
cytokine solubility was decreased. Compared to GlyPheTre, phenylalanine and MOPS were 
replaced by glutamic acid and arginine in the formulation GlyGluArg. Turbidity (3.8 FNU) as well 
aggregate level (4.1 %) was in an acceptable range. Thus, although widely applied as stabilizer 
in cytokine formulations, glycine was less effective in stabilizing the cytokine formulated as 
PCMCs compared to valine. Hawe and Friess developed stable liquid and lyophilized 
formulations for a hydrophobic cytokine that were based on a 20 mM glycine buffer [5]. 
Various patents claim glycine as stabilizing agent in liquid as well as in lyophilized interferon 
formulations [38-41, 46, 48-50]. However, a long-term stability study of IgG coated 
microcrystals showed that glycine may even result in destabilization depending on the storage 
conditions due to a change in glycine modification [23]. 
In comparison to glycine, the protein stabilizing effect of phenylalanine and glutamic acid has 
rarely been investigated [51-53]. Though, some patents include the stabilizing ability of 
glutamic as well as aspartic acid in interferon formulations [39, 46, 47]. The latter was used as 
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carrier component in two formulations precipitated at pH 5.5 (Asp5.5) and 3.0 (Asp 3.0). As 
turbidity generally depends on the protein concentration and the low solubility of aspartic acid 
required a reduction in protein concentration to 0.5 mg/mL instead of 1.0 mg/mL, the turbidity 
values could not be compared to the other formulations [54]. The monomer level of the two 
formulations was lower and the aggregate level higher (5.7 and 5.2 % aggregates) than 
detected for the majority of the other samples, whereas the biological activity was rather high 
(0.94 and 0.70). Thus, the presence of an increased amount of soluble aggregates was not 
reflected in the bioactivity of the formulations. The lower pH of 3.0 prior to precipitation 
reduced the amount of aggregates in HP-SEC, but resulted in an increased turbidity. 
Consequently, a decreased precipitation pH value did not improve the overall PCMC process 
stability of the cytokine and the preference of an acidic over a neutral pH value, as reported by 
Hawe and Friess for a hydrophobic cytokine as well as claimed in several patents on interferon 
formulations, could not be transferred to the manufacturing of cytokine PCMCs [5, 38, 40, 46-
48]. 
Overall, PCMCs represent a complex mixture of various carrier components and protein. 
Therefore, stabilizing or destabilizing effects observed in the current study could not easily be 
attributed to single excipients. As the PCMC formation mechanism is not understood in detail 
yet, explanations derived from other protein technologies, such as lyophilization, are not 
readily transferrable to the challenging PCMC manufacturing process. Altogether, all cytokine 
formulations provided rather good protein process stability considering the formation of 
soluble and insoluble aggregates as well as the preservation of the biological activity. In 
comparison to the other samples, the formulation ValSuc-NaCl provided slightly superior 
stability. Besides, the bioactivity of ValSuc-NaCl PCMCs was equivalent to the standard 
lyophilized product of the cytokine and was not affected by the manufacturing process which 
includes three potentially rather stressful steps, namely precipitation, concentration and 
supercritical drying. This formulation was thus chosen for a long-term stability study. 
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4.3 Long-term storage stability 
4.3.1 Protein stability 
The formulation ValSuc-NaCl, selected for the storage stability study, was tested for both 
protein and carrier stability. As reported by Mahler et al. as well as by Bondos and Bicknell, 
turbidimetry represents an appropriate tool for the detection of insoluble protein aggregates 
[55, 56]. The turbidity values of the samples ranged between 0.2 and 1.7 FNU and, 
consequently, were very moderate and significantly lower than the value of the reference 
suspension I of the Ph.Eur.. Thus, supported by the absence of large particles visible by the 
naked eye, the formulations were considered as clear for all analytical time points, essentially 
free from large aggregates and unchanged over 52 weeks.  
The minimal increase of aggregates (dimers to oligomers) by 0.4 % within 52 weeks at 5 ± 3 °C, 
as detected by HP-SEC, additionally proved the high stability of the PCMC formulation. As 
typically seen for protein formulations, less aggregates were detected in the samples stored at 
5 ± 3 °C, 1.5 % for both air and N2 in the headspace, compared to PCMCs stored at 22 ± 3 °C 
with 2.6 % (air) and 2.2 % (N2) aggregates, respectively. It has to be taken into consideration 
that SDS was present in the exclusively aqueous mobile phase of HP-SEC method A, which is the 
standard SEC method for the hydrophobic cytokine [5]. As the adsorption tendency of 
hydrophobic proteins is well known [5], the addition of SDS aims to reduce the adsorption of 
the protein to the column matrix. However, SDS denatures proteins depending on the 
concentration used and is discussed to dissociate non-covalently linked protein aggregates [57, 
58]. Therefore, a second HP-SEC method based on a SDS-free, but acetonitrile containing 
eluent, method B, was developed and applied. Both methods gave the same results. 
Nevertheless, one has to bear in mind that acetonitrile is reported to dissociate insulin 
hexamers and hence may have similar dissociation properties on cytokine aggregates as SDS 
[59]. 
The evaluation of protein aggregation within a particular formulation requires the application 
of orthogonal methods because of the great variability of the nature of aggregates [57, 60]. 
Mahler et al. listed sedimentation velocity analytical ultracentrifugation (SV-AUC), flow field 
flow fractionation (FFFF) as well as light scattering (e.g. dynamic light scattering (DLS)) as 
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possible additional methods to accurately and reproducibly quantify the level of aggregates 
[54]. Hawe and Friess used DLS in addition to HP-SEC for the characterization of the aggregate 
level in formulations of a hydrophobic cytokine. The intensity of a second peak in the DLS-size 
distribution with a maximum of 13.5 nm was assigned to aggregated protein. An intensity of 
about 1 % was correlated to 2.5 % aggregates detected via HP-SEC. As the aggregation level 
revealed during our stability study was significantly lower than 2.5 %, with exception to the 
samples stored at room temperature for 52 weeks, DLS did not represent an appropriate 
orthogonal method in this case.  
SDS-PAGE was additionally applied for the detection of soluble covalently linked aggregates. 
The bands between 30 and 36 kDa, which were present in the initial PCMC powder as well as in 
the samples stored for 52 weeks, originated from dimer formation. These aggregate bands 
were slightly more pronounced in samples stored at room temperature, compared to the initial 
value and to the samples stored at 5 ± 3 °C, indicating a marginal formation of covalently linked 
aggregates. One of the dimer bands persisted under reducing conditions and thus indicated 
that some of these aggregates were caused by non-disulfide bridging. The evaluation of the gels 
was based on silver staining and hence only the detection of supplementary bands can be 
evaluated as significant differences between the samples [54]. Nevertheless, SDS-PAGE 
underlined the result of the HP-SEC that only slight dimer formation took place at 22 ± 3 °C. It 
further specified that at least some of the soluble dimeric species were covalently linked, not 
exclusively via intermolecular disulfide bridging. 
Related to their positioning within the native conformation of the cytokine, three out of four 
methionine residues are sensitive towards oxidation, as detected in previous studies 
(unpublished data) and described by Orru et al. [61]. Within 52 weeks, the amount of oxidized 
cytokine detected via RP-HPLC increased by 2.1 % (air) and 1.6 % (N2) for the samples stored at 
22 ± 3 °C. Upon storage at 5 ± 3 °C the level of oxidized protein augmented by 0.9 % for the 
samples with air headspace and by 0.8 % for those with N2. Thus, the use of nitrogen in the 
headspace decreased the oxidation rate of the cytokine at room temperature, but did not 
affect the more slowly progressing oxidation at 5 ± 3 °C.  
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The secondary and tertiary structure of the reconstituted cytokine was analyzed by several 
spectroscopic methods, including FT-IR, intrinsic protein fluorescence and 2nd-derivative UV 
spectroscopy, as recommended by Baudys and Kim [62]. Besides the wide application of FT-IR 
techniques to protein solutions, e.g. high-concentration liquid formulations [63], the method is 
used to investigate changes in the native secondary structure during various manufacturing 
processes of solid protein formulations, such as lyophilization [29], spray drying [64] or 
incorporation in particulate delivery systems [65], as reviewed by van de Weert and Joergesen 
[66]. Intrinsic fluorescence spectroscopy and 2nd-derivative UV spectroscopy enables the 
monitoring of conformational changes in the tertiary protein structure. None of these 
spectroscopic techniques revealed changes in secondary or tertiary structure of the 
reconstituted cytokine in our long-term stability study. Hence, independent of the conditions, 
storage over 52 weeks did not impact the conformational structure of the cytokine formulated 
as PCMCs. Moreover, the spectroscopic methods were not sensitive enough to be affected by 
the low cytokine aggregation level of 0.8-2.5 % identified via HP-SEC. In contrast, a 
dimer/oligomer content of 19-76 % resulted in conformational changes of recombinant human 
interferon beta recorded via 2nd-derivative UV spectroscopy [67]. 
In summary, the cytokine PCMCs provided high physicochemical protein stability over 
52 weeks. Storage at 5 ± 3 °C as opposed to 22 ± 3 °C reduced the aggregation and oxidation 
rate of the cytokine, but both conditions appear suitable from commercial product perspective. 
The use of nitrogen headspace, compared to ambient air, is not required for room temperature 
storage. 
4.3.2 Carrier and morphology stability 
Besides protein stability, the carrier and morphology stability of PCMC formulations need to be 
addressed during long-term storage studies because they are often associated with each other. 
For example, a polymorphic transformation of glycine incorporated in mAb PCMCs at 
25 °C/60 % RH which was detected via XRD and by structural changes in SEM, resulted in 
increased mAb aggregation [23]. Referring to the cytokine coated microcrystals, x-ray spectra of 
all samples recorded after 52 weeks of storage did not differ from the initial pattern. This 
indicated the absence of recrystallization processes of sucrose and citrate that were considered 
to be at least partially amorphous after the precipitation step. SEM pictures did not provide any 
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indication of excipient recrystallization or collapse either, proving high excipient and 
morphology stability of the PCMCs. However, it has to be taken into consideration that the 
cytokine PCMCs were not exposed to high moisture levels during storage. 
4.3.3 Comparison to lyophilized cytokine formulations 
The objective evaluation of the PCMC results requires stability data of other solid cytokine 
formulations for comparison. However, many formulations contain a multiple surplus of HSA 
that impedes the determination of the aggregation and oxidation level of the cytokine. 
Moreover, there are often differences in the design of the stability studies, e.g. storage time 
and conditions or analytical techniques applied, which make a direct comparison difficult. 
The stability study conducted by Hawe and Friess on a hydrophobic cytokine included at least in 
parts comparable storage conditions and analytical methods [5]. Based on a low pH glycine 
buffer, they stored five liquid and five lyophilized HSA-free cytokine formulations. Within 
6 months of storage the level of dimers and trimers in the lyophilisates, analyzed via HP-SEC, 
increased by about 0.3-0.7 % at 2-8 °C and up to 6.5 % at 25 °C/60 % RH, respectively, 
depending on the formulation. Formulated as PCMCs, the aggregation level of the cytokine 
augmented by 1.1-1.4 % at 22 ± 3 °C and by only about 0.4 % at 5 ± 3 °C within 52 weeks. 
According to Hawe and Friess, Met-oxidized cytokine formed as a function of storage 
temperature and time. In lyophilized samples stored at 2-8 °C the amount of oxidized protein, 
detected in RP-HPLC, enlarged by 1.4-2.4 %. Storage at 25 °C/60 % RH increased the oxidation 
level by 2.0-4.5 %. Consequently, storage at 2-8 °C was recommended. The cytokine coated 
microcrystals showed the same oxidation tendency as the lyophilisates studied by Hawe and 
Friess, but the increase in met-oxidized cytokine, 1.6-2.1 % at 22 ± 3 °C and 0.8-0.9 % at 
5 ± 3 °C, was clearly lower for the PCMCs than for the lyophilized formulations, despite a 
twofold longer storage period. Thus, the PCMCs represent a good alternative towards those 
lyophilized cytokine formulations, with an improved long-term stability and the potential for 
storage at room temperature. 
Several patents that claim cytokine lyophilisates also provide information on the stability of the 
formulations [38, 40, 41, 46, 49, 50]. In most cases a comparison between the stability of the 
PCMCs and the stability of the lyophilisates could not easily be drawn. WO 2012/071366 claims 
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that less than 10 % of the interferon-beta formulation is aggregated, fragmented or oxidized 
over an extended period of time, such as 12, 24 or 36 months or longer [38]. Furthermore, the 
biological activity is postulated to be within 10 % of the bioactivity exhibited at the time of 
preparation. The cytokine PCMC formulation met the first requirement, as only 4.9-7.4 % of the 
cytokine was aggregated, oxidized or fragmented after 52 weeks. The bioactivity of the cytokine 
PCMCs was not monitored over the storage time because, according to Geigert et al., it does 
not enable to accurately assess subtle changes of the protein as opposed to physicochemical 
analytical methods [68]. 
5 Conclusion 
The basic mechanism of protein stabilization via PCMC technology is still unknown. Based on 
the high complexity of PCMC formulations in combination with the sophisticated manufacturing 
process, which can be divided into the three steps precipitation, concentration and supercritical 
drying, stabilizing effects can hardly be correlated to the presence of single carrier components. 
Nevertheless, the PCMC process was found to be very robust because all formulations showed 
good overall cytokine stability. Apart from the precipitation behavior and the morphology of 
the precipitates, only minor differences in protein process stability resulted between the eight 
cytokine PCMC formulations tested. Compared to glycine, the use of valine as main carrier 
component provided higher cytokine process stability. As the absence of NaCl in valine PCMCs 
increased the solubility of the cytokine, it further resulted in a decreased turbidity and an 
increased bioactivity of the formulation. Sucrose was found to reduce the aggregation level of 
cytokine valine PCMCs. The carrier combination of valine and sucrose in absence of NaCl 
(ValSuc-NaCl) also showed high bioactivity, equivalent to the biological activity of the standard 
lyophilized formulation. Thus, ValSuc-NaCl PCMCs were selected to investigate the storage 
stability over 52 weeks. The long-term stability study revealed a small increase in dimers 
(approx. 0.4 % at 5 ± 3 °C and 1 % at 22 ± 3 °C) as well as a slightly augmented level of oxidized 
species (approx. 1 % at 5 ± 3 °C and 2 % at 22 ± 3 °C). Irrespective of the storage conditions, the 
secondary and tertiary structure of the cytokine as well as the particle morphology was not 
altered. SEM analysis revealed the presence of larger rosette-shaped crystals beside smaller 
less compact material, assumed to be composed of protein and amorphous sucrose and citrate. 
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Compared to lyophilized formulations of the cytokine, the PCMC technology provided overall 
very good protein stabilization and therefore represents a promising alternative to 
lyophilization for the manufacturing of stable HSA-free formulations of the hydrophobic 
cytokine. 
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7 Appendix: supplementary material 
 
Figure 2-9: 2nd-Derivative UV spectra of ValSuc-NaCl PCMCs after separation from carrier 
components in long-term stability study; arbitrary offset for better comparison. 
 
Figure 2-10: Intrinsic fluorescence spectra of ValSuc-NaCl PCMCs after separation from carrier 
components in long-term stability study. 
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Chapter 3  
F o r m u l a t i o n  o f  a  t h e r a p e u t i c  
m o n o c l o n a l  a n t i b o d y  v i a  P C M C  
t e c h n o l o g y  
This chapter is intended for publication: 
K. Berkenhoff, V. Saller, V. Christ, S. Bassarab, K. Bechtold-Peters, W. Friess, Formulation of a 
therapeutic monoclonal antibody via PCMC technology; in preparation. 
Abstract 
Protein-coated microcrystals (PCMCs) are formed upon rapid co-precipitation of a protein with 
carrier components after addition of an excess of organic anti-solvent. After concentration and 
supercritical drying of the resulting suspension the PCMCs provide protein stabilization in the 
solid state. In the current study, we applied the PCMC technology to a therapeutic monoclonal 
antibody (mAb2) and investigated the influence of each formulation component, including 
sodium chloride, glycine, histidine, phenylalanine and trehalose, on PCMC powder properties. 
Sodium chloride had positive effects on the manufacturability of PCMCs and prevented the 
antibody from the formation of insoluble protein particles. Glycine, histidine and trehalose 
elicited positive effects on the monomer content. Trehalose was further necessary to inhibit 
glycine crystallization and thus to achieve a homogenous and amorphous product. As no 
further benefits regarding PCMC product quality could be ascribed to the excipient 
phenylalanine, this component was excluded in the lead formulation to reduce the complexity 
of the system. The optimum protein loading of the lead formulation of around 50-62.5 % was 
derived from an accelerated short-term stability study conducted at 40 °C over 4-8 weeks. 
Higher protein load resulted in increased amounts of soluble aggregates detected via HP-SEC 
and SDS-PAGE. Alterations of the tertiary protein structure were not observed in 2nd-derivative 
UV and intrinsic fluorescence spectra. Overall, the mAb2 formulated as PCMCs provided good 
storage stability especially in comparison to corresponding liquid formulations. Besides 
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aggregation phenomena, these antibody solutions were prone to fragmentation that was 
successfully inhibited in PCMCs representing an effective way of protein stabilization in the 
solid state. 
1 Introduction 
The increasing importance of biopharmaceuticals on the pharmaceutical market is evident. 
According to VFA (Verband Forschender Arzneimittelhersteller e.V.) data, sales volume of 
biopharmaceuticals on the German market reached nearly 5.4 billion Euros in 2011 [1]. Nearly 
every fourth new licensed drug is currently a therapeutic protein [2]. Especially the class of 
monoclonal antibodies (mAbs) as therapeutics is of high interest because they are considered 
to be safe drugs due to their specific interactions with the body’s own toolkit of proteins [3]. 
The major aspect addressed during formulation development of a new biological entity is the 
stabilization of the protein’s structure and its monomeric state during storage to ensure drug 
efficacy and safety. It is known that proteins are more stable in the solid state than in aqueous 
solution [4]. The overall idea is that in the solid state the protein molecules’ mobility is reduced 
[5, 6] and through the addition of excipients physical dilution and separation of protein 
molecules is achieved [7]. Thus, protein-protein interactions which are a prerequisite especially 
for aggregation are reduced. Nevertheless, chemical and physical instabilities can occur in the 
solid state as well [5, 8] and need to be studied during formulation development. To date, the 
most widely used technique to obtain solid-state biopharmaceuticals is freeze-drying [8]. 
Lyophilization results in elegant cakes that are reconstituted with aqueous media prior to 
parenteral application. With biopharmaceutical powders alternative delivery routes, e.g. 
pulmonary or intradermal delivery, can be addressed. Such powders can be obtained by 
methods like spray-drying, spray freeze-drying, pulverization, supercritical fluid drying or 
precipitation [4].  
Benefits of the most commonly used techniques like freeze-drying and spray-drying are 
compromised by e.g. high acquisition costs and long process times. Therefore new methods for 
obtaining solid dosage forms of proteins are of interest. In this study, the innovative PCMC 
technology was employed to achieve pharmaceutically relevant powders. These so-called 
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protein-coated microcrystals are formed upon mixing an aqueous solution of protein and 
carrier with organic solvent in which the protein and carrier components co-precipitate due to 
low solubility [9]. An initial PCMC formulation development study for another monoclonal 
antibody (mAb1) resulted in a rather complex formulation containing several amino acids, a 
sugar and an inorganic salt component for mAb stabilization [10]. For future mAb product 
development, especially at early stages of development, a simplified platform technology 
would be of great benefit. 
Therefore, in our study we transferred this initial PCMC formulation to another mAb (mAb2) 
and aimed at reducing the complexity of the system. By subsequent elimination of single 
excipients the influence of each formulation component on mAb2 process stability was to be 
elucidated. Protein content, aggregation (turbidity, HP-SEC) and potential changes in tertiary 
protein structure (2nd-derivative UV and intrinsic fluorescence spectroscopy) were monitored. 
Furthermore, the protein load of the optimal formulation was to be maximized in an 
accelerated short-term storage stability study because often high doses (several mg/kg) in low 
volumes are required in the treatment with antibody therapeutics [11]. High concentration 
liquid protein formulations are associated with challenges such as pronounced aggregation 
tendencies, high viscosity and poor overall stability [11]. The comparison between the 
optimized mAb2 PCMC formulation and liquid formulations of the antibody should reveal 
possible stability advantages and disadvantages of the PCMC technology. 
2 Materials and methods 
2.1 Materials 
Chemicals employed during this study included glycine, L-histidine hydrochloride monohydrate, 
L-histidine, L-arginine (Ajinomoto OmniChem, Louvain-la-Neuve, B), disodium EDTA dihydrate, 
acetic acid 100 % (Merck, Darmstadt, D), trehalose dihydrate (Ferro Pfanstiehl, Waukegan, IL, 
USA), sodium chloride (Akzo Nobel, Hengelo, NL), polysorbate 20 (Croda, Nettetal, D), 
ammonium sulfate, sodium hydroxide, L-phenylalanine from non-animal source, isopropyl 
alcohol Chromasolv® for HPLC (Sigma-Aldrich, Steinheim, D), sodium dodecyl sulfate (Serva, 
Heidelberg, D), methanol (Avantor, Deventer, NL), dithiothreitol (Biomol, Hamburg, D) and 
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MOPS (3-(N-morpholino)-1-propanesulfonic acid) (Carl Roth, Karlsruhe, D). For pH adjustments, 
Titrisol® Hydrochloric acid 0.1 M (Merck, Darmstadt, D) and 85 % ortho phosphoric acid (Fluka, 
Buchs, CH) were used. The anti-solvent isobutanol (Emplura® quality) was purchased from 
Merck (Darmstadt, D). Carbon dioxide was procured from Sauerstoffwerk Friedrichshafen 
(Friedrichshafen, D). All chemicals were utilized without further purification. 
The protein bulk drug substance composed of 10.1 mg/mL mAb2 in 25 mM citrate buffer pH 6.0 
containing 115 mM sodium chloride and 0.2 mg/mL polysorbate 20 was provided by Boehringer 
Ingelheim. 
2.2 Methods 
2.2.1 Preparation of protein solutions 
For the manufacturing of PCMCs, the buffer of the bulk drug substance was exchanged during 
ultra- and diafiltration resulting in a solution of 30-40 mg/mL mAb2, 40 mM histidine 
(formulation D no histidine), 20 mM trehalose dihydrate (formulation C no trehalose), 
0.2 mg/mL Di-Na-EDTA dihydrate and approx. 0.7 mg/ml polysorbate 20 (crossflow buffer 
exchange and concentration unit, Boehringer Ingelheim, Biberach/Riss, D; membrane cassette 
PESU Sartocon Slice, 30 kd, 0.1 m², Sartorius, Göttingen, D; Quattroflow 150 S membrane 
pump, Quattroflow Fluid Systems, Hardegsen, D). 
The preparation of liquid antibody formulations included 300fold buffer exchange 
(Slide-A-Lyzer® 20 K Dialysis Cassettes, Thermo Scientific, Rockford, IL, USA) of the protein bulk 
drug substance against 40 mM histidine buffer pH 5.5 containing 20 mM trehalose dihydrate 
and 0.2 mg/mL Di-Na-EDTA dihydrate at 22 ± 3 °C within 18 h, followed by concentration via 
centrifugation (Heraeus® Biofuge® primo, Carl Roth, Karlsruhe, D) in filtration units (Amicon® 
Ultra-15 Ultracel-30k, Millipore, Schwalbach, D) to 10, 50, 75 and 100 mg/mL protein. Samples 
were filtered through a 0.22 µm filter (73 mm, PES membrane, Millipore, Billerica, MA, USA). 
2.2.2 PCMC production process 
The PCMC production process is divided into four main steps: preparation of protein-carrier 
solution, precipitation, concentration/solvent exchange, and drying. For the preparation of the 
protein-carrier solution, the carrier material was dissolved in water and the solution pH value 
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was adjusted to 5.5 prior to the addition of the protein solution. The composition of the 
protein-carrier solutions for the formulation screening with a consistent protein content of 
43.6 % and approx. 0.2 mg/mL polysorbate 20 is presented in Table 3-1. Elimination of one or 
several components led to an increase of the relative amount of the remaining carrier 
components (glycine, phenylalanine, sodium chloride, trehalose dihydrate) to ensure a constant 
solid content of the protein-carrier solutions of 25.7 mg/mL. For the accelerated short-term 
stability study, the protein content of the formulations with a solid content of 51.4 mg/mL was 
in the range from 25 to 75 % resulting in varying amounts of carrier components and 
polysorbate 20 concentration of approx. 0.3-0.8 mg/mL (Table 3-2). 
Table 3-1: Composition of protein-carrier solutions in the formulation screening [% w/w]. 
Excipient Initial formulation 
A 
(no 
phe) 
B 
(no 
NaCl) 
C 
(no 
tre) 
D 
(no 
his) 
E 
(no 
gly) 
F 
(no gly/ 
phe/NaCl) 
G 
(no 
gly/phe) 
mAb2 43.6 43.6 43.6 43.6 43.6 43.6 43.6 43.6 
L-Histidine HCl 
monohydrate 2.6 2.6 2.6 2.6 -- 2.6 2.6 2.6 
L-Histidine 0.5 0.5 0.5 0.5 -- 0.5 0.5 0.5 
NaCl 5.2 5.4 -- 12.2 5.5 7.4 -- 7.8 
Glycine 15.8 16.3 17.5 36.9 16.7 -- -- -- 
L-Phenylalanine 1.7 -- 1.9 4.1 1.9 2.5 -- -- 
Trehalose 
dihydrate 30.5 31.5 33.8 -- 32.3 43.3 53.2 45.4 
Di-Na-EDTA 
dihydrate 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
 
Table 3-2: Composition of protein-carrier solutions in the accelerated short-term storage 
stability study for optimization of protein load (PL) [% w/w]. 
Excipient 25 % PL 37.5 % PL 50 % PL 62.5 % PL 75 % PL 
mAb2 25.0 37.5 50.0 62.5 75.0 
L-Histidine HCl monohydrate 2.6 2.6 2.6 2.6 2.6 
L-Histidine 0.5 0.5 0.5 0.5 0.5 
NaCl 7.3 6.0 4.8 3.5 2.2 
Glycine 22.0 18.2 14.3 10.5 6.7 
Trehalose dihydrate 42.5 35.1 27.7 20.3 12.9 
Di-Na-EDTA dihydrate 0.1 0.1 0.1 0.1 0.1 
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The precipitation was carried out as described in detail by König [12]. Briefly, two equal streams 
of precipitating agent were mixed with one stream of protein-carrier solution in a small double 
jet impingement mixer of an inner diameter of 1.5 mm (Boehringer Ingelheim, Biberach/Riss, 
D). The mixing ratio of the precipitating agent, isobutanol saturated with all carrier 
components, and the protein-carrier solution was set to 95 : 5 (v/v). The modular mixing 
platform from Ehrfeld (Bayer Technology, Wendelsheim, D) encompassed three micro gear 
pumps (HNP pumps mzr 11507 and 7255, Hydraulik Nord Fluidtechnik, Parchim, D), pressure 
sensors and temperature sensors to monitor the precipitation step. The total flow rate of 
1000 mL/min was controlled by the software LabView (National Instruments, Munich, D) and 
Coriflow mass flow meters (Bronkhorst, Kamen, D). The final suspension volume after 
precipitation was 2 L for the formulation screening and 4 L for the accelerated short-term 
storage stability study. 
Solvent exchange was achieved by decanting the supernatant of the PCMC suspension 18 h 
after the precipitating step. The supernatant was replaced with fresh saturated isobutanol.  
After 24 h of sedimentation the sediment, i.e. the concentrated suspension, was used for the 
supercritical drying process (Thar SFE-500, Thar Technologies, Pittsburgh, PA, USA) with carbon 
dioxide at 100 bar and a flow rate of 25 g/min. After drying of 240 mL concentrated suspension 
within 90 min at 45 °C the pressure was decreased by 3 bar/min. Subsequently, vacuum drying 
of the PCMC powder was performed at 30 mbar and 40 °C for 2 h (APT.line™ VDL, Binder, 
Tuttlingen, D; diaphragm membrane pump MZ 2C, Vacuubrand, Wertheim, D). 
2.2.3 Accelerated short-term storage stability study of PCMC powder 
Vials were filled with 120 mg PCMC powder with protein loading rates of 25 %, 37.5 %, 50 %, 
62.5 % and 75 %, stoppered under lab atmosphere in the glove box, crimped and subsequently 
stored at 40 °C for eight (25 %, 50 % and 75 %) or four (37.5 % and 62.5 %) weeks (2 R Fiolax® 
vials, Schott, Mühlheim, D; Gusto C 1503 6720 GC grey 6 TP, Stelmi, Roissy Charles De Gaulle 
Cedex, France). PCMCs were analyzed for protein content, turbidity and monomer content 
directly after PCMC production (t0), after 7 (t7d), 14 (t14d), 28 (t28d) and 56 days (t56d). For 
formulations with loading rates of 25 %, 50 % and 75 % protein structure integrity was 
additionally monitored via 2nd-derivative UV scans, intrinsic fluorescence spectroscopy and SDS-
PAGE analysis at t0 and after 28 and 56 days.  
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2.2.4 Accelerated short-term storage stability study of liquid mAb2 formulations 
Under a laminar flow cabinet 2.0 mL of filtered mAb2 solutions with protein concentrations of 
10, 50, 75 and 100 mg/mL were filled into autoclaved 2R vials which were subsequently closed 
with 13 mm stoppers and crimped for storage at 40 °C (2 R Fiolax® vials, Schott, Mühlheim, D; 
Gusto C 1503 6720 GC grey 6 TP, Stelmi, Roissy Charles De Gaulle Cedex, France). Analysis of 
protein concentration, turbidity and monomer content was performed at t0, t7d, t14d, and t28d. 
2nd-derivative UV scans, intrinsic fluorescence spectroscopy and SDS-PAGE analysis were carried 
out at t0 and after 28 days.  
2.2.5 Analysis of PCMCs 
2.2.5.1 Turbidimetry 
60 min after dissolution of PCMC powder with deionized water, turbidity was measured at a 
protein concentration of 1 mg/mL by 90 ° light scattering at λ = 633 nm (UH turbidimeter, 
Boehringer Ingelheim, self-construction) and expressed in formazine nephelometric units 
(FNU). For turbidity measurement of liquid antibody formulations, undiluted protein solutions 
were employed. Mean values and standard deviations from three duplicates per formulation 
were calculated. 
2.2.5.2 Protein concentration and protein recovery via UV measurement 
PCMC powder was dissolved in deionized water to give a concentration of approx. 0.4 mg/mL 
to ensure absorption within the linear range of the spectrometer (0.3 to 0.8 AU). 60 min after 
reconstitution, the solution was filtered through a 0.45 µm syringe filter (Rotilabo-Spritzenfilter 
steril 0.45 µm PVDF, Carl Roth, Karlsruhe, D) to provide a particle-free sample. Liquid mAb2 
formulations were diluted in deionized water resulting in a protein concentration of approx. 
0.4 mg/mL. Absorption in Halfmicro Plastibrand® cuvettes (Brand, Wertheim, D) was measured 
at 279 nm based on an extinction coefficient of 1.72 with a Lambda 20 spectrometer 
(PerkinElmer, Rodgau-Jügesheim, D) and deionized water serving as blank. Protein recovery 
was calculated as the quotient of the antibody concentration in the sample to the theoretical 
protein concentration based on the antibody fraction in the total solid mass of the protein-
carrier solution. Mean values and standard deviations from three triplicates per formulation 
were calculated. 
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2.2.5.3 Protein aggregation and fragmentation via high performance size exclusion 
chromatography (HP-SEC) 
60 min after reconstitution of PCMC powder in deionized water, the solution was filtered 
through a 0.45 µm syringe filter (Rotilabo-Spritzenfilter steril 0.45 µm PVDF, Carl Roth, 
Karlsruhe, D) and 50 µl samples of 2.0 mg/mL protein were injected in duplicate. Liquid mAb2 
formulations were diluted with histidine buffer to give a final protein concentration of 
10 mg/mL, filtered (0.45 µm) and injected (10 µl) in duplicate. Soluble protein aggregates, 
monomers and fragments were separated on an Äkta micro (GE Healthcare, Uppsala, S) with a 
TSKGel G3000 SWXL column (7.8 mm ID x 30.0 cm L, Tosoh, Stuttgart, D), equipped with a 40 x 
6.0 mm TSKgel SWXL Guardcol precolumn. Filtered (0.22 µm) and degassed mobile phase with 
a pH of 7.3 consisted of 200 mM L-arginine, 120 mM ammonium sulfate and 10 % isopropanol 
in deionized water. At a flow rate of 0.5 mL/min UV detection was performed at 280 nm. 
Aggregation and fragmentation in percent was calculated based on the ratio of the area under 
the curve (AUC) of soluble aggregates and fragments to the total AUC of aggregates, monomer 
and fragments (n=2). Relative monomer content in % was defined in reference to the monomer 
content of the protein-carrier solution prior to precipitation which was set to 100 %. 
2.2.5.4 Protein aggregation and fragmentation via SDS-PAGE 
SDS-PAGE was conducted at 200 V with Power Ease 500 and XCell Sure Lock in combination 
with 12 % Bis-Tris gels (NuPAGE®, 1 mm, 10 wells, Invitrogen, Darmstadt, D) and NuPAGE® 
MOPS SDS running buffer. Samples were mixed 8:2 with NuPAGE® LDS sample buffer, and 7:2:1 
with NuPAGE® LDS sample buffer and 0.5 M dithiothreitol for the reducing SDS-PAGE. After 
heating up to 95 °C for 5 min, 5 µl of the samples and the marker (Precision Plus Protein 
Standard, Bio-Rad, Hercules, CA, USA), representing 1 µg protein, were loaded to each well. 
Furthermore, 2 ng BSA were loaded to one well for the purpose of sensitivity control. The gels 
were stained with SilverXpress® Silver Staining Kit. All equipment was from Invitrogen 
(Darmstadt, D). 
2.2.5.5 Protein structure via intrinsic fluorescence spectroscopy 
Samples of 0.1 mg/mL protein in SUPRASIL® 114-QS precision cuvettes (10 mm, Hellma, 
Mühlheim, D) were excited at 295 nm and 25 °C and the emission was scanned from 305 nm 
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to 400 nm with a step size of 1 nm and 1 s integration time (Fluorimeter QM-4-CW, PTI, 
Birmingham, NJ, USA). The evaluation was based on normalized spectra (n=3). 
2.2.5.6 Protein structure via 2nd-derivative UV spectroscopy 
Samples, diluted to 0.3 mg/mL protein with deionized water, were scanned from 240 to 350 nm 
against deionized water as blank (UV/VIS Spectrometer Lambda 20, PerkinElmer, Rodgau-
Jügesheim, D). The second derivative of the absorption was used (n=3). 
2.2.5.7 Quantification of trehalose by high performance liquid chromatography 
(HPLC) 
Lower molecular weight substances, such as trehalose and the amino acids, were separated 
from protein via centrifugation (Heraeus® Biofuge® primo, Carl Roth, Karlsruhe, D). The 
filtration units (Amicon® Ultra-0.5 Ultracel-10k, Millipore, Schwalbach, D) were rinsed with 
0.5 mL 0.1 N NaOH and subsequently equilibrated with dissolved PCMCs containing 2 mg/mL 
mAb2 in deionized water at 12000 g for 10 min. 0.5 mL samples of dissolved PCMCs with 
2 mg/mL protein were subsequently separated at 12000 g for 10 min. The filtrate was checked 
for protein residues via UV absorption and analyzed (2 x 40 µl) by HPLC using a Rezex RCM 
Monosaccharide Ca2+ 300 x 7.80 mm column with guard column (SecurityGuard Cartridges 
Carbo-Ca 4 x 3.0 mm, Phenomenex, Torrance, CA, USA) at 85 °C. Filtered HPLC-water 
(Chromasolv® plus, Sigma-Aldrich, Steinheim, D) was used for elution at a flow rate of 
0.6 mL/min. Detection was performed via changes in refractive index (RI). The trehalose RI 
signal between 5.5 and 6.9 mL was integrated and the trehalose content was calculated using 
the linear calibration curve for concentrations up to 4 mg/mL (n=3). 
2.2.5.8 Particle size via laser diffractometry (LD) 
The particle size was determined in suspension by laser diffractometry (OASIS equipped with 
HELOS/BF, CUVETTE CUV-50ML/US, SUCELL/M, SVA, Sympatec, Clausthal-Zellerfeld, D). PCMC 
powder or suspension was added until an optical concentration of about 5 % was reached in 
the cuvette that contained 50 mL of saturated isobutanol at a stirring intensity of 60 %. Based 
on Fraunhofer model the particle size distribution was calculated and expressed as volume 
distribution (Q3). The mean value was ciphered (n=3). 
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2.2.5.9 Particle morphology via scanning electron microscopy (SEM) 
Particle morphology of PCMC powder was analyzed by the use of a scanning electron 
microscope (Model Tescan Vega II SBH, Tescan, Brno, CZ). Samples were prepared on an 
aluminum stub and coated with gold/palladium (Model Cressington 108auto/SE Cool Sputter 
Coater, Cressington, Watford, GB). 
2.2.5.10 Crystallinity via x-ray powder diffraction (XRD) 
The crystallinity of mAb2 PCMCs was analyzed with XRD in transmission mode from 
3 °- 40 ° 2 Θ, 0.5 ° steps and 20 s/step based on 1.5406 Å CuKα-radiation at 40 kV and 
40 mA (Stoe, Darmstadt, D). Samples were fixed in the sample holder between two Ultraphan 
foils (cellulose diacetate) with a thickness of 0.014 mm (Stoe, Darmstadt, D). 
2.2.5.11 Zeta potential measurement 
ζ-potentials of protein-carrier solutions of the initial formulation and formulation B (no NaCl) 
were measured with a Malvern Zetasizer nano ZS (Malvern Instruments, Malvern, UK). 
Measurements in folded capillary cell DTS 1060 cuvettes were performed in triplicates with a 
total of 100 single measurements per run at 20 °C. 
3 Results and discussion 
3.1 Formulation screening 
Based on the initial formulation, the influence of each excipient on PCMC powder properties 
and mAb2 process stability was tested by elimination of single components as well as carrier 
combinations. The aim was to minimize the number of carrier components in order to reduce 
the complexity of the system while obtaining PCMC powders of high quality at the same time. 
PCMC powder was analyzed for particle size and morphology. Quality features with respect to 
protein process stability encompassed low turbidity values, high monomer contents, limited 
aggregate formation and preservation of tertiary mAb2 structure. 
3.1.1 Characterization of PCMC powder 
Based on their macroscopic appearance, mAb2 PCMC powders were subdivided into three 
groups (Table 3-3). Formulations that included both sodium chloride and trehalose (group 1) 
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resulted in smooth and voluminous, but agglomerated powders of poor flowability. As 
described by Chew and Chan, agglomerates are formed due to inherently strong cohesive 
forces between micro- or nanometer-sized particles [13]. Variations concerning the other 
components resulted in only minor changes concerning powder performance. Formulation 
D (no his) appeared slightly more compact and clumpy, whereas formulations E (no gly) and 
G (no gly/phe) revealed extremely poor flowability due to electrostatic particle interactions and 
adhesion to vial walls. Formulations B (no NaCl), F (no gly/phe/NaCl) and C (no tre), without 
sodium chloride or trehalose, differed from these PCMC powders. MAb2 PCMC powders lacking 
sodium chloride (group 2) were of granulous character with enhanced flowability. Formulation 
C (no tre) formed smooth, shiny needle-like crystals of poor flowability. 
Table 3-3: Macroscopic appearance of mAb2 PCMC powder in the formulation screening. 
Group 1 2 3 
Formulations 
Initial formulation, 
A (no phe), D (no his), 
E (no gly), G (no 
gly/phe) 
B (no NaCl), 
F (no gly/phe/NaCl) C (no tre) 
Macroscopic 
appearance 
Description 
smooth, voluminous, 
poor flowability, forms 
agglomerates 
granulous, enhanced 
flowability 
smooth, shiny, needle-
like crystals, poor 
flowability 
 
Visually detected differences between these three groups were also observed microscopically. 
Figure 3-1a shows a SEM image of formulation A representing all other formulations of group 1 
which contained trehalose and sodium chloride. Spherical particles with an appearance similar 
to spray-dried products [4, 14, 15] were found. The surface of mAb2 PCMCs without sodium 
chloride appeared less crisp and rather molten (Figure 3-1b). The SEM image of the formulation 
without trehalose clearly showed large and crystalline saw-like structures (> 100 µm) next to 
smaller spherical particles (Figure 3-1c). 
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a  b  
c  
Figure 3-1: SEM images of mAb2 PCMC powders of (a) formulation A (representing powders 
of group 1), (b) formulation B (representing powders of group 2) and (c) formulation C 
(group 3) in the formulation screening. 
The particle size of mAb2 PCMC powders containing trehalose and sodium chloride (group 1), 
determined via laser diffractometry, was smaller than that of group 2 and 3 (Figure 3-2). 
Moreover, x50 values gained from suspensions and PCMC powders of group 1 did not correlate 
because the particle size in suspension was bigger (3.7-5.8 µm) than in the final powder (1.9-
2.0 µm). This effect was associated with the presence of particle agglomerates in the 
suspensions that were dispersed during the supercritical drying process. 
Elimination of sodium chloride resulted in very small suspension particles of about 1 µm for 
formulation B (no NaCl) and F (no gly/phe/NaCl). These particles showed very poor 
sedimentation/concentrating behavior and, consequently, solvent exchange could not be 
performed before drying. The higher x50 values for the corresponding PCMC powders 
(B: 7.0 µm, F: 30.0 µm) were consistent with the granulous macroscopic appearance and were 
caused by compaction of the small suspended particles during the drying process. The 
assumption that sodium chloride may lead to an increase in particle size in suspension due to 
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shielding of repulsive electrostatic charges [16] could not be confirmed. Protein-carrier 
solutions of both the initial formulation and formulation B without sodium chloride had similar 
ζ-potentials of 7 to 8 mV. Therefore, it is more likely that sodium chloride somehow acted as a 
nucleation enhancer during the PCMC formation process. Nucleation and growth as well as 
spinodal decomposition are possible particle formation mechanisms [16]. In short, the favored 
spinodal decomposition mechanism can be understood as a phase separation and partitioning 
process which is followed by crystallization. Vos also stated that salts enhanced binding of 
protein to PCMCs and should be of great benefit for the formulation of proteins with this 
technology [16]. 
 
Figure 3-2: Particle sizes of mAb2 PCMCs in suspension and powder as determined by LD 
measurements: A (no phe), B (no NaCl), C (no tre), D (no his), E (no gly), F (no gly/phe/NaCl), 
G (no gly/phe); particle size of PCMC suspensions was determined before solvent exchange. 
In accordance with macroscopic and microscopic observations, LD data confirmed the presence 
of large particles in formulation C that was prepared without trehalose. The continuous 
increase in particle size from approx. 71 µm in suspension before the concentration/solvent 
exchange step to 103 µm after concentration/solvent exchange and to 137 µm after drying 
pointed to secondary particle growth during PCMC manufacturing (Figure 3-2). X-ray 
diffractometry of the PCMC powder revealed that the large crystals were made of α-glycine 
(Figure 3-3). Glycine is a rapidly crystallizing amino acid [12] and poor glass former [6], but its 
crystallization could be inhibited by the addition of trehalose. Glycine usually precipitates as the 
kinetically controlled β-polymorph during the PCMC production process, but transition into α-
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glycine and finally the most stable γ-form occurs upon exposition to moisture [10]. With respect 
to mAb PCMCs, König reported that this transformation was accompanied by a loss of protein 
integrity [12]. Inhibition of glycine crystallization during lyophilization in the presence of 
trehalose was also reported by Chatterjee et al. [17]. In that case, the prevention of glycine 
crystallization required a weight ratio of glycine to trehalose dihydrate ratio of > 1. For mAb2 
PCMCs, however, a weight ratio of glycine to trehalose dihydrate of 0.5 was sufficient to inhibit 
crystallization of the disaccharide. 
 
Figure 3-3: XRD spectra of mAb2 PCMCs; spectrum assignment: I: α-glycine; 
II: formulation C (no tre); III: initial formulation; arbitrary offset for better comparison. 
Rapid precipitation by anti-solvent addition is discussed as familiar route towards the 
amorphous state [6]. Although no traces of crystallinity were detected for the initial 
formulation in XRD analysis (Figure 3-3) and SEM images were similar to those of amorphous 
spray-dried products, not only an amorphous but also a microcrystalline state could be 
hypothesized for these PCMC powders. Attempts to determine glass transition temperatures 
with DSC and thus to confirm the amorphous state [18] for the initial formulation as well as 
formulations A (no phe), B (no NaCl) and F (no gly/phe/NaCl) failed. On the other hand, strong 
glass formers like proteins often show only very small changes in heat capacity at Tg and 
complex mixtures can lead to a broadening of the glass transition event due to nonidealities, so 
that detecting Tg can be difficult [19]. In any case, truly crystalline protein-coated microcrystals 
5 10 15 20 25 30 35 40
0
20
40
60
80
100
120
140
160
180
III
II
I
 
 
R
el
at
iv
e 
in
te
ns
ity
 [%
]
Diffraction angle 2 Theta [°]
Chapter 3 
67 
as defined by the inventors of this technology [9] were not achieved with the present mAb2 
formulation. 
3.1.2 Protein process stability 
Surfactants, such as polysorbate 20 and 80, frequently used in antibody formulation, are known 
to influence protein stability [20, 21]. With respect to mAb2 PCMCs, it has to be considered that 
these surfactants were assumed to be removed by the PCMC precipitation step due to their 
solubility in aliphatic alcohols [22], such as isopropanol, and that they were most likely not 
included in the final mAb2 powders. 
The observation that PCMCs lacking trehalose or sodium chloride (formulations C, B, F) differed 
from all other formulations was confirmed by protein recovery, aggregation data and turbidity 
(Table 3-4). For formulation C (no tre), only 71.1 % of the theoretical mAb2 content based on 
complete precipitation was recovered in the PCMC powder, indicating incomplete precipitation 
of the antibody in the absence of trehalose. In HP-SEC, an increase of higher molecular weight 
species by 1.2 % to 1.6 % and of dimers by 2.6 % to 3.9 %, compared to the initial formulation 
of the antibody, was found when trehalose was omitted from the formulation. Moreover, the 
stabilizing effect of trehalose against protein aggregation was not limited to soluble protein 
species, as detected via turbidity measurement, which is frequently applied in formulation 
development and purification of therapeutic proteins to detect insoluble protein aggregates 
[23, 24]. A high turbidity value of 48.8 FNU was revealed in the absence of trehalose, opposed 
to 5.6 FNU for the initial formulation containing the disaccharide. Hence, trehalose prevented 
the antibody from the formation of insoluble protein particles during the PCMC manufacturing 
process. The augmented level of insoluble protein particles could also explain, at least partially, 
the reduced protein recovery because this protein fraction was assumed to be removed via 
filtration during sample preparation for UV measurement. Sugars in general, commonly used as 
stabilizers during lyophilization, are expected to physically stabilize the protein in the solid state 
either thermodynamically via formation of hydrogen bonds with the protein (water substitution 
hypothesis) or by a kinetic mechanism based on immobilization (glass dynamics hypothesis) [5]. 
Trehalose has successfully been introduced as stabilizing agent in a number of solid antibody 
dosage forms including lyophilisates [25, 26], spray-dried formulations [27, 28], spray freeze-
dried particles [29] and protein powder generated via spray-drying in supercritical CO2 [30]. 
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Nevertheless, its superiority especially over sucrose is unproven, although addition of trehalose 
usually leads to higher Tg values which are considered to be beneficial for storage stability [6]. 
In the case of mAb2 PCMCs, the stabilizing effect of trehalose, representing an indispensable 
formulation component, was attributed to the formation of a glassy matrix discussed in 
section 3.1.1. 
Table 3-4: Protein recovery, monomers, dimers, higher molecular weight aggregates and 
turbidity of mAb2 PCMCs; * PCMC powder B (no NaCl) and F (no gly/phe/NaCl) did not 
completely dissolve in deionized water, therefore turbidity could not be measured (n.m.) and 
the values of monomers, dimers and higher molecular weight aggregates refer to the soluble 
protein fraction. 
 
Protein 
recovery 
[%] 
Monomers 
[%] 
Dimers 
[%] 
Higher 
molecular 
weight 
aggregates 
[%] 
Turbidity 
[FNU] 
Initial formulation 129.2 ± 3.3 98.4 ± 0.1 1.3 ± < 0.1 0.4 ± < 0.1 5.6 ± 0.6 
A (no Phe) 128.3 ± 3.4 99.0 ± < 0.1 1.0 ± < 0.1 < 0.1 13.5 ± 2.1 
B (no NaCl)* 83.8 ± 2.6 98.8 ± 0.1 1.2 ± 0.1 < 0.1 n.m. 
C (no tre) 71.1 ± 4.4 94.5 ± < 0.1 3.9 ± < 0.1 1.6 ± < 0.1 48.8 ± 2.5 
D (no his) 132.9 ± 2.1 96.9 ± 0.1 2.2 ± 0.1 0.9 ± < 0.1 10.6 ± 2.0 
E (no gly) 125.1 ± 3.0 97.3 ± 0.1 1.8 ± 0.1 0.9 ± < 0.1 5.5 ± 1.0 
F (no gly/phe/NaCl)* 95.1 ± 3.0 98.7 ± 0.4 1.3 ± 0.4 < 0.1 n.m. 
G (no gly/phe) 135.0 ±1.0 96.3 ± < 0.1 2.1 ± < 0.1 1.6 ± < 0.1 4.5 ± 0.5 
 
The absence of NaCl did not only affect the particle size and morphology of PCMCs, as 
discussed in section 3.1.1, but also mAb2 process stability (Table 3-4). The reduced protein 
recovery of 83.8 % (formulation B: no NaCl) and 95.1 % (formulation F: no gly/phe/NaCl) was 
caused by incomplete dissolution behavior of the powder in deionized water indicating the 
formation of insoluble protein particles. These particles were eliminated via filtration during 
sample preparation for UV measurement. Due to sedimentation of the particles, the aqueous 
suspension was not stable and thus turbidity could not be measured reliably. The level of 
soluble protein particles assessed via HP-SEC, however, was not influenced by the elimination 
of NaCl as the aggregate levels of both formulation B (no NaCl) and F (no gly/phe/NaCl) were 
not increased compared to the initial formulation. The AUC normalized to the protein 
concentration of the samples did not differ from the data of the initial formulation either. 
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Hence, NaCl was suggested to play a key role in the formulation of PCMCs because it prevented 
the antibody from forming substantial amounts of insoluble aggregates. Thus, NaCl could not 
be eliminated from the mAb2 formulation. Due to multiple mechanisms of interacting with 
protein molecules and of affecting protein-protein interactions, including preferential binding 
and charge-shielding effects, the use of salts can result in both stabilization and destabilization 
of protein formulations [31-33]. NaCl is included in many marketed antibody formulations 
representing either liquid or lyophilized dosage forms, as listed by Wang et al. and Daugherty 
and Mrsny [21, 34]. 
Amino acids are the excipients with the highest weight fraction in PCMCs. All formulations that 
lacked one (A, D, E) or two amino acids (G) showed a protein recovery ranging from 125.1 % to 
135.0 % (Table 3-4), comparable to the initial formulation (129.2 %). These high values above 
100 % indicated that the loss of carrier material during the PCMC production process was 
relatively more pronounced than a potential protein loss. HPLC analysis of the carrier fraction 
revealed that the high protein recovery was associated with significantly reduced trehalose 
contents. Exemplarily, trehalose recoveries were 87.4 and 84.5 %, respectively, for the initial 
formulation and formulation A (no phe). Incomplete precipitation was attributed to the 
trehalose concentration (8.1-13.7 mg/mL) in the protein-carrier solutions that was far below 
the solubility limit (50 g/L) of the disaccharide due to low total solid content of the solutions 
[35]. The level of both higher molecular weight aggregated species and dimers increased by 0.5-
1.2 % and 0.5-0.9 % at the expense of monomers, when histidine, glycine or the combination of 
phenylalanine and glycine were omitted from the formulation. On the contrary, the elimination 
of only phenylalanine slightly reduced both the higher molecular weight aggregated species and 
the dimer amount. The turbidity of the formulations A (no phe) and D (no his), was slightly 
higher, with values of 13.5 FNU and 10.6 FNU, whereas for the formulations E (no gly) and 
G (no phe/gly) turbidity values (5.5 FNU and 4.5 FNU) similar to the initial carrier formulation 
were detected. Furthermore, the absence of histidine, acting as buffering agent, significantly 
increased the pH of reconstituted mAb2 PCMCs. Dissolving formulation D PCMCs (no his) in 
deionized water resulted in a pH value of 7.4, as opposed to pH 6.4-6.6 detected for all other 
completely soluble formulations (initial formulation, A, C, E, G). Thus, the pH of histidine-free 
formulations was governed by the pI of the antibody, being 7.8-8.4. Therefore, histidine buffer 
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was considered to be essential in the formulation of mAb2 PCMCs. This amino acid is reported 
to protect antibodies against aggregation and structural perturbation during lyophilization [36, 
37]. Amongst the amino acid formulations investigated in their FTIR studies of a lyophilized 
monoclonal antibody, Tian et al. found histidine to be an effective amino acid in inhibiting 
changes in protein secondary structure [38]. Arakawa et al. speculated that the stabilizing effect 
of histidine during protein lyophilization is attributed to its tendency to become amorphous in 
combination with the ability of protein binding [39]. With respect to mAb PCMCs, histidine was 
also assumed to be amorphous after precipitation and subsequent supercritical drying because 
crystals were not seen in SEM nor did XRD analysis show any peaks. 
Glycine is routinely used as co-freeze-drying excipient in protein formulations due to its ability 
to form a strong, porous and elegant cake structure in the final lyophilized product [25, 40]. As 
discussed in section 3.1.1, it exists in several polymorphous forms. During lyophilization, glycine 
had protective effects on antibody stability only if retained amorphous [37]. In the case of 
mAb2 PCMCs, glycine crystallized in the absence of trehalose resulting in significantly reduced 
monomer level, whereas amorphous glycine prevented the protein from aggregation and thus 
represented an obligatory component of the formulation. 
Regarding the specific role of phenylalanine in protein formulations, Mattern et al. reported 
that arginine/phenylalanine glasses enhanced process and storage stability of vacuum-dried 
LDH and rhG-CSF and suggested that sugar-free amino acid formulations were potential 
stabilizers for proteins [41]. In the formulation development of mAb2 PCMCs, the elimination of 
phenylalanine resulted in a slightly higher absolute monomer content than in the initial 
formulation, but also in an increase in turbidity. For this reason, both formulations were further 
investigated in the course of an accelerated short-term stability study. The exclusion of 
phenylalanine would at least partially reduce the complexity of the mAb2 PCMCs. All other 
carrier components were needed to provide maximal protein process stability. Sodium chloride 
was necessary in terms of manufacturability and aggregation. The addition of trehalose as well 
as glycine and histidine were pivotal for protein stabilization towards aggregation, too. 
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3.1.3 Selection of the lead formulation via accelerated short-term storage stability 
study 
A short-term stability study was conducted over eight weeks at 40 °C to identify potential 
differences between the initial formulation and formulation A (no phe) with a protein load of 
50 % and a solid content of 51.4 mg/mL. Analysis of protein content, turbidity and monomer 
content was performed at t0, t7d, t14d, t28d and t56d. Moreover, tertiary protein structure was 
studied via 2nd-derivative UV and intrinsic fluorescence spectroscopy at t0 and after 28 and 
56 days. 
 (a) (b) 
  
Figure 3-4: (a) Protein recovery, turbidity and (b) monomer content of the initial formulation 
and formulation A (no phe) stored at 40 °C for 8 weeks. 
Protein content, turbidity values and monomer contents for both powders were comparable 
and constant during the course of the study (Figure 3-4). No differences in tertiary structure 
were detected at any time point. Thus, the elimination of phenylalanine did not have any 
detrimental effects on mAb2 PCMC powder storage stability, additionally to powder properties 
and protein process stability discussed in detail in sections 3.1.1 and 3.1.2. Based on these 
results, formulation A was subsequently chosen as lead formulation for further studies due to 
its reduced complexity. 
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3.2 Optimization of protein load via accelerated short-term storage stability 
study 
Short-term stability studies are most commonly conducted at elevated temperatures as 
degradation rates usually increase with increasing temperature. The idea is that data analysis 
based on an Arrhenius’ plot allows estimation of stability at ambient temperature [42]. Wang 
pointed out that such an extrapolation is generally problematic with antibodies due to the 
presence of complex and multiple degradation pathways which may have different degrees of 
temperature dependency [21]. Moreover, stability studies with amorphous solids should 
usually be carried out below the glass transition temperature of the formulation as degradation 
kinetics above Tg are not comparable to those below Tg [5, 43]. Based on standards defined by 
the World Health Organization (WHO), the aggregate level in commercial intravenous 
immunoglobulin products should not exceed 5 % upon administration [21]. This aggregate 
content must further be ensured over a shelf life of 18 months which is usually the minimum 
requirement for protein pharmaceutical products [7]. 
Accelerated short-term storage stability studies performed for mAb2 PCMCs were not intended 
to draw conclusions about room temperature stabilities, but aimed to identify the most stable 
PCMC composition more rapidly and clearly. To determine the optimal protein load, mAb2 
PCMCs based on the lead formulation (section 3.1.3) with protein loadings of 25, 37.5, 50, 62.5 
and 75 % were stored at 40 °C for either eight (25, 50 and 75 % protein load) or 4 weeks (37.5 
and 62.5 %). PCMCs were analyzed for protein content, turbidity and monomer content at t0, 
t7d, t14d, t28d and t56d. For formulations with loading rates of 25, 50 and 75 %, protein structure 
and integrity were additionally monitored via 2nd-derivative UV scans, intrinsic fluorescence 
spectroscopy and SDS-PAGE analysis after 0, 28 and 56 days of storage. PCMC particle size and 
morphology were characterized directly after manufacturing. SEM pictures were additionally 
taken at t0 and after 4 weeks of storage to assess potential carrier and morphology instability. 
3.2.1 Characterization of powder properties and morphology stability 
Macroscopic evaluation of PCMC powders revealed that powders with low protein loadings (25 
and 37.5 %) were very smooth and voluminous with relatively good flowability. With increasing 
protein content the powders were grainier and elicited worse flowability characteristics. At the 
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same time, in accordance with literature, laser diffractometry revealed decreasing particle size 
with increasing protein load (Figure 3-5a) [10, 16]. Furthermore, the bulk density of the 
powders increased as well (Figure 3-5b). This was consistent with the rather compact 
macroscopic appearance of the powder with a protein loading of 75 %. Usually, flowability 
correlates with particle size because with decreasing particle size interparticular attraction 
forces increase, causing agglomerate formation and reducing flowability [13]. 
 (a) (b) 
  
Figure 3-5: MAb2 PCMCs (lead formulation) with varying protein load; (a) particle size via LD 
measurements; particle size of PCMC suspensions was determined after solvent exchange; 
(b) vials filled with 120 mg PCMC powder; from left to right: protein loading of 25 %, 37.5 %, 
50 %, 62.5 % and 75 %. 
PCMCs with protein loadings of 25 %, 50 % and 75 % were further evaluated using scanning 
electron microscopy (Figure 3-6a-c). The samples with a protein loading of 25 % showed rather 
molten textures in comparison to the more crisp appearance of the samples with 50 % protein 
loading. As expected, the morphology of this latter sample was similar to the powders of 
group 1 during formulation screening (see section 3.1.1) because the lead formulation selected 
was allocated to this group and had a comparable protein load. Moreover, donut-shaped 
particles, also described for spray-dried antibody formulations [4, 15], were found within all 
samples, most pronounced in the powder with 75 % protein load (Figure 3-6c). 
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a  b  
c  d  
Figure 3-6: SEM images of mAb2 PCMC powders (lead formulation) at (a-c) t0 with a protein 
loading of (a) 25 %, (b) 50 %, (c) 75 % and at (d) t28d with a protein loading of 50 %. 
Besides protein stability, the carrier and morphology stability of PCMC formulations need to be 
addressed during accelerated short-term storage studies because they often correlate (see 
chapter 2 section 4.3.2). Referring to mAb2 coated microcrystals, SEM pictures taken after 
4 week storage did not provide any indication of excipient recrystallization or collapse either, as 
exemplarily shown for the powder with 50 % protein load (Figure 3-6d). 
3.2.2  Protein storage stability 
As mentioned above, the most critical parameter that defines product shelf life of protein 
therapeutics is aggregation. Aggregation should be kept to a minimum as especially large, 
insoluble and irreversible aggregates are considered of being immunogenic [44, 45]. Turbidity 
measurements and visual inspection are the analytical methods of choice to detect large and 
insoluble particles, although they are not specific for protein aggregates [46]. The presence of 
detectable smaller and soluble aggregates in a formulation has to be seen as a warning for 
potential immunogenicity issues, too. Richard described such multimers as “the signature of 
aggregation-competent species” [45]. 
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Apart from a slightly decreased protein recovery after seven days for protein loadings of 25 %, 
50 % and 75 %, protein recovery was found to be consistent, irrespective of the protein content 
(Figure 3-7).  A decrease in protein recovery might point to protein loss due to removal of large 
soluble and insoluble protein aggregates by sample filtration (0.45 µm) prior to UV 
measurements. However, aside from single fibers probably introduced during supercritical 
drying, the colorless samples were free from visible insoluble particles, as confirmed by 
turbidity measurement, and the AUC in HP-SEC was not impacted either (see below). 
 
Figure 3-7: Protein recovery of mAb2 PCMCs (lead formulation) with varying protein load 
stored at 40 °C. 
No significant increase in turbidity was detected after four and eight weeks of storage, 
respectively. Turbidity values for all samples were low, between 0.4 and 2.4 FNU (Figure 3-8). 
Thus, turbidity was significantly lower than that of reference suspension I of the European 
Pharmacopoeia which exhibits a value of 3 NTU and which indicates a clear solution [47]. 
Hence, independent of the protein load, all PCMC samples were free of larger amounts of 
insoluble protein aggregates. 
0 10 20 30 40 50 60
0
10
80
90
100
110
120
 
 
Pr
ot
ei
n 
re
co
ve
ry
 [%
]
Storage time [d]
 25 %
 37.5 %
 50 %
 62.5 %
 75 %
Formulation of a therapeutic monoclonal antibody via PCMC technology 
76 
 
Figure 3-8: Turbidity of mAb2 PCMCs (lead formulation) with varying protein load stored at 
40 °C. 
Monomer content analysis via HP-SEC revealed significant differences in storage stability with 
respect to aggregation in dependence of protein loadings (Figure 3-9). Monomer degradation 
of samples with protein loadings of up to 62.5 % was minimal or not existent. Over 4 or 8 weeks 
storage, the monomer contents of these formulations varied only by maximal 1.3 %. Monomer 
loss was clearly more pronounced for PCMCs with a protein content of 75 %. A decrease by 
3.7 % was detected within eight weeks. Thus, this formulation did not provide sufficient 
stability of the antibody with respect to the formation of soluble aggregates [48]. According to 
the HP-SEC results of the formulation screening (section 3.1.2), the decrease of the monomer 
content was associated with an increase in both higher molecular weight species and dimers for 
all samples investigated. Fragmentation of the antibody was not observed. The AUC normalized 
to the protein concentration of the samples was not affected, irrespective of protein load and 
storage time. Hence, all PCMC samples were free of significant amounts of larger soluble 
protein aggregates that are typically prone to be removed via filtration during sample 
preparation or to accumulate at the column top or precolumn [48]. 
Protein stability of other solid dosage forms, such as lyophilized products, was found to depend 
on the ratio between stabilizing excipient and protein [25, 26, 49]. For example, a specific molar 
ratio of sugar to protein of 360:1 was required to adequately stabilize rhuMab HER2 during 
lyophilization and storage against aggregation and deamidation [25]. Andya et al. reported that 
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the use of sucrose or trehalose prevented an IgG1 against aggregation during storage at 30 °C 
to a maximum degree when the ratio between sugar and protein was ≥ 500. This number was 
approximately equivalent to the number of water-bindings sites on the protein surface [26]. 
Based on the storage of an lyophilized IgG1 at 40 °C, Chang et al. even recommended a molar 
ratio of sucrose to protein of ≥ 800:1 to achieve a maximum of protection against chemical 
degradation and aggregation [49]. Relating to mAb2 PCMCs, the molar ratio between the main 
carrier component trehalose and protein varied from approx. 670:1 to 70:1. For a protein load 
of ≥ 50 %, it was thus significantly smaller (≤ 220) than the overall recommended ratio of ≥ 360. 
However, reduced PCMC protein storage stability based on the formation of soluble aggregates 
was only revealed in the case of 75 % antibody load. This overall high protein stability against 
aggregation provided by the PCMC technology was attributed to the presence of additional 
carrier components acting as supplementary protein stabilizers, as discussed in section 3.1. 
 
Figure 3-9: Monomer content via HP-SEC of mAb2 PCMCs (lead formulation) with varying 
protein load stored at 40 °C. 
SDS-PAGE, representing an orthogonal method for the analysis of soluble protein aggregates 
[50], confirmed the HP-SEC results with a slight increase in aggregates for 75 % mAb2 loaded 
PCMCs (Figure 3-10). The aggregate band above 250 kDa under non-reducing conditions (gel a) 
in lanes VIII and XI was more pronounced than in all other lanes. Likewise, the band at about 
100 kDa and 75 kDa under reducing conditions (gel b) was slightly darker in lanes VIII and XI. 
However, as silver stained bands cannot be quantified reliably, interpretation should mainly be 
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restricted to qualitative evaluation [50]. Extra bands indicating mAb2 degradation with 
prolonged storage time or increased protein loading were not detected. The band between 50 
and 75 kDa in lane VI in gel (b) was attributed to some external contamination as it was not 
present in the eight-week sample or on the non-reduced gel and was not detected in SDS-PAGE 
analysis after four weeks either. No further differences between the samples with varying 
protein load were observed over 8 weeks storage. Under non-reducing conditions not only the 
intact antibody with a molecular weight of 150 kDa was detected, but aggregates (> 150 kDa) 
and fragments (< 150 kDa) were present as well. Fragments were not detected during HP-SEC 
analysis and therefore fragment levels were assumed to be very low. A closer look revealed 
that there was in fact more than one band at around 150 kDa. Similar observations have been 
ascribed to the heterogeneity of a purified antibody resulting from differences in glycosylation 
patterns, instability during production and terminal processing [21]. Bands in both gels with 
molecular weights of 100 kDa, 75 kDa, 50 kDa and 25 kDa were attributed to varying 
combinations of light and heavy chains. Light chains of IgGs have a molecular weight of 25 kDa 
and heavy chains are around 50 kDa [21]. The 25 kDa and 50 kDa bands were very strong under 
reducing conditions. Non-reducible aggregates were not detected because no aggregate band 
persisted under reducing conditions. Overall, all mAb2 PCMC samples were free of considerable 
amounts of soluble protein aggregates. 
In 2nd-derivative UV spectroscopy the broad peak at λ = 240-300 nm is composed of multiple 
overlapping spectra, including phenylalanine, tyrosine and tryptophan [51]. The calculation of a 
second derivative spectrum from UV scans is beneficial as it preserves and even highlights fine 
spectral differences initiated by vibrational transitions of the aromatic amino acid chains, but 
on the other side eliminates possible interferences related to the measuring system, the sample 
itself or external factors. Distinct spectral changes can be interpreted as conformational 
alterations of protein structure [52]. Similarly, in intrinsic fluorescence studies with an 
excitation wavelength of 295 nm tryptophan fluorescence emission, being very sensitive to 
conformational changes of a protein, can be selectively studied [53, 54]. Especially upon 
thermal denaturation the intensity of the fluorescence signal is evaluated [55]. 
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(a) 
 
(b) 
 
Figure 3-10: SDS-PAGE of mAb2 PCMCs (lead formulation) with varying protein load stored at 
40 °C for 28 and 56 days; (a) non-reducing and (b) reducing conditions; lane assignment: 
I: BSA control; II: Precision Plus Protein Standard; III-XI: reconstituted mAb2 PCMC samples 
with protein loading of 25 %, 50 % and 75 % ; XII: Precision Plus Protein Standard. 
For mAb2 PCMCs, no spectral differences in dependence of the protein load were found, as 
presented in Figure 3-11a and Figure 3-12a for t0. Furthermore, 2nd-derivative UV scans and 
intrinsic fluorescence spectra did not reveal any conformational changes over time for any 
formulation (exemplarily shown for the lead formulation with a protein loading of 50 % in 
Figure 3-11b and Figure 3-12b). In general, it is believed that the formation of aggregates is 
accompanied by an alteration of protein structure due to unfolding. For mAb2 PCMCs with a 
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protein loading of 75 %, the small amount of soluble aggregates (3.7 %) determined via HP-SEC 
did not result in detectable changes of the tertiary protein structure probably because of 
limited sensitivity of the spectroscopic methods. The formation of non-denatured aggregate 
species has also been reported [56] as well as the formation of aggregates from protein 
molecules which only exhibited marginal local unfolding [7]. 
 (a) (b) 
  
Figure 3-11: 2nd-derivative UV analysis of mAb2 PCMCs (lead formulation) with (a) different 
protein loadings at t0 and (b) a protein loading of 50 % stored at 40 °C for 28 and 56 days; 
arbitrary offset for better comparison. 
 (a) (b) 
  
Figure 3-12: Intrinsic fluorescence spectroscopic analysis of mAb PCMCs (lead formulation) 
with (a) different protein loadings at t0 and (b) a protein loading of 50 % stored at 40 °C for 28 
and 56 days; arbitrary offset for better comparison. 
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In summary, mAb2 PCMCs provided high physicochemical protein stability over 8 weeks at 
40 °C. Apart from slightly increasing soluble aggregate levels at the highest protein loading, 
antibody degradation was not observed. No changes in protein tertiary structure or in powder 
morphology were detected. The augmented monomer loss for the formulation with a protein 
loading of 75 % indicated that a certain minimum proportion of excipients was necessary for 
effective stabilization of the protein during storage. Thus, the maximal protein load of this 
antibody formulation should not exceed 62.5 %, confirmed by considerations on protein 
process stability presented in section 3.2.3. 
3.2.3 Considerations on protein process stability 
Besides information on protein storage stability, some information on protein process stability 
could be derived from the data collected during the accelerated short-term storage stability 
study. Protein quantification revealed that protein recovery approached 100 % with increasing 
protein load (Figure 3-7). Relative loss of carrier decreased with increasing protein fraction 
although the amount of total carrier declined at the same time. Carrier solubility in the PCMC 
suspension medium was potentially reduced at higher protein concentrations and thus resulted 
in a more quantitative recovery of carrier components in the final PCMC powder. Furthermore, 
comparison of the initial relative monomer content related to the monomer content of the 
corresponding protein-carrier solution implied that the optimum process stability might be 
around 37.5-50 % protein load (Figure 3-13). 
 
Figure 3-13: Relative monomer content of mAb2 PCMCs (lead formulation) with varying 
protein loading at t0. 
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3.3 Comparison to liquid mAb2 formulations 
An accelerated short-term storage stability study conducted at 40 °C over 4 weeks with four 
mAb2 solutions aimed to compare liquid formulation stability with the stability provided by the 
PCMC technology. The liquid formulations contained 10 mg/mL, 50 mg/mL, 75 mg/mL and 
100 mg/mL protein in 40 mM histidine buffer pH 5.5 with 20 mM trehalose dihydrate and 
0.2 mg/mL Di-Na-EDTA dihydrate. Analysis of protein concentration, turbidity and monomer 
content was performed at t0, t7d, t14d and t28d. Second derivative UV scans, intrinsic fluorescence 
spectroscopy and SDS-PAGE analysis were carried out at t0 and after 28 days. 
Protein concentration of the different formulations was constant over time (Figure 3-14a). The 
slight turbidity increase by 6.2-10.1 FNU clearly indicated an increase in insoluble aggregates 
over time for protein solutions of 50 mg/mL, 75 mg/mL and 100 mg/mL (Figure 3-14b). This was 
in accordance to visual examinations. At t0 all formulations were clear and colorless. After 
28 days at 40 °C all solutions stayed macroscopically clear, but only the formulation with 
10 mg/mL remained colorless. The higher concentrated solutions had turned yellowish. This 
discoloration of liquid mAb formulations was confirmed by Stroop et al. who investigated 
fluorescent light photodegradation of a monoclonal antibody formulated in histidine buffer 
[57]. The exposure to yellowish photosensitizers extracted from photo-aged histidine buffer 
was further found to promote oxidation, fragmentation and aggregation of the antibody. 
 (a) (b) 
  
Figure 3-14: Protein concentration (a) and turbidity (b) of liquid mAb2 formulations with 10, 
50, 75 and 100 mg/mL protein stored at 40 °C for 4 weeks. 
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Monomer loss depended on the protein concentration and was more pronounced for 
formulations with higher protein concentrations (Figure 3-15a). The monomer content of the 
formulation with 10 mg/mL protein decreased by less than 1 % from 98.7 % to 97.9 % within 
four weeks at 40 °C. The monomer content of the 100 mg/mL formulation was slightly lower at 
the beginning of the stability study and also decreased by 2.6 % from 98.5 % to 95.9 % over 
storage time. The monomer loss was mainly attributed to the formation of soluble protein 
dimers, as opposed to mAb2 PCMCs that additionally contained higher molecular weight 
aggregated species (Figure 3-16). Moreover, independent of the protein concentration, 
fragments were detected in the chromatograms of all liquid formulations after 7-28 days of 
storage (Figure 3-15b). The formation of fragments observed in liquid formulations was 
successfully inhibited by the stabilization of the antibody in the solid state. 
 (a) (b) 
 
Figure 3-15: Monomer content (a) and fragment content (b) detected via HP-SEC of liquid 
mAb2 formulations with 10, 50, 75 and 100 mg/mL protein stored at 40 °C for 4 weeks. 
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 (a) (b) 
 
Figure 3-16: (a) Overlay of chromatograms of the liquid formulation with 100 mg/mL protein 
after 0 (blue) and 28 (red) days at 40 °C; (b) comparison of chromatograms obtained from 
mAb2 PCMCs with 75 % protein load (red) and the liquid formulation with 100 mg/mL protein 
(blue) after 28 days at 40 °C; x-axis: elution volume [mL], y-axis: UV signal at 280 nm [mAU]; 
signals between 12 and 14 mL were caused by the elution of buffer components. 
SDS-PAGE analysis under non-reducing conditions revealed an additional band at below 50 kDa 
for all protein solutions that were stored at 40 °C for four weeks (Figure 3-17a). Moreover, a 
faint extra band at 15 kDa was identified and attributed to fragmentation within these samples. 
These observations were consistent with the fragments detected in HP-SEC. Furthermore, the 
aggregate band above the 250 kDa marker band was darker for formulations of 50 mg/mL, 
75 mg/mL and 100 mg/mL protein after thermal stress, being in accordance with HP-SEC and 
turbidity data. Under reducing conditions (Figure 3-17b) no extra bands where detected, but 
faint bands for t0 samples at 37 kDa, around 30 kDa and 15 kDa were more pronounced after 
28 days at 40 °C. Bands at 15 kDa indicating fragmentation as well as bands between 25 and 
37 kDa under reducing conditions were not detected in SDS-PAGE analysis of reconstituted 
mAb2 PCMCs. 
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(a) 
 
(b) 
 
Figure 3-17: SDS-PAGE of liquid mAb2 formulations stored at 40 °C for 28 days; (a) non-
reducing and (b) reducing conditions; lane assignment: I: BSA control; II: Precision Plus 
Protein Standard; III-X: liquid mAb2 formulations with 10, 50, 75 and 100 mg/mL protein ; 
XI: Precision Plus Protein Standard. 
Analysis of tertiary structure did not reveal any conformational perturbations, irrespective of 
the initial protein concentration and storage time (Figure 3-18). 
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 (a) (b) 
  
Figure 3-18: Tertiary protein structure of liquid mAb2 formulations with 10, 50, 75 and 
100 mg/mL protein stored at 40 °C for 4 weeks and investigated via (a) intrinsic fluorescence 
spectroscopy and (b) 2nd-derivative UV spectroscopy. 
Summing up, the data indicated that the mAb2 under investigation could be effectively 
stabilized as PCMC powder at certain protein loading rates, whereas aqueous formulations 
especially of higher concentrations were significantly impacted by the formation of aggregates 
and fragments over storage time. The aggregates were both of soluble and insoluble nature as 
detected via HP-SEC, SDS-PAGE analysis and turbidity measurement. The tendency of partially 
hydrophobic proteins, such as mAb2, towards aggregation is well known [7]. Comprising 
histidine buffer, trehalose and EDTA, the composition of the formulation, apart from optionally 
lacking salt additives, was comparable to commercially available therapeutic mAb formulations. 
The buffering agent histidine and the disaccharide trehalose are not only effective in stabilizing 
proteins in the solid state as described above, but are also frequently used in liquid antibody 
formulations [21]. The chelating agent EDTA reduces oxidation stress due to the complexation 
of metal ions [58]. 
4 Conclusion 
The current study revealed the effects of single carrier components on the overall process 
stability of mAb2 formulated as PCMCs. Sodium chloride influenced the manufacturability of 
PCMCs because its absence resulted in slow sedimentation and consequently concentration of 
the precipitated suspension. Furthermore, without sodium chloride the PCMC powder did not 
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completely dissolve in water indicating the formation of insoluble protein particles. The amino 
acids glycine and histidine had positive effects on protein monomer recovery as detected via 
HP-SEC. Trehalose was not only most effective in the protection against aggregation, but had a 
significant impact on the overall appearance of the PCMC particles because it inhibited glycine 
crystallization. The resulting amorphous state of the formulation provided high protein process 
stability. However, literally, the term ‘protein-coated microcrystals’ did not apply for these 
PCMCs. Detrimental effects upon elimination of phenylalanine were not observed, even after 
storage at 40 °C for eight weeks. 
Based on a lead formulation containing sodium chloride, glycine, histidine and trehalose, the 
influence of the protein load on storage stability of mAb2 PCMCs was assessed at 40 °C for 4-
8 weeks. Overall, the storage stability of the mAb2 PCMCs was very good. Conformational 
changes in tertiary protein structure were not observed for any formulation. A maximal 
increase in soluble aggregates of 3.7 % was detected for a protein load of 75 % after 8 week 
storage at 40 °C. 50 % to 62.5 % protein load was optimal for retaining high monomer content. 
In accordance with reports on the stabilization of lyophilized protein formulations, a specific 
protein to excipient ratio was necessary to successfully stabilize the protein as PCMC powder. 
The storage stability of the PCMC powder was superior to liquid mAb2 formulations with 
10 mg/mL, 50 mg/mL, 75 mg/mL and 100 mg/mL protein. Although alterations of protein 
conformation in the liquid formulations were not detected, increased aggregation rates and 
fragmentation were observed via HP-SEC and SDS-PAGE analysis. Therefore, the PCMC 
technology provided an efficient and beneficial way of formulating this mAb as an example of 
therapeutic proteins of which high doses are required. 
The basic mechanism of protein stabilization via PCMC technology is still unclear because this 
technology combines a challenging manufacturing process, based on precipitation, 
concentration and supercritical drying, with complex formulations. Therefore, questions 
concerning the stabilization mechanism need to be addressed in subsequent studies to 
contribute to a better understanding of essential formulation and production parameters. 
Especially solid state analytics of protein structure should be performed because analysis of 
reconstituted PCMCs does not reflect the actual situation in the dry powder. 
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Chapter 4  
E v a l u a t i o n  o f  o r g a n i c  w a t e r -
m i s c i b l e  s o l v e n t s  a s  s u s p e n s i o n  
m e d i a  f o r  P C M C s  
Abstract 
For the development of PCMC suspensions for subcutaneous administration physiologically 
acceptable solvents are required that show good protein compatibility and that do not, at least 
substantially, dissolve the PCMC powder prior to application. This study aimed to screen 
glycerol, NMP, propylene glycol and PEG 400, pure as well as mixed with 10 to 90 % water (v/v), 
as potential organic water-miscible solvents for the resuspension of mAb1 PCMC powder. The 
focus was on macroscopic appearance of the suspensions as well as on protein aggregation 
(turbidimetry, HP-SEC) and protein structure (FT-IR, intrinsic fluorescence and 2nd-derivative UV 
spectroscopy). Glycerol and PEG 400 were found to be overall compatible with mAb1 PCMCs. 
Irrespective of the solvent content, the protein integrity was not affected, including the specific 
antigen binding capacity of the antibody. Furthermore, suspensions were formed in the 
presence of ≥ 50 % solvent. With respect to propylene glycol, at least 90 % solvent was 
necessary for the formation of a suspension. However, these high propylene glycol 
concentrations resulted in considerable levels of insoluble and soluble aggregates and 
perturbation of secondary and tertiary protein structure. For NMP, a PCMC suspension was 
formed in the presence of the pure solvent, but the antibody was found to be aggregated to a 
significant extend. Reduction of the solvent concentration either resulted in complete 
dissolution of the PCMC powder (90 and 70 % NMP) or protein instability in terms of aggregate 
formation or/and conformational changes (≤ 50 % NMP). Consequently, the use of glycerol and 
PEG 400 is recommended for further development of non-aqueous PCMC suspensions in water-
miscible organic solvents for subcutaneous delivery. 
Evaluation of organic water-miscible solvents as suspension media for PCMCs 
94 
1 Introduction 
The formulation development of subcutaneous high concentration protein injectables bears 
particular challenges. The most significant restrictions for subcutaneous formulations are the 
low injection volume of 0.5-2 mL administered via 0.5-1 inch 23-gauge (or smaller) needle, a 
need for isotonicity and low viscosity and a pH range of 2.7-9.0 [1-4]. High concentration 
protein, specifically mAb, solutions are frequently associated with problems including high 
viscosity, protein aggregation, and poor overall stability [5, 6]. Thus, high concentration 
suspensions, e.g. formulated as PCMCs, represent a promising alternative. The development of 
PCMC suspensions for subcutaneous delivery requires the evaluation of appropriate suspension 
media that do not dissolve the PCMC powder and that are physiologically acceptable and 
compatible with the protein. Moreover, the ideal non-aqueous suspension medium should be 
miscible with water and body fluids, remain stable under normal conditions of pharmaceutical 
use, have a high boiling point for potential heat sterilization and a viscosity allowing for easy 
injection [7, 8]. Constant purity and degree of flammability are additional considerations. 
Obviously, the ideal solvent does not exist yet [7, 8]. Commonly used organic water-miscible 
cosolvents for parenteral administration that are numerously reviewed include ethanol, 
glycerol, polyethylene glycol (PEG) 300 and 400, N-methyl-pyrrolidone (NMP), propylene glycol, 
dimethylacetamide, dimethyl sulfoxide etc. [2-4, 7-16]. However, only a few of them are 
administered subcutaneously and their amount is limited to e.g. 6 % ethanol, 32 % glycerol and 
10 % propylene glycol [2, 9]. 
The aim of this study was to evaluate organic water-miscible solvents, namely glycerol, NMP, 
propylene glycol and PEG 400, as resuspension media for mAb1 PCMC powder. Pure solvents as 
well as mixtures with water (90:10, 70:30, 50:50, 30:70 and 10:90 (v/v)) were screened. The 
study focused on the macroscopic appearance of the suspensions as well as on protein stability 
after dissolution of the PCMC powder with regard to aggregation (turbidimetry, HP-SEC) and 
changes in the structure of the monoclonal antibody (FT-IR, intrinsic fluorescence and 
2nd-derivative UV spectroscopy). For glycerol and PEG 400, the binding activity of the antibody 
after solvent incubation and dissolution of residual PCMC powder was additionally analyzed. 
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2 Materials and methods 
2.1 Materials 
L-Phenylalanine and sodium hydroxide were purchased from Sigma-Aldrich, Steinheim, D, 
disodium EDTA dihydrate, hydrochloric acid (1 mol/L), water free glycerin (Emprove®) and 
isobutanol (Emplura®) from Merck, Darmstadt, D. Glycine, L-histidine and L-histidine 
hydrochloride monohydrate were procured from Ajinomoto Omnichem, Louvain-la-Neuve, B. 
Sodium dihydrogen phosphate dihydrate was delivered by Dr. Paul Lohmann, Hungen, D, 
sodium chloride by Akzo Nobel, Hengelo, NL, and trehalose dihydrate by Ferro Pfanstiehl, 
Waukegan, IL, USA. N-Methyl-pyrrolidone (Pharmasolve®) was obtained from ISP (Köln, D). 
Highly purified polyethylene glycol 400 (Super Refined PEG 400-LQ-/MH) was acquired from 
Croda (Nettetal, D), propylene glycol (1,2-propanediol Ph.Eur.) from Fluka, Buchs, CH.  
The protein bulk drug substance provided by Boehringer Ingelheim was composed of 20 mg/mL 
mAb1, representing a human IgG2 monoclonal antibody, 0.68 mg/mL L-histidine, 3.27 mg/mL 
L-histidine hydrochloride monohydrate, 0.1 mg/mL disodium EDTA dihydrate, 84.0 mg/mL 
trehalose dihydrate and 0.02 % polysorbate 80. The buffer of the bulk drug substance was 
exchanged via ultra- and diafiltration resulting in a protein solution that consisted of 
105.6 mg/mL protein, 0.68 mg/mL L-histidine, 3.27 mg/mL L-histidine hydrochloride 
monohydrate, 0.1 mg/mL disodium EDTA dihydrate and 56.0 mg/mL trehalose dihydrate 
(crossflow buffer exchange and concentration unit, Boehringer Ingelheim, Biberach/Riss, D; 
membrane cassette Sartocon Slice, Hydrosart, 30 kd, Sartorius, Göttingen, D; Quattroflow 150 S 
membrane pump, Quattroflow Fluid Systems, Hardegsen, D). Furthermore, polysorbate 80 was 
present in the protein solution because it cannot be removed via ultra-/diafiltration, as 
reported by Mahler at al. for polysorbate 20 [17]. 
2.2 Methods 
2.2.1 PCMC production process 
The PCMC production process is divided into four main steps: preparation of protein-carrier 
solution, precipitation, concentration/solvent exchange, and drying. For the preparation of the 
protein-carrier solution (Table 4-1) the carrier material was dissolved in deionized water and 
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the solution pH value was adjusted to 5.5 prior to the addition of the protein solution. The final 
solution was filtered through a 0.22 µm membrane filter (Stericup-GV, 47mm, PVDF, Sartorius, 
Göttingen, D). 
Table 4-1: Composition of protein-carrier solution. 
Substance Mass [mg] in 200.0 ml Percent by weight [%] 
mAb1 2239.8 43.6 
L-Histidine 27.8 0.5 
L-Histidine HCl monohydrate 133.7 2.6 
Disodium EDTA dihydrate 4.1 0.1 
Glycine 811.1 15.8 
L-Phenylalanine 89.5 1.7 
Sodium chloride 269.0 5.2 
Trehalose dihydrate 1568.1 30.5 
Sum 5143.1 100.0 
 
The precipitation was carried out as described in detail by König [18]. Briefly, two equal streams 
of precipitating agent were mixed with one stream of protein-carrier solution in a small double 
jet impingement mixer of an inner diameter of 1.5 mm (Boehringer Ingelheim, Biberach/Riss, 
D). The precipitating agent was isobutanol saturated with all carrier components. The mixing 
ratio of the precipitating agent and the protein-carrier solution was set to 95 : 5 (v/v). The 
modular mixing platform from Ehrfeld (Bayer Technology, Wendelsheim, D) emcopassed three 
micro gear pumps (HNP pumps mzr 11507 and 7255, Hydraulik Nord Fluidtechnik, Parchim, D), 
pressure sensors and temperature sensors to monitor the precipitation step. The total flow rate 
of 1000 mL/min was controlled by the software LabView (National Instruments, Munich, D) and 
Coriflow mass flow meters (Bronkhorst, Kamen, D). The final suspension volume after 
precipitation was 4 L. Solvent exchange was achieved by decanting the supernatant of the 
PCMC suspension 18 h after the precipitating step. The supernatant was replaced with fresh 
saturated isobutanol. After further 24 h of sedimentation the sediment, i.e. the concentrated 
suspension, was used for the supercritical drying process (Thar SFE-500, Thar Technologies, 
Pittsburgh, PA, USA) with carbon dioxide at 100 bar and a flow rate of 25 g/min. After drying of 
240 mL concentrated suspension within 130 min at 45 °C the pressure was decreased by 
3 bar/min. 
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2.2.2 Incubation of PCMC powder with organic water-miscible solvents 
NMP, PEG 400, glycerol and propylene glycol served as organic water-miscible solvents selected 
for the incubation of the PCMC powder. Apart from the pure solvents, mixtures with deionized 
water were prepared in ratios of 90:10, 70:30, 50:50, 30:70 and 10:90 (v/v). PCMC powder 
incubated with pure water was used as reference sample. 68.9 mg powder was incubated with 
3.0 mL of the solvent or solvent water mixture in 20 R vials (CRP-NBB-20ml, type FC, Schott, 
Mühlheim, D) for 5 min on a horizontal shaker (Kombischüttler KL 2, Edmund Bühler, 
Hechingen, D) at a shaking speed of 250 rpm. 
2.2.3 Macroscopic appearance after solvent incubation 
The macroscopic appearance of the suspensions after solvent incubation was evaluated with 
respect to agglomeration tendency, turbidity and coloration. 
2.2.4 Analysis of protein integrity 
After solvent incubation 12.0 mL deionized water was added to achieve complete dissolution of 
the PCMC powder required for protein analysis. In that case, the final protein concentration in 
the solutions was 2 mg/mL and the solvent content ranged from 2 to 18 % (v/v). 
2.2.4.1 Dissolution behavior 
The dissolution behavior (agglomeration tendency, turbidity and coloration) of the suspensions 
was macroscopically investigated after the addition of water (see section 2.2.4). 
2.2.4.2 Turbidimetry 
Turbidity was measured at a protein concentration of 2 mg/mL by 90 ° light scattering at 
λ = 633 nm (UH turbidimeter, Boehringer Ingelheim, self-construction) and expressed in 
formazine nephelometric units (FNU) (n=3).  
2.2.4.3 High pressure size exclusion chromatography (HP-SEC) 
HP-SEC was performed on an Äkta micro (GE Healthcare, Uppsala, Sweden) with a TSKgel 
G3000SWXl column (7.8 mm ID x 30.0 cm L) and a 40 x 6.0 mm TSKgel SWXL Guardcol 
precolumn (Tosoh Bioscience, Stuttgart, D) at a flow rate of 1 mL/min. The mobile phase was 
composed of 60 mM sodium chloride and 5 mM sodium dihydrogen phosphate with a pH 
adjusted to 7.0. After filtration through a 0.45 µm membrane filter (Millex® HV, Cork, IRL), 25 µl 
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samples of 2.0 mg/mL protein were injected in duplicate and protein elution was monitored via 
UV-detection at 280 nm. Aggregation in percent was calculated based on the ratio of the area 
under the curve (AUC) of soluble aggregates to the total AUC of aggregates and monomer 
(n=2). Furthermore, changes in the AUC were considered. 
2.2.4.4 Analysis of protein structure 
Conformational changes of the protein were analyzed via Fourier transform infrared 
spectroscopy (FT-IR), intrinsic fluorescence spectroscopy and 2nd-derivative UV spectroscopy. A 
special form of sample preparation was required prior to measurement, because amino acids 
that were used as carrier components may interfere with spectroscopic methods, such as FT-IR 
analysis [19, 20]. Therefore, diafiltration of 5.0 mL samples was performed against 500 mL 
water for injection (WFI) with stirring at room temperature (Spectra/Por® 7 Dialysis Membrane 
MWCO 25,000, Carl Roth, Karlsruhe, D). WFI was exchanged twice within 18 h of diafiltration.  
2.2.4.4.1 Fourier transform infrared spectroscopy 
As the precision of FT-IR depends on the protein concentration, dialyzed samples were 
concentrated in the centrifuge (Heraeus® Biofuge® primo, Carl Roth, Karlsruhe, D). The 
filtration units (Amicon® Ultra-4 Ultracel-30k, Millipore, Schwalbach, D) were rinsed with 4.0 mL 
0.1 N NaOH and subsequently equilibrated with water at 7500 g for 10 min. Concentration of 
4.0 mL samples at 7500 g for 10-20 min resulted in a final protein concentration of 5-20 mg/mL. 
Samples were filtered through a 0.2 µm syringe filter (Acrodisc® Syringe Filters with Supor® 
Membrane, Pall, Dreieich, D). 
FT-IR spectroscopy was performed using a Tensor 37 and a Confocheck measuring cell (Bruker, 
Ettlingen, D). Spectra were recorded from 4000 to 900 cm-1 with 120 scans and a resolution of 
2 cm-1 at 25° C. Atmospheric compensation was done and WFI served as reference. Spectra 
were processed by vector normalization prior to calculating the average spectrum based on 
three measurements. Second derivative was built applying 17 smoothing points (Savitzky-Golay 
algorithm).  
2.2.4.4.2 Intrinsic fluorescence spectroscopy 
Samples of 0.1 mg/mL protein in SUPRASIL® 114-QS precision cuvettes (10 mm, Hellma, 
Mühlheim, D) were excited at 295 nm and 25 °C. The emission was scanned from 305 nm 
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to 400 nm with a step size of 1 nm and 1 s integration time (Fluorimeter QM-4-CW, PTI, 
Birmingham, NJ, USA). The evaluation was based on normalized spectra (n=3). 
2.2.4.4.3 2nd-derivative UV spectroscopy 
Samples of 0.3 mg/mL protein were scanned in Halfmicro Plastibrand® cuvettes (Brand, 
Wertheim, D) from 240 to 350 nm (UV/VIS Spectrometer Lambda 20, PerkinElmer, Rodgau-
Jügesheim, D). The second derivative of the absorption was used (n=3). 
2.2.4.5 Binding assay 
MAb1 prevents the target antigen from binding to a specific cell surface protein (CSP). 
Consequently, binding activity of the antibody to the target antigen was analyzed according to 
BI internal method using a competitive ELISA following typical protocols [21]. Briefly, mAb1 and 
the target antigen were added to CSP immobilized on a microtiter plate. Decreasing 
concentration of mAb1 resulted in decreasing inhibition of binding of target antigen to CSP. 
After the addition of goat anti-mouse-IgG horseradish peroxidase that bound to CSP and of 
tetramethylbenzidine dye, the amount of colored product, being inversely proportional to the 
binding activity of the antibody, was measured based on the absorption at 450 nm (n=2). 
3 Results and discussion 
Solvent incubation, carried out with glycerol, NMP, propylene glycol and PEG 400 on a 
horizontal shaker, was limited to 5 min because the PCMC powder and the suspension medium 
are intended to be marketed in a dual chamber syringe system. Thus, the suspension, 
representing the final dosage form, would be prepared immediately before subcutaneous 
injection. After solvent incubation the macroscopic appearance of the suspension was 
analyzed. Subsequent dissolution of residual PCMC powder allowed for analysis of protein 
integrity, including aggregation level and structural changes. 
3.1 Macroscopic appearance after solvent incubation 
The incubation of mAb1 PCMC powder with pure glycerol resulted in a big powder nest located 
in the middle of the vial (Figure 4-1). Pure glycerol was too viscous to disperse the powder 
under the shaking conditions selected [22]. Down to a mixing ratio of glycerol to water of 50:50 
suspensions with many powder particles were formed during shaking. Apart from the particles 
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detected by the naked eye, the suspensions were macroscopically turbid. In the samples 
incubated with smaller amounts of glycerol (30 % and 10 %) only few powder agglomerates 
were visible. Thus, 70 % of water was sufficient for the dissolution of mAb1 PCMC powder in 
the presence of glycerol. The sample that was incubated with pure water and hence served as 
reference sample was a clear solution. The good water solubility found in this study is typical of 
most of the PCMC powders [18, 23]. 
 
Figure 4-1: Incubation of PCMC powder with glycerol and corresponding water mixtures; 
glycerol to water ratio (v/v): (1) 100:0, (2) 90:10, (3) 70:30, (4) 50:50, (5) 30:70, (6) 10:90, 
(7) 0:100 = pure water. 
The appearance of the samples incubated with NMP and NMP water mixtures strongly 
depended on the mixing ratio (Figure 4-2). Sample (8) with pure NMP represented a turbid 
suspension, whereas clear solutions were detected when 90 or 70 % NMP was used. In the 
presence of an increasing amount of water, namely 50 and 70 %, the PCMC powder was not 
completely dissolved. Powder agglomerates were detected in these samples. The sample that 
contained 10 % NMP and 90 % water represented a turbid suspension without any big 
agglomerate.  
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Figure 4-2: Incubation of PCMC powder with NMP and corresponding water mixtures; NMP to 
water ratio (v/v): (8) 100:0, (9) 90:10, (10) 70:30, (11) 50:50, (12) 30:70, (13) 10:90, 
(14) 0:100 = pure water. 
In contrast to NMP, the solubility of PCMC powder in the presence of propylene glycol clearly 
increased with increasing amount of water. A turbid suspension with many powder 
agglomerates was formed after the incubation with pure propylene glycol (Figure 4-3). Still 
there were some powder agglomerates visible in the samples containing 90, 70 and 50 % 
propylene glycol, but the number decreased with rising water content. Clear solutions were 
detected when the amount of propylene glycol was reduced to 30 % or less. 
 
Figure 4-3: Incubation of PCMC powder with propylene glycol and corresponding water 
mixtures; propylene glycol to water ratio (v/v): (15) 100:0, (16) 90:10, (17) 70:30, (18) 50:50, 
(19) 30:70, (20) 10:90, (21) 0:100 = pure water. 
PCMC powder incubated with PEG 400 and PEG 400 water mixtures showed the same solubility 
tendency. The amount of powder agglomerates and the turbidity of the samples increased 
when the volume fraction of PEG 400 was augmented (Figure 4-4). In the presence of only 10 % 
PEG 400 the powder completely dissolved and no agglomerates were macroscopically visible. 
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Figure 4-4: Incubation of PCMC powder with PEG 400 and corresponding water mixtures; 
PEG 400 to water ratio (v/v): (22) 100:0, (23) 90:10, (24) 70:30, (25) 50:50, (26) 30:70, 
(27) 10:90, (28) 0:100 = pure water. 
Overall, the solubility of mAb1 PCMCs in the presence of glycerol, propylene glycol and PEG 400 
improved with increasing amount of water. In the case of NMP, a stronger turbidity in 
NMP/water mixtures was seen with higher water content. At least 50 % glycerol or PEG 400 and 
90 % propylene glycol were required to form a suspension. Suspensions were also detected for 
30:70 and 10:90 NMP water mixtures as well as for pure NMP. 
3.2 Protein integrity after solvent incubation 
After solvent incubation protein analysis, focusing on aggregation and structural alterations, 
required the addition of 12.0 mL water to achieve complete dissolution of residual PCMC 
powder. Consequently, the solvent content ranged from 2 to 18 % (v/v). The dissolution 
behavior may also provide information on the compatibility between the solvent and the 
monoclonal antibody. For example, high turbidity of protein solutions typically indicates the 
presence of insoluble aggregates [24]. 
In the samples incubated with glycerol or glycerol water mixtures the residual powder could be 
easily dissolved. Clear solutions were obtained independent of the initial glycerol content 
(Figure 4-5). Turbidity measurement underlined the macroscopic appearance of the samples 
with turbidity values ranging from 4.4 to 11.1 FNU (Figure 4-9). Thus, all samples were free of 
larger amounts of insoluble protein aggregates. Samples with an initial glycerol content of 
≥ 70 % showed turbidity values of 4-5 FNU as opposed to 10-11 FNU detected for PCMC powder 
incubated with a lower amount of glycerol. The turbidity of those samples was even lower than 
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the one detected for PCMC powder reconstituted with pure water in the absence of glycerol 
(10.8 FNU). As reported by Chen et al., the refractive index of glycerol water mixtures 
augmented linearly with increasing volume percentage of glycerol [25]. Various studies in the 
field of micro-flow imaging and light obscuration on suspensions, either glass bead suspensions 
or high concentration protein solutions contaminated with insoluble proteinaceous particles, 
showed that increasing refractive indexes of the surrounding medium decreased the difference 
in refractive index between the particles and the medium resulting in reduced contrast and 
thus significant underestimation of particle number or undersizing [26, 27]. Pan et al. found 
that the turbidity of highly charged fluorinated monodisperse spherical particles suspended in 
ethylene glycol water mixtures decreased with increasing refractive index within a certain range 
[28]. Hence, the observation of reduced turbidity for PCMCs dissolved in glycerol water 
mixtures in the presence of increasing glycerol concentrations was attributed to a shift of the 
refractive index of the solvent. 
 
Figure 4-5: Dissolution behavior of PCMC suspensions, made of 68.9 mg mAb1 PCMC powder 
and 3.0 mL solvent, after addition of 12.0 mL water; initial glycerol to water ratio (v/v): 
(1) 100:0, (2) 90:10, (3) 70:30, (4) 50:50, (5) 30:70, (6) 10:90, (7) 0:100 = pure water. 
The samples initially incubated with 90 and 70 % NMP were macroscopically clear after the 
addition of water and showed low turbidity values of 7-8 FNU (Figure 4-6 and Figure 4-9). 
Turbidity measurement of the sample originally incubated with pure NMP also revealed a value 
of 7 FNU despite a few individual large flakes in the vial visible by the naked eye. Flake-shaped 
particles were also found after incubation with 50 and 30 % NMP. The turbidity of these 
samples was 20 and 24 FNU. Turbidity was particularly pronounced after the addition of water 
to the powder dispensed with 10 % NMP, reaching a value of 130 FNU. Hence, apart from the 
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samples initially containing 90 and 70% NMP, larger amounts of insoluble protein aggregates 
were apparently present in all formulations. 
 
Figure 4-6: Dissolution behavior of PCMC suspensions, made of 68.9 mg mAb1 PCMC powder 
and 3.0 mL solvent, after addition of 12.0 mL water; initial NMP to water ratio (v/v): 
(8) 100:0, (9) 90:10, (10) 70:30, (11) 50:50, (12) 30:70, (13) 10:90, (14) 0:100 = pure water. 
 
Figure 4-7: Dissolution behavior of PCMC suspensions, made of 68.9 mg mAb1 PCMC powder 
and 3.0 mL solvent, after addition of 12.0 mL water; initial propylene glycol to water 
ratio (v/v): (15) 100:0, (16) 90:10, (17) 70:30, (18) 50:50, (19) 30:70, (20) 10:90, 
(21) 0:100 = pure water. 
With respect to propylene glycol, all samples initially incubated with ≤ 70 % solvent were 
macroscopically clear. Their turbidity ranged from 3-12 FNU with lower values (3 and 5 FNU) for 
the samples incubated with 70 % and 50 % propylene glycol (Figure 4-9), as detected for 
glycerol water mixtures, too. Similarly, this observation was associated with an increasing 
refractive index of the solvent system with augmenting propylene glycol concentration, as 
likewise reported by Fogg et al. for ethylene glycol [29]. However, incubation with higher 
amounts of propylene glycol, namely 90 % and 100 %, resulted in turbidity values of 16 and 
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42 FNUs indicating an increased amount of insoluble protein particles. Moreover, flakes were 
macroscopically detected in these samples. 
 
Figure 4-8: Dissolution behavior of PCMC suspensions, made of 68.9 mg mAb1 PCMC powder 
and 3.0 mL solvent, after addition of 12.0 mL water; initial PEG 400 to water ratio (v/v): 
(22) 100:0, (23) 90:10, (24) 70:30, (25) 50:50, (26) 30:70, (27) 10:90, (28) 0:100 = pure water. 
 (a) (b) 
  
Figure 4-9: Turbidity after incubation with 3.0 mL glycerol, NMP, propylene glycol and 
PEG 400 as well as solvent water mixtures (v/v) and subsequent dissolution of residual PCMC 
powder with 12.0 mL water (a); (b) zoomed in between 0 and 20 FNU. 
At first sight, all samples incubated with PEG 400 or mixtures made of PEG 400 and water 
appeared clear (Figure 4-8). The turbidity was low with values between 4-12 FNU (Figure 4-9), 
although single flake-shaped particles were detected in the formulations with 50 and 30 % 
PEG 400. Similar to glycerol and propylene glycol incubation, the turbidity values were lower for 
the samples containing a higher amount of PEG 400, very likely due to changes of the refractive 
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index (see above). An increase of the refractive index of mixtures made of PEG 300 and water 
with augmenting mole ratio of PEG 300 was detected by Rajulu and Sab [30]. 
Size exclusion chromatography is one of the most commonly used techniques for the analysis 
and quantification of soluble protein aggregates, oligomers, monomers and fragments [24, 31]. 
The presence of larger soluble aggregates and protein particles that accumulate in the 
precolumn or at the top of the column or that are removed via filtration during sample 
preparation can be assessed by a decrease in the AUC [32].  
The monomer content in the samples incubated with glycerol and corresponding mixtures with 
water ranged from 98-100 % (Figure 4-10a). Compared to the reference sample incubated with 
pure water, the AUC of those samples was not decreased either. Thus, the incubation with 
glycerol and glycerol water mixtures did not induce considerable aggregation levels of the mAb 
formulated as PCMCs. The use of glycerol as stabilizer in protein formulations is widely 
described [33-36]. According to Gekko and Timasheff, glycerol is preferentially excluded from 
the protein surface in aqueous solution and hence favors the folded native state of the protein 
[37]. Vagenende et al. further specified that glycerol additionally tends to interact with 
hydrophobic surface regions of the protein, usually responsible for protein aggregation. The 
amphiphilic interface orientation of glycerol hence prevents the protein from aggregation 
processes [38].  
Significant differences in the aggregation level were found after the incubation with NMP 
(Figure 4-10a). Samples initially incubated with 90 and 70 % NMP were free of soluble 
aggregates in HP-SEC. Incubation with pure NMP resulted in 6 % soluble protein aggregates. 
Significant larger amounts of aggregated species were detected in the samples with 50 and 
30 % NMP, with residual monomer contents of 68 and 65 %. The soluble aggregate level 
resulting from incubation with 10 % NMP could not be assessed because the chromatogram did 
not show any protein peak indicating that the mAb was completely aggregated forming 
insoluble large particles. The AUC was also reduced for the samples incubated with pure NMP 
and 30 % NMP, by approx. 35 and 95 %, respectively (Figure 4-10b). NMP is used as solvent in 
the in situ hardening parenteral drug delivery formulation of leuprolide actetate, marketed as 
Eligard® [39]. The formulation is based on the Atrigel® technology, combining a biodegradable 
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polymer of D,L-lactide-co-glycolic acid (PLGA) and a biocompatible solvent, developed by Dunn 
et al. [40]. Protein aggregation after release from NMP containing drug delivery systems was 
reported by Tae et al. and Dong et al. [41, 42]. Figueiredo et al. further found that myoglobin 
was severely deteriorated, indicated by a color change and an increase in temperature, when it 
was dissolved in NMP [43]. In addition, rhGDF-5 underwent substantial oxidation upon 
incubation in NMP, which was induced by oxidizing species existing in the solvent [44]. 
 (a) (b) 
  
Figure 4-10: Monomer content (a) and peak area (b) in HP-SEC after incubation with 3.0 mL 
glycerol, NMP, propylene glycol and PEG 400 as well as solvent water mixtures (v/v) and 
subsequent dissolution of residual PCMC powder with 12.0 mL water. 
Dispersing mAb1 PCMC powder in 90 and 100 % propylene glycol led to the formation of high 
amounts of soluble aggregates (Figure 4-10a). In these samples, 44 and 41 % aggregated 
species were found. Furthermore, the AUC was significantly decreased by approx. 33 and 44 %, 
respectively, indicating the formation of larger oligomers that could not be analyzed via HP-SEC 
(Figure 4-10b). This finding was in line with the macroscopic appearance after the addition of 
water because flake-shaped particles were present in both samples. For all the other samples, 
neither the monomer content nor the AUC was affected. Liu et al. who investigated the effects 
of polyols on the stability of whey proteins detected an increase in protein aggregation to 
almost 100 % at the three levels tested, including 33, 50 and 67 wt% propylene glycol [45].  
Incubation with PEG 400 did not influence the monomer content in the samples, irrespective of 
the solvent concentration (Figure 4-10a). Changes in the AUC were not detected either. Not 
many data on protein aggregation caused by PEG 400 are available in literature. Knepp et al. 
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found that lyophilized plasma derived factor IX significantly aggregated within 1.5 week storage 
at 37 °C when it was suspended in PEG 400. They argued that protein instability might in part 
be caused by an oxidative attack arising from peroxides formed upon oxidation of the ether 
moieties [46]. The formation of peroxides in PEG upon light exposure and aging as well as 
subsequent protein degradation is well-known [47-49]. The absence of such degradation 
reactions in the recent study on mAb1 PCMCs might be attributed to the high quality of 
PEG 400 used for incubation in combination with the short incubation time. 
As recommended by Baudys and Kim, several spectroscopic methods, namely FT-IR, intrinsic 
fluorescence and 2nd-derivative UV spectroscopy, were used to analyze potential 
conformational alterations of the secondary and tertiary structure of the reconstituted mAb 
[50] (see chapter 2 section 4.3.1). Independent of the solvent concentration, the incubation 
with glycerol did not change the secondary or tertiary conformational structure of the mAb as 
all spectra were identical to the one recorded after reconstitution of PCMCs with pure water 
(Figure 4-11a-Figure 4-13a). By comparison to previously published IgG FT-IR spectra, the bands 
can be assigned to protein structural elements [51, 52]. For example, typical intramolecular 
β-sheet bands occurred at 1692 and 1638 cm-1 showing the predominance of β-sheets in IgGs. 
Well-resolved bands at frequencies of 1678 and 1662 cm-1 represented turn structure and 
peaks at 1616 cm-1 could be attributed either to more β-sheet structure or to side-chain effects. 
Monitoring of changes in protein tertiary structure via intrinsic fluorescence spectroscopy can 
for example be applied in forced degradation studies or to probe thermal stability of proteins in 
preformulation development [53, 54]. After incubation with glycerol or glycerol water mixtures 
the emission maximum was located at a wavelength of λ = 299 nm for all samples 
(Figure 4-12a). In 2nd-derivative UV spectroscopy the broad peak at λ = 240-300 nm is 
composed of multiple overlapping absorbance spectra, including phenylalanine, tyrosine and 
tryptophan [55]. Peaks between 245 nm and 270 nm are affected by phenylalanine, while peaks 
in the wavelength of 265-285 nm can be attributed mainly to tyrosine. Absorbance between 
265 and 295 nm primarily arises from tryptophan. The 2nd-derivative UV spectrum of 
reconstituted PCMCs after incubation with glycerol and corresponding water mixtures was 
characterized by peak minima occurring at 277, 284 and 292 nm, while peak maxima were 
found at 265, 279, 288 and 297 nm (Figure 4-13a). Corresponding to the results for mAb1 
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PCMCs, Wakankar et al. found that the tertiary structure of a recombinant humanized 
monoclonal antibody was not affected by the addition of glycerol in a concentration of up to 
80 % (v/v), analyzed via intrinsic fluorescence spectroscopy [56]. The structural protein stability 
in differential scanning calorimetry was even increased with increasing glycerol concentration. 
However, Figueiredo et al. reported that the secondary structure of myoglobin was retained in 
aqueous solution containing 50 % (v/v) glycerol, while the use of 96 % (v/v) glycerol caused 
turbidity of the system. 
 (a) (b) 
  
 (c) (d) 
 
Figure 4-11: FT-IR spectra after incubation with 3.0 mL (a) glycerol (G), (b) NMP (N), 
(c) propylene glycol (P) and (d) PEG 400 as well as solvent water (W) mixtures (v/v) and 
subsequent dissolution of residual PCMC powder with 12.0 mL water. 
Again for NMP, differences between the samples were seen in the overlay of the spectra. With 
respect to FT-IR spectroscopy, incubation of PCMC powder with 30 and 10 % NMP induced a 
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signal at 1618-1624 cm-1 and a weak intensity peak at 1698 cm-1 at the expense of signal 
intensity at 1692 and 1638 cm-1 (Figure 4-11b). Equivalent changes in FT-IR spectra reported by 
Matheus et al. for high-concentration IgG formulations upon heating were associated with 
intermolecular hydrogen-bonded antiparallel β-sheet structure typical of aggregated protein 
[57, 58]. Referring to HP-SEC, the samples incubated with 30 and 10 % NMP revealed the 
highest loss of AUC indicating the presence of considerable amounts of either insoluble or 
larger soluble aggregates that cannot be assessed chromatographically (see above). The use of 
50 % NMP, however, resulted in the formation of 32 % soluble aggregates in HP-SEC, but did 
neither affect the AUC nor the FT-IR spectrum. Thus, soluble aggregates detectable via HP-SEC 
had no impact on the FT-IR spectrum.  
The spectra recorded via intrinsic fluorescence spectroscopy supported the structural changes 
detected in FT-IR spectroscopy after incubation with 30 and 10 % NMP. The maximum of both 
spectra was shifted from λ = 299 nm to λ = 335 nm and λ = 337 nm, respectively, and both 
spectra contained a second maximum with a lower fluorescence intensity at λ = 383 nm and 
λ = 381 nm (Figure 4-12). Furthermore, the shape of the spectra was broader in both cases, as 
compared to the other samples. The shift of λmax to a higher wavelength, referred to as red 
shift, generally indicates changes in the hydration of tryptophan residues and subsequently in 
protein structure [53]. Hence, structural changes of the monoclonal antibody after the 
incubation with NMP in concentrations of 30 and 10 % did not only involve the secondary but 
also the tertiary protein structure, as also reflected in 2nd-derivative UV spectroscopy 
(Figure 4-13b). The shape of the UV spectra was the same for all samples, but the amplitude 
was significantly decreased in all regions in the case of 30 and 10 % NMP. Van Beers et al. also 
observed reduced intensities of the positive and negative peaks in the 2nd-derivative UV spectra 
of metal-catalyzed oxidized interferon beta, demonstrating changes in the tertiary protein 
structure [59]. Apart from Figueiredo et al. who studied the structural stability of myoglobin in 
organic media via circular dichroism, including NMP, and who detected deterioration of the 
native protein folding, investigations of protein conformation in presence of NMP have not 
been reported in literature [43]. 
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 (a) (b) 
  
 (c) (d) 
  
Figure 4-12: Intrinsic fluorescence spectra after incubation with 3.0 mL (a) glycerol (G), 
(b) NMP (N), (c) propylene glycol (P) and (d) PEG 400 as well as solvent water (W) 
mixtures (v/v) and subsequent dissolution of residual PCMC powder with 12.0 mL water; 
normalized intensity for better comparison. 
Incubation with 100 and 90 % propylene glycol resulted in alterations of the secondary protein 
structure as analyzed by FT-IR. Peak intensities at λ = 1638 cm-1 and λ = 1692 cm-1 decreased, 
while bands at λ = 1624 cm-1 and λ = 1698 cm-1 increased (Figure 4-11c). However, these 
spectroscopic changes representing the formation of intermolecular at the expense of 
intramolecular β-sheets were significantly less pronounced than for the samples incubated with 
30 and 10 % NMP. In accordance with those NMP samples, the level of soluble aggregates and 
the reduction of the AUC in HP-SEC were considerable for the PCMC powder incubated with 
100 and 90 % propylene glycol. The amount of soluble aggregates was higher for the propylene 
glycol samples (41 and 44 %) than for the NMP samples (35 % and not measurable). The loss in 
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AUC amounted to 33 and 44 % for the incubation with propylene glycol, while a reduction by 95 
and 100 % was detected in the case of NMP. This observation supported the hypothesis that 
mainly the presence of larger soluble aggregated species was related to alterations of the 
secondary structure of the monoclonal antibody. Initial propylene glycol concentrations of 
≤ 70 % did not affect the secondary protein structure. In intrinsic fluorescence spectroscopy, 
the spectra recorded after incubation with 100 and 90 % propylene glycol also showed minor 
differences in comparison to the other samples. The emission maximum was not shifted to a 
higher wavelength, but the spectra were broader (Figure 4-12c). Changes were not visible in 
2nd-derivative UV spectroscopy (Figure 4-13c), independent of the propylene glycol 
concentration, due to lower sensitivity of the latter method [55]. Thus, the clear changes in the 
secondary structure did come along with only marginal effects on the tertiary level of the mAb. 
Based on densitometric and CD investigations Gekko and Koga found that propylene glycol 
could induce weakening of the tertiary structure of bovine serum albumin via hydrophobic 
bonding and hence promotion of α-helix formation [60]. The effect depended on the solvent 
concentration and the pH value, being more pronounced in the acidic range as opposed to 
neutral pH. Changes of secondary protein structure, namely a decrease of β-sheets and an 
increase of α-helices, in the presence of at least 40 % propylene glycol were also described by 
Chobert et al. for β-lactoglobulin [61]. The promotion of α-helical secondary structure in FT-IR 
by propylene glycol was confirmed by Liu et al. who studied the effects of polyols on the 
stability of whey proteins [45]. Furthermore, aggregation phenomena were explained by the 
induction of intermolecular β-sheets detected in FT-IR. DSC studies further revealed a loss of 
most of the tertiary structures in the presence of 50 wt% propylene glycol. Minor changes in 
the secondary and tertiary structure of the mAb formulated as PCMCs were also detected via 
FT-IR and intrinsic fluorescence spectroscopy after incubation with 100 and 90 % propylene 
glycol. Intramolecular β-sheets were replaced by intermolecular ones, but promotion of α-helix 
was not observed. However, in the case of mAb1 PCMCs incubation with the initial solvent 
concentration was carried out for only 5 min at room temperature, as opposed to 7 days at 
45 °C for whey proteins. 
With respect to PEG 400, none of the three spectroscopic methods revealed any structural 
changes of mAb1 after incubation (Figure 4-11d-Figure 4-13d). The secondary and tertiary 
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protein structure was completely preserved independent of the solvent concentration. In 
contrast, Ahmad et al. reported that PEG 400 was capable of inducing a molten globule like 
state from acid-denatured stem bromelain and that small amounts of nonnative tertiary 
contacts were formed in the presence of 70 % (w/v) PEG 400 [62]. Moreover, far UV-CD 
spectroscopy conducted by Kumar et al. revealed a slight loss of secondary structural elements 
of bovine serum albumin in the presence of 10 % (w/v) PEG 400 [63]. 
 (a) (b) 
  
 (c) (d) 
  
Figure 4-13: 2nd-derivative UV spectra after incubation with 3.0 mL (a) glycerol (G), 
(b) NMP (N), (c) propylene glycol (P) and (d) PEG 400 as well as solvent water (W) 
mixtures (v/v) and subsequent dissolution of residual PCMC powder with 12.0 mL water. 
Additionally, a binding assay was conducted for the samples incubated with glycerol and 
PEG 400 to verify whether suspending mAb1 PCMCs in these solvents affected the specific 
antigen binding of the antibody. This investigation was limited to glycerol and PEG 400 because 
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these samples showed neither aggregation phenomena nor changes of the secondary or 
tertiary protein structure. Figure 4-14 visualizes that the binding activity of the antibody was 
completely retained for all glycerol and PEG 400 concentrations investigated as the values were 
within the specification limits of 65-130 % of the standard reference sample. 
 
Figure 4-14: Binding activity referred to standard reference sample after incubation with 
3.0 mL glycerol or PEG 400 as well as solvent water mixtures (v/v) and subsequent dissolution 
of residual PCMC powder with 12.0 mL water; dotted lines indicate specification limits. 
4 Conclusion 
The screening of glycerol, NMP, propylene glycol and PEG 400 as organic water-miscible 
resuspension media for mAb1 PCMCs focused on the macroscopic appearance after solvent 
incubation and on protein stability, including aggregation tendency and secondary and tertiary 
protein structure. An overview of the results is presented in the summary tables of Table 4-2. 
At first sight, the tables for glycerol and PEG 400 show a good compatibility of these solvents 
with mAb1 PCMCS. In glycerol, attractive suspensions were formed in the presence of ≤ 50 % 
water. Moreover, protein integrity, specific antigen binding and conformational structure were 
not disrupted in the presence of glycerol. Similar outcomes were found for the incubation with 
PEG 400. At least 50 % PEG 400 was required to form a PCMC suspension. Apart from single 
flake-shaped particles detected in 50:50 and 30:70 mixtures of PEG 400 and water, clear 
solutions were achieved by the addition of water. The protein stability, including the binding 
capacity of the antibody, was not affected by the solvent. With respect to NMP, appropriate 
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suspension quality was only found when pure NMP was used for dispensing the PCMC powder. 
However, incomplete dissolution behavior and the presence of soluble aggregates were 
observed after the addition of water. Protein stability was high when 90 and 70 % NMP was 
used, but these mixtures were capable of completely dissolving the PCMC powder. At higher 
amounts of water (≥ 50 %) protein stability was severely reduced with substantial aggregation 
and a loss in protein structure. Similar to NMP, good suspending properties were provided by 
pure and 90 % propylene glycol, but the antibody was found to be aggregated to a significant 
extent and slight changes in the secondary and tertiary protein structure were revealed. At 
least 30 % water was required to prevent the monoclonal antibody from aggregation and 
structural alterations, but also resulted in complete dissolution of the PCMC powder. Hence, 
neither NMP nor propylene glycol was appropriate for PCMC resuspension, but glycerol and 
PEG 400 represented promising media for the manufacturing of subcutaneous PCMC 
suspensions. 
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Table 4-2: Summary tables of PCMC stability results after incubation with 3.0 mL (a) glycerol, 
(b) NMP, (c) propylene glycol and (d) PEG 400 as well as solvent water mixtures (v/v); color 
assignment: suspension: green indicates the formation of a suspension, yellow the presence 
of single powder agglomerates, red complete dissolution of the PCMC powder after solvent 
incubation; dissolution: green designates the formation of a clear solution, yellow the 
presence of single powder agglomerates, red the presence of considerable amounts of 
insoluble material after dissolution of residual PCMC powder with 12.0 mL water; turbidity: 
green indicates turbidity values comparable to those of PCMC powder incubated with pure 
water of ≤ 10-12 FNU, yellow slightly increased turbidity values of approx. 19-24 FNU, red 
significantly higher turbidity values of ≥ 42 FNU or the presence of many particle flakes; HP-
SEC: green designates monomer levels comparable to those of PCMC powder incubated with 
pure water of ≥ 98 %, yellow a slightly reduced monomer level of approx. 94 %, red 
considerable decreased monomer contents of 56-68 % or the absence of any evaluable peak; 
FT-IR, IF and UV spectroscopy: green indicates spectra overlapping with those of PCMC 
powder incubated with pure water, red deviating curve shapes. 
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Abstract 
The protein-coated microcrystals (PCMC) technology that is based on coprecipitation offers the 
possibility to stabilize protein in the solid state. As PCMCs can be administered as subcutaneous 
suspension by injection appropriate suspensions media are required that are physiologically 
acceptable and compatible with the protein. The study aimed to develop biocompatible and 
injectable oily mAb1 PCMC suspensions based on sesame oil, benzyl benzoate and medium-
chain triglycerides (MCT) and comprised the development of an appropriate in vitro release 
model, the investigation of protein integrity after release from oily suspensions, the 
compatibility between the oily solvents and primary packaging material as well as the 
characterization of rheology and injectability of the suspensions. 100 % recovery of the 
monoclonal antibody mAb1 was found after 24 h incubation at 40 °C in water with integrated 
short-term stirring and final centrifugation at 100 g for 30 min. After release from oily PCMC 
suspensions, the integrity of mAb1 was completely retained with respect to aggregation, 
secondary and tertiary protein structure and specific antigen binding affinity, irrespective of the 
choice of oily solvent. The injectability of the oily solvents depended on the siliconization 
process of the glass syringes and was not affected during 6 months storage at 22 ± 3 °C 
indicating compatibility with the primary packaging material. Only swelling of the tip caps 
occurred due to oil uptake. Oily suspensions based on MCT and 70:30 and 30:70 (v/v) mixtures 
of sesame oil and benzyl benzoate were prepared up to a solid content of 316 mg/mL, 
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corresponding to 138 mg/mL protein. The viscosity of the suspensions that depended on the 
viscosity of the oily solvent augmented with increasing solid content and was characterized by 
shear thinning. A linear relationship between the viscosity and the injectability of the 
suspensions was revealed. Maximal injection forces were approx. 40 N for a 30:70 (v/v) sesame 
oil benzyl benzoate suspension with a solid content of 316 mg/mL, opposed to 50 N for the 
inverse mixture and MCT. Although it was not beneficial with respect to viscosity and 
injectability compared to a corresponding mAb1 solution, formulating mAb1 as oily PCMC 
suspension was feasible, including compatibility with the protein and injectability, and thus 
represents an alternative to high concentration liquid formulations typically associated with 
challenges such as low solubility, aggregation phenomena and poor overall stability. 
1 Introduction 
Apart from organic water-miscible solvents, analyzed in detail in chapter 4, oily liquids 
represent potential media for the development of subcutaneous mAb1 PCMC suspensions. 
Advantages of oily vehicles over organic water-miscible solvents generally include high chemical 
stability and low toxicity [1, 2]. However, vegetable oils containing large amounts of 
polyunsaturated fatty acids are prone to the formation of hydroperoxides that might lead to 
protein instability and increasing overall toxicity [3-6]. The use of highly purified oils that are 
mostly free of hydroperoxides and other impurities further improves their bioacompatibility. As 
these solvents are not water-miscible, their application is discussed to provide a sustained 
release effect [1, 3, 7]. Consequently, the frequency of administration can be reduced resulting 
in higher patient convenience and compliance [3, 7]. Therefore, oily solvents, such as sesame 
oil or cottonseed oil, are often applied to lipophilic steroid hormones or psychotropic drugs for 
intramuscular administration providing a depot for sustained drug delivery over several weeks 
[8, 9]. Though, the general high viscosity of oily solvents is suspected of requiring high injection 
forces for parenteral administration [10]. The investigation of injectability and syringeability is 
thus indispensable in the development of oily parenteral formulations [11]. Injectability 
describes the performance of the formulation during injection, including force or pressure 
required for injection, evenness of flow and freedom from clogging, whereas syringeability is 
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defined as ability of an injectable therapeutic to pass easily through a hypodermic needle on 
transfer from a vial prior to an injection [11-14]. 
The purpose of the study was to evaluate the three oily solvents sesame oil (S), benzyl 
benzoate (B) and MCT (M) as resuspension media for mAb1 PCMC powder. Benzyl benzoate 
was screened as additive to reduce the viscosity of sesame oil based preparations allowing for 
easier injection because sesame oil has a significantly higher viscosity than MCT. The 
investigation of the compatibility between the oleaginous vehicles and mAb1 formulated as 
PCMCs required the development of a suitable in vitro release model ensuring 100 % protein 
recovery. Subsequently, the integrity (HP-SEC, binding assay) and structure (FT-IR, intrinsic 
fluorescence, 2nd-derivative UV spectroscopy) of the monoclonal antibody was analyzed after 
release from oily PCMC suspensions. To avoid administration problems arising from the high 
viscosity of the solvents, the pure oils were tested for injectability. A 6 months storage study of 
oily vehicles in glass syringes was additionally included to detect potential incompatibility with 
the primary packaging material suspected of complicating the injection due to swelling 
phenomena. Finally, the rheology and injectability of oily mAb1 PCMC suspensions was 
investigated and compared to a high concentration liquid formulation of the protein. 
2 Materials and methods 
2.1 Materials 
L-Phenylalanine, sodium hydroxide, benzyl benzoate and phosphate buffered saline pH 7.4 
were purchased from Sigma-Aldrich, Steinheim, D, disodium EDTA dihydrate, hydrochloric acid 
(1 mol/L), isobutanol (Emplura®) from Merck, Darmstadt, D. Glycine, L-histidine and L-histidine 
hydrochloride monohydrate were procured from Ajinomoto Omnichem, Louvain-la-Neuve, B. 
Sodium dihydrogen phosphate dihydrate was delivered by Dr. Paul Lohmann, Hungen, D, 
sodium chloride by Akzo Nobel, Hengelo, NL, and trehalose dihydrate by Ferro Pfanstiehl, 
Waukegan, IL, USA. Highly purified sesame oil (Super Refined Sesame NF-LQ-(MH)) was 
acquired from Croda (Nettetal, D), MCT (Miglyol® 812 N) from Sasol, Witten, D. All chemicals 
were utilized without further purification. 
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The protein bulk drug substance provided by Boehringer Ingelheim was composed of 20 mg/mL 
mAb1, representing a human IgG2 monoclonal antibody, 0.68 mg/mL L-histidine, 3.27 mg/mL 
L-histidine hydrochloride monohydrate, 0.1 mg/mL disodium EDTA dihydrate, 84.0 mg/mL 
trehalose dihydrate and 0.02 % polysorbate 80. 
The buffer of the bulk drug substance was exchanged via ultra- and diafiltration resulting in a 
protein solution that consisted of 105.6 mg/mL protein, 0.68 mg/mL L-histidine, 3.27 mg/mL 
L-histidine hydrochloride monohydrate, 0.1 mg/mL disodium EDTA dihydrate and 56.0 mg/mL 
trehalose dihydrate (crossflow buffer exchange and concentration unit, Boehringer Ingelheim, 
Biberach/Riss, D; membrane cassette Sartocon Slice, Hydrosart, 30 kd, Sartorius, Göttingen, D; 
Quattroflow 150 S membrane pump, Quattroflow Fluid Systems, Hardegsen, D). Furthermore, 
polysorbate 80 was present in the protein solution because it cannot be removed via ultra-
/diafiltration, as reported by Mahler at al. for polysorbate 20 [15]. 
2.2 Methods 
2.2.1 PCMC production process 
The PCMC production process is divided into four main steps: preparation of protein-carrier 
solution, precipitation, concentration/solvent exchange, and drying. For the preparation of the 
protein-carrier solution (Table 4-1) the carrier material was dissolved in deionized water and 
the solution pH value was adjusted to 5.5 prior to the addition of the protein solution. The final 
solution was filtered through a 0.22 µm membrane filter (Stericup-GV, 47mm, PVDF, Sartorius, 
Göttingen, D). 
Table 5-1: Composition of protein-carrier solution. 
Substance Mass [mg] in 200.0 ml Percent by weight [%] 
mAb1 2239.8 43.6 
L-Histidine 27.8 0.5 
L-Histidine HCl monohydrate 133.7 2.6 
Disodium EDTA dihydrate 4.1 0.1 
Glycine 811.1 15.8 
L-Phenylalanine 89.5 1.7 
Sodium chloride 269.0 5.2 
Trehalose dihydrate 1568.1 30.5 
Sum 5143.1 100.0 
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The precipitation was carried out as described in detail by König [16]. Briefly, two equal streams 
of precipitating agent were mixed with one stream of protein-carrier solution in a small double 
jet impingement mixer of an inner diameter of 1.5 mm (Boehringer Ingelheim, Biberach/Riss, 
D). The mixing ratio of the precipitating agent, isobutanol saturated with all carrier 
components, and the protein-carrier solution was set to 95 : 5 (v/v). The modular mixing 
platform from Ehrfeld (Bayer Technology, Wendelsheim, D) emcopassed three micro gear 
pumps (HNP pumps mzr 11507 and 7255, Hydraulik Nord Fluidtechnik, Parchim, D), pressure 
sensors and temperature sensors to monitor the precipitation step. The total flow rate of 
1000 mL/min was controlled by the software LabView (National Instruments, Munich, D) and 
Coriflow mass flow meters (Bronkhorst, Kamen, D). The final suspension volume after 
precipitation was 4 L. 
Solvent exchange was achieved by decanting the supernatant of the PCMC suspension 18 h 
after the precipitating step. The supernatant was replaced with fresh saturated isobutanol. 
After 24 h of sedimentation the sediment, i.e. the concentrated suspension, was used for the 
supercritical drying process (Thar SFE-500, Thar Technologies, Pittsburgh, PA, USA) with carbon 
dioxide at 100 bar and a flow rate of 25 g/min. After drying of 240 mL concentrated suspension 
within 90 min at 45 °C the pressure was decreased by 3 bar/min. Subsequently, vacuum drying 
of the PCMC powder was performed at 125 mbar and 40 °C for 2 h (APT.line™ VDL, Binder, 
Tuttlingen, D; diaphragm membrane pump MZ 2C, Vacuubrand, Wertheim, D). 
2.2.2 Development of an in vitro release model for oily PCMC suspensions 
The development of an in vitro release model was based on a mAb1 PCMC sesame oil 
suspension, prepared by dispersing 305 mg mAb1 PCMC powder in 14.0 mL sesame oil on a 
magnetic stirrer. 25.0 mL of the aqueous phase, either water for injection (WFI) or 10 mM 
phosphate buffered saline pH 7.4 (PBS), and 1.25 or 2.5 mL oily suspension were incubated in 
plastic syringes (Omnifix® 30 mL Luer lock, Braun, Melsungen, D) equipped with a magnetic 
stirring bar and a tip cap (7025/65 grey, West, Eschweiler, D) (Figure 5-1). The influence of 
incubation time (24 or 96 h), temperature (22 ± 3, 37.5 or 40 °C), agitation (2 min stirring or 
24 h shaking) and centrifugation (10 min, 300 g; Heraeus® Biofuge® primo, Carl Roth, Karlsruhe, 
D) on protein recovery was analyzed via UV spectroscopy. Stirring in horizontally lying syringes 
was carried out via magnetic stirrer at 300 rpm (Modell RT 10 power IKAMAG®, IKA, Staufen, 
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D), while horizontal shaking was performed in a shaking water bath with a frequency of 
130 min-1 (Modell 1086, GFL, Burgwedel, D). After incubation the aqueous phase was harvested 
through the tip of the syringe and UV measurement (UV/VIS Spectrometer Lambda 20, 
PerkinElmer, Rodgau-Jügesheim, D) was performed in Halfmicro Plastibrand® cuvettes (Brand, 
Wertheim, D) at 280 nm, corrected against WFI or PBS, based on an extinction coefficient of 
1.43 (n=3). Protein recovery was calculated as the quotient of the antibody concentration in the 
aqueous phase to the theoretical protein concentration of 0.5 or 1.0 mg/mL, based on the 
antibody fraction in the total solid mass of the protein-carrier solution. If necessary, samples 
were filtered through a 0.45 µm syringe filter (Rotilabo® Spritzenfilter steril, 33 mm, PVDF, Carl 
Roth, Karlsruhe, D) prior to UV measurement. In this case, light microscopy (Axio Imager Z2m, 
Zeiss, Jena, D) was additionally performed to analyze the origin of turbidity. 
 
Figure 5-1: In vitro release model for oily PCMC suspensions. 
2.2.3 Compatibility between mAb1 PCMCs and oily solvents 
2.2.3.1 MAb1 release from oily PCMC suspensions 
For the release of mAb1 from oily PCMC suspensions, 25.0 mL WFI and 1.25 mL oily suspension, 
composed of 27.2 mg mAb1 PCMC powder dispersed into sesame oil, benzyl benzoate or MCT, 
were incubated in 30 mL plastic syringes for 24 h at 40 °C with integrated 2 min horizontal 
stirring and final centrifugation for 30 min at 100 g (section 3.1). MAb1 PCMC powder dissolved 
into WFI, incubated in the same way as the oily suspensions, served as reference. After 
incubation the aqueous phase was harvested and analyzed for protein integrity. 
Plunger 
Rubber plunger head 
Oily PCMC suspension 
Aqueous acceptor 
Stirring bar 
Tip cap 
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2.2.3.2 Turbidimetry 
Turbidity of the native aqueous phase and after 0.45 µm filtration (Rotilabo® Spritzenfilter, 
33 mm, PVDF, Carl Roth, Karlsruhe, D) was measured at a protein concentration of 0.5 mg/mL 
by 90 ° light scattering at λ = 633 nm (UH turbidimeter, Boehringer Ingelheim, self-construction) 
and expressed in formazine nephelometric units (FNU) (n=3).  
2.2.3.3 Microflow-imaging (MFI) 
Microflow imaging analysis of the native aqueous acceptor was performed with a Brightwell 
DPA 4200 instrument equipped with a 470 nm LED laser and a 100 µm flow cell (Brightwell, 
Ottawa, Canada) (n=2). Samples were drawn with a peristaltic pump (Masterflex® Plus P/S, 
Thermo Fisher, Waltham, MA, USA). Before each 0.5 mL sample run within 5 min, 0.22 µm 
filtered (Steritop, 0.22 µm, PVDF, Millipore, Schwalbach, D) deionized water was flushed 
through the system to optimize illumination and to achieve a clean baseline. Sesame oil and 
MCT samples with particle counts above the manufacturer´s recommended limit were diluted 
in 0.22 µm filtered deionized water 5-fold prior to analysis and results were multiplied by 5 to 
report final particle counts [17, 18]. 
2.2.3.4 Light microscopy 
An optical light microscope was used to characterize the native aqueous phase (Axio 
Imager Z2m, Zeiss, Jena, D). 
2.2.3.5 Protein recovery 
UV measurements were conducted as described in section 2.2.2. 
2.2.3.6 High pressure size exclusion chromatography (HP-SEC) 
The aqueous acceptors were concentrated in the centrifuge prior to analysis (Heraeus® 
Biofuge® primo, Carl Roth, Karlsruhe, D). The filtration units (Amicon® Ultra-15 Ultracel-30k, 
Millipore, Schwalbach, D) were rinsed with 10.0 mL 0.1 N NaOH and subsequently equilibrated 
with water at 3500 g for 10 min. Samples were filtered through a 0.45 µm filter (Rotilabo® 
Spritzenfilter steril, 33 mm, PVDF, Carl Roth, Karlsruhe, D). Concentration of 6.0 mL samples at 
3500 g for 5-10 min resulted in a final protein concentration of approx. 2 mg/mL. 
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HP-SEC was performed on an Äkta micro (GE Healthcare, Uppsala, Sweden) with a TSKgel 
G3000SWXL column (7.8 mm ID x 30.0 cm L, Tosoh, Stuttgart, D) and a 40 x 6.0 mm TSKgel 
SWXL Guardcol precolumn (Tosoh Bioscience, Stuttgart, D) at a flow rate of 1 mL/min. The 
mobile phase was composed of 60 mM sodium chloride and 5 mM sodium dihydrogen 
phosphate with a pH adjusted to 7.0. Samples were injected in duplicate (2 x 40 µl) and protein 
elution was monitored via UV-detection at 280 nm. Aggregation in percent was calculated 
based on the ratio of the area under the curve (AUC) of soluble aggregates to the total AUC of 
aggregates and monomer (n=3). Furthermore, changes in AUC were considered. 
2.2.3.7 Fourier transform infrared spectroscopy 
Sample concentration for FT-IR measurement was conducted in the centrifuge, described in 
detail in section 2.2.3.6. Concentrated samples were filtered through a 0.45 µm syringe filter 
(Rotilabo® Spritzenfilter steril, 33 mm, PVDF, Carl Roth, Karlsruhe, D). As amino acids that were 
used as carrier components of mAb1 PCMCs may interfere with FT-IR analysis [19, 20], 
diafiltration of 0.75 mL concentrated and filtered samples was performed against 500 mL WFI 
with stirring at room temperature (Slide-A-Lyzer® Dialysis Cassette G2 MWCO 20,000, Thermo 
Scientific, Rockford, IL, USA). WFI was exchanged twice within 18 h of diafiltration.  
FT-IR spectroscopy was performed using a Tensor 37 and a Confocheck measuring cell (Bruker, 
Ettlingen, D). Spectra were recorded from 4000 to 900 cm-1 with 120 scans and a resolution of 
2 cm-1 at 25° C (n=3). Atmospheric compensation was done and WFI served as reference. 
Spectra were processed by vector normalization prior to calculating the average spectrum 
based on three measurements. Second derivative was built applying 17 smoothing points 
(Savitzky-Golay algorithm). 
2.2.3.8 Intrinsic fluorescence spectroscopy 
Samples of 0.1 mg/mL protein in SUPRASIL® 114-QS precision cuvettes (10 mm, Hellma, 
Mühlheim, D) were excited at 295 nm and 25 °C. The emission was scanned from 
305 to 400 nm with a step size of 1 nm and 1 s integration time (Fluorimeter QM-4-CW, PTI, 
Birmingham, NJ, USA). The evaluation was based on normalized spectra (n=3). 
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2.2.3.9 2nd-derivative UV spectroscopy 
Samples of 0.3 mg/mL protein were scanned from 240 to 350 nm (UV/VIS Spectrometer 
Lambda 20, PerkinElmer, Rodgau-Jügesheim, D). The second derivative of the absorption was 
used (n=3). 
2.2.3.10 Binding assay 
MAb1 prevents the target antigen from binding to a specific cell surface protein (CSP). 
Consequently, binding activity of the antibody to the target antigen was analyzed according to 
BI internal method using a competitive ELISA following typical protocols [21]. Briefly, mAb1 and 
the target antigen were added to CSP immobilized on a microtiter plate. Decreasing 
concentration of mAb1 resulted in decreasing inhibition of binding of target antigen to CSP. 
After the addition of goat anti-mouse-IgG horseradish peroxidase that bound to CSP and of 
tetramethylbenzidine dye, the amount of colored product, being inversely proportional to the 
binding activity of the antibody, was measured based on the absorption at 450 nm (n=2). 
2.2.4 Characterization of oleaginous solvents and oily suspensions 
2.2.4.1 Viscosity 
Viscosity was determined by a cone-plate rheometer (Haake RheoStress 600, Thermo Electron, 
Karlsruhe, D) equipped with a 35 mm 1° angle cone (C35/1, Thermo Electron, Karlsruhe, D). 
Recorded in the range of  = 10-2000/s at 20 °C, viscosity was determined at  = 1000/s (n=3). 
2.2.4.2 Preparation of oily mAb1 suspensions 
Mixing of mAb1 PCMC powder and oily solvents was performed in 10 R or 20 R vials (Fiolax® 
clear, Schott, Mühlheim, D) via vortexer (MS2 Minishaker, IKA, Wilmington, NC, USA) at 
1500 min-1 until a visually even dispersion was observed. The solid content of the oily 
suspensions finally ranged from 133 to 316 mg/mL, corresponding to 58-138 mg/mL protein. 
2.2.4.3 Syringe filling 
With respect to the oily solvents, baked-on siliconized and spray siliconized 1 mL long syringes 
(RTF-syringe with luer cone, Gerresheimer, Düsseldorf, D) with tip caps (7025/65 grey, West, 
Eschweiler, D) were manually filled with 1 mL oil (sesame oil, benzyl benzoate or MCT) and 
closed with rubber stoppers. Manual closing was performed by the use of a 1 inch 18 G needle 
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(Becton Dickinson, Heidelberg, D), resulting in a headspace of approx. 2 mm. The rubber 
stoppers were either coated with a fluorocarbon film (FluroTec PH4023/50, grey, West, 
Eschweiler, D) or a fluorinated polymer (Omniflex FM257/2, Hoelvet, Karlsbad, D). 
For injectability testing of the oily mAb1 suspensions, spray siliconized 1 mL long syringes (RTF-
syringe with luer cone, Gerresheimer, Düsseldorf, D) equipped with tip caps (7025/65 grey, 
West, Eschweiler, D) and rubber stoppers (FluroTec PH4023/50, grey, West, Eschweiler, D) 
were manually filled with 1 mL suspension. 
2.2.4.4 Injectability 
Injectability testing was performed with a tensile compression testing machine (Zwicki-TN1S, 
Zwick, Ulm, D) at a crosshead speed of 100 mm/min and 22 ± 3 °C (n=6). The syringes were 
vertically inserted with the tip downwards and injection of pure oils and oily PCMC suspensions 
was carried out into air. Force-displacement curves were recorded to calculate the mean force 
required to expel the oils from the syringe, in the range from 8 to 29 mm. For injectability 
testing of the oily solvents, 23 G 1 inch needles (BD Microlance TM 33 Nr. 16, Becton Dickinson, 
Heidelberg, D) were used. Thin wall 23 G 1 inch needles (Terumo Neolus, Leuven, B) served for 
the investigation of the injectability of oily PCMC suspensions. Furthermore, thin wall 20 G 
1 inch and 25 G 1 inch needles (Terumo Neolus, Leuven, B) were utilized to analyze the 
influence of the inner needle diameter on injectability. 
2.2.4.5 Light microscopy 
Light microscopy was performed as presented in 2.2.3.4. 
2.2.4.6 X-ray powder diffraction 
The crystallinity of mAb1 PCMCs was analyzed with XRD in transmission mode from 
3 °- 40 ° 2 Θ, 0.5 ° steps and 20 s/step based on 1.5406 Å CuKα-radiation at 40 kV and 
40 mA (Stoe, Darmstadt, D). Samples were fixed in the sample holder between two Ultraphan 
foils (cellulose diacetate) with a thickness of 0.014 mm (Stoe, Darmstadt, D). 
2.2.4.7 Swelling of stoppers and tip caps 
The swelling of stoppers (FluroTec PH4023/50, grey, West, Eschweiler, D; Omniflex FM257/2, 
Hoelvet, Karlsbad, D) and tip caps (7025/65 grey, West, Eschweiler, D) was investigated after 
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incubation over 24, 48 and 98 h in a beaker with sesame oil, benzyl benzoate or MCT. The 
height of stoppers and the length of tip caps were measured with a caliper (n=3). 
2.2.4.8 Storage of prefilled syringes 
Storage of oily solvents was performed with baked-on siliconized and spray siliconized syringes 
(see section 2.2.4.3 for detailed preparation) equipped with West rubber stoppers (FluroTec 
PH4023/50, grey, West, Eschweiler, D) and tip caps (7025/65 grey, West, Eschweiler, D). The 
syringes were stored horizontally in the dark at 22 ± 3 °C for 3 and 6 months (n=6). 
2.2.4.9 Concentration of liquid mAb1 formulation 
Concentration of mAb1 bulk, containing 3.27 mg/mL L-histidine HCl monohydrate, 0.68 mg/mL 
L-histidine, 84.0 mg/mL trehalose dihydrate and 0.1 mg/mL disodium EDTA dihydrate, was 
conducted via centrifugation, described in detail in section 2.2.3.6. Buffer, equivalent to the 
composition of the protein bulk, was used for equilibration of the filtration units. Solutions with 
final protein concentrations of 63, 83, 120, 127, 151, 172 and 193 mg/mL, measured via UV 
spectroscopy (section 2.2.3.5), were analyzed for viscosity and injectability. 
3 Results and discussion 
3.1 Development of an in vitro release model for oily PCMC suspensions 
The aim of this investigation was to optimize the incubation conditions for mAb1 PCMC sesame 
oil suspensions to achieve 100 % protein recovery, prerequisite for assessing the entire mAb 
population in subsequent analysis of protein stability. The release process, performed in 30 mL 
plastic syringes, encompassed three steps, namely sedimentation of the PCMC powder towards 
the oil-water interface, dissolution of the PCMC powder and diffusion of the protein, and the 
carrier components, into the aqueous acceptor. The influence of the maximal protein 
concentration in the aqueous phase, the composition of the aqueous phase, variation of 
incubation time and temperature as well as agitation and final centrifugation on protein 
recovery and macroscopic appearance of the oily and the aqueous phase was investigated. 
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Table 5-2: Influence of incubation conditions on protein recovery: agitation: a integrated 
2 min stirring with a magnetic stirrer at 300 rpm; b continuous shaking with a frequency of 
130 min-1 for 24 h in a water bath; centrifugation: 30 min at 100 g 
 
Incubation conditions Protein 
recovery 
[%] 
cmAb 
[mg/mL] 
Incubation 
time [h] T [°C] Agitation 
Aqueous 
phase 
Centri-
fugation 
A 0.5 24 22 ± 3 - WFI - 42.5 ± 1.9 
B 1.0 24 22 ± 3 - WFI - 32.3 ± 1.8 
C 0.5 24 40 - WFI - 62.2 ± 2.3 
D 0.5 24 40 - PBS - 21.0 ± 0.8 
E 0.5 24 40 +a WFI + 99.9 ± 0.8 
F 0.5 24 40 - WFI + 98.9 ± 1.3 
G 0.5 96 40 - WFI - 95.2 ± 1.1 
H 0.5 96 40 - WFI + 103.4 ± 1.1 
I 0.5 24 37.5 +b WFI + 84.7 ± 3.2 
 
After incubation at 22 ± 3 °C or 40 °C for 24 h without agitation or centrifugation (A-D, 
Table 5-2), the aqueous acceptor medium and the upper part of the oily phase were clear. 
Many powder particles were detected by the naked eye in the oil close to the liquid-liquid 
interface. Their number was reduced in samples incubated at 40 °C for 96 h (G) or for 24 h and 
96 h in combination with final centrifugation (F, H), all showing clear aqueous phases. Hence, 
prolonged incubation time at an elevated temperature as well as centrifugation supported the 
sedimentation of PCMC powder in sesame oil allowing for faster dissolution of the particles. 
Applying 24 h incubation at 40 °C with 2 min of integrated horizontal stirring (E) resulted in the 
dispersion of the oil into numerous small droplets floating on the opalescent aqueous phase 
and not substantially coalescing during final centrifugation (Figure 5-2). Considering the 
surface-activity of proteins, the mAb fraction located at the oil-water interface was assumed to 
reduce the surface energy and thus to prevent the oil droplets from coalescence, as likewise 
described in the area of protein-silicone oil interactions [22-24]. Furthermore, proteins are 
widely applied for the stabilization of emulsions and foams, for example in food industry [25, 
26]. Similarly to stirring, continuous shaking (I) of oily PCMC suspensions resulted in a powder-
free oily phase composed of many non-coalesced droplets. As suggested by their macroscopic 
appearance (Figure 5-2), the microscopic analysis of the aqueous acceptors revealed the 
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presence of oil droplets after integrated short-term stirring, in contrast to supplementary 
protein particles in the case of continuous shaking (Figure 5-3). 
 
Figure 5-2: Macroscopic appearance of aqueous acceptor after incubation with sesame oil 
mAb1 PCMC suspension; incubation conditions: left: 0.5 mg/mL protein, 24 h at 40 °C, WFI, 
integrated 2 min stirring, centrifugation (E), middle: 0.5 mg/mL protein, 24 h at 40 °C, WFI, no 
agitation or centrifugation (A), right: 0.5 mg/mL protein, 24 h shaking at 37.5 °C, WFI, 
centrifugation (I). 
a  b  
Figure 5-3: Microscopic appearance of aqueous acceptor after incubation with sesame oil 
mAb1 PCMC suspension; a) oil droplets, incubation conditions: 0.5 mg/mL protein, 24 h at 
40 °C, WFI, 2 min stirring, centrifugation (E); b) oil droplets and protein particles, incubation 
conditions: 0.5 mg/mL protein, 24 h shaking at 37.5 °C, WFI, centrifugation (I). 
In accordance with literature, the oil droplets had a circular cross section with an annular 
appearance [17, 18, 27], whereas the protein particles were of heterogeneous shape [18, 28]. 
Thus, continuous shaking led to the formation of insoluble protein aggregates, but not 
integrated short-term stirring. The potential destabilizing effect of silicone oil on proteins is 
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ambiguously discussed. For example, Li et al. as well as Ludwig et al. found that different 
proteins did not undergo homogenous aggregation in the presence of silicone oil [23, 28], 
whereas Thirumangalathu et al. observed synergistic stimulation of aggregation by a 
combination of silicone oil and agitation [24]. Unlike static isothermal incubation, continuous 
shaking at 350 rpm for several days resulted in a substantial loss of mAb monomer at both 4 °C 
and 37 °C [24]. In contrast, slight short-term agitation, namely shaking for 5 min at 78 rpm, had 
no impact on the aggregation level of albinterferon alfa-2b [17]. 
Table 5-2 summarizes the influence of the incubation conditions on the protein recovery in the 
aqueous phase. Increasing the maximal protein concentration in the aqueous acceptor from 0.5 
to 1.0 mg/mL decreased the protein recovery by approx. 10 % (A: 43 %  B: 32 %). Probably, 
this was a simple effect of increased powder amount e.g. impeding the sedimentation and the 
surface contact of the individual particles. Moreover, the antibody release from the oily 
suspension was significantly augmented with increasing temperature (A: 43 %  B: 62 %), 
presumably in consequence of reduced viscosity facilitating the sedimentation of the PCMC 
powder towards the oil-water interface, and with prolonged incubation time 
(C: 62 %  G: 95 %). Centrifugation, which accelerates the transport of the powder particles to 
the liquid-liquid interface, further improved the protein recovery when incubation was 
performed for either 96 h (G: 95 %  H: 103 %) or 24 h (A: 43 %  F: 99 %). Combining final 
centrifugation and agitation increased the amount of protein released from the oily suspension 
by approx. 40 % (C: 62 %  E: 100 %) in the case of short-term stirring and by approx. 20 % 
when continuous shaking was performed in the water bath for 24 h (C: 62 %  I: 85 %). The 
incomplete protein recovery after shaking can be attributed to the formation of insoluble 
protein aggregates, as previously discussed. 
The use of 10 mM PBS pH 7.4 instead of WFI as acceptor medium considerably decreased the 
protein recovery (C: 62 %  D: 21 %). A clear solution formed when mAb1 PCMC powder was 
simply dissolved in 10 mM PBS pH 7.4 at 1 mg/mL protein, but increasing turbidity could be 
noticed within 24 h at 22 ± 3 °C. These observations pointed at reduced solubility of at least one 
mAb1 PCMC component in PBS buffer. 
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Overall, higher temperature, prolonged incubation time, the use of water as acceptor as well as 
short-term stirring and final centrifugation turned out to improve the release of the antibody. 
On the other hand, the use of PBS buffer resulted in reduced protein recovery and continuous 
shaking caused protein aggregation as indicated by an increase in turbidity. Consequently, 
incubation with WFI at 40 °C for 24 h with integrated short-term stirring and final 
centrifugation (E) was chosen as optimal incubation conditions for the subsequent investigation 
of the compatibility between mAb1 PCMCs and oily solvents. 
3.2 Compatibility between mAb1 PCMCs and oily solvents 
The compatibility study aimed to investigate whether the antibody could be released to 100 % 
from sesame oil, benzyl benzoate and MCT mAb1 PCMC suspensions without any deleterious 
effect, including aggregation, structural perturbation or decrease in specific binding activity. 
Only very few literature is available concerning the stability of protein released from oily 
suspensions [29], but protein instability resulting from exposure to oil-water interfaces is widely 
discussed in the area of protein-silicone oil interactions [17, 22-24, 27, 28, 30-33]. 
Table 5-3: Turbidity and subvisible particle count in the native aqueous phase after 
incubation with sesame oil, benzyl benzoate and MCT mAb1 PCMC suspension; reference 
sample: mAb1 PCMC powder in WFI. 
 Turbidity [FNU] 
Particles 1-50 µm 
[103ml-1] 
 Non-oily particles 5-50 µm 
[ml-1] 
Sesame oil 18.9 ± 2.2  3441 ± 342 9865 ± 7581 
Benzyl benzoate 5.8 ± 1.6 41 ± 13 5286 ± 1570 
MCT 17.5 ± 1.5 4876 ± 1278 2447± 823 
Reference 0.5 ± 0.1 29 ± 5 1498 ± 522 
 
Turbidity measurements are frequently performed to detect insoluble protein aggregates of 
medium size [34, 35], typically < 1 µm [36]. Compared to the reference (0.5 FNU), the turbidity 
of the aqueous acceptor media after incubation with the oily PCMC suspensions was 
significantly higher, ranging from 6 to 19 FNU (Table 5-3), and was noticeable by the naked eye. 
As the particles could be removed via 0.45 µm filtration, as indicated by turbidity values below 
the calibration limit of the turbidimeter (1.5 FNU) after filtration, they were assumed to be very 
large. Optical light microscopy revealed the presence of numerous oil droplets in all unfiltered 
aqueous phases (Figure 5-4). The absence of proteinaceous particles in light microscopy 
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indicated that the antibody formulated as PCMCs was released from the oily suspensions 
without forming significant amounts of insoluble aggregates, irrespective of the choice of oil. 
Additionally, microflow imaging was performed as orthogonal method because it may allow for 
differentiation between insoluble protein particles and dispersed oil droplets [18]. The total 
number of subvisible particles with a size of 1-50 µm correlated well with the turbidity values 
(Table 5-3). As the vast majority (86-98 %) of particles were smaller than 5 µm, an adequate 
aspect ratio could not be analyzed and, thus, the differentiation between these two types of 
particles was not feasible [18, 30]. The number of non-oily larger particles (5-50 µm) detected 
after incubation with oleaginous suspensions was not significantly higher than for the 
reference, except for sesame oil (Table 5-3).  
a  b  
c  
Figure 5-4: Microscopic appearance of native aqueous acceptor after mAb1 release from 
a) sesame oil, b) MCT and c) benzyl benzoate PCMC suspension. 
Irrespective of the type of oil, the antibody was completely recovered in the aqueous phase 
with a monomer level of approx. 99 % detected via HP-SEC. Hence, the incubation with oily 
suspensions did not induce the formation of soluble mAb1 aggregates, at least not to a 
significant extent. 
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Similarly to the investigations on organic water-miscible solvents (chapter 4), several 
spectroscopic methods, namely FT-IR, intrinsic fluorescence and 2nd-derivative UV spectroscopy 
were used to analyze the secondary and tertiary IgG structure after release [37]. Independent 
of the oily solvent, the release did not change the secondary or tertiary conformational 
structure of the monoclonal antibody because all spectra were identical to the one recorded 
after incubation of mAb1 PCMCs with pure water (Figure 5-5). In FT-IR, typical intramolecular 
β-sheet bands occurred at 1692 and 1637 cm-1 showing the predominance of β-sheets in IgGs 
[38, 39]. Well-resolved bands at frequencies of 1678 and 1662 cm-1 represented turn structure 
and peaks at 1616 cm-1 could be attributed either to more β-sheet structure or to side-chain 
effects [38, 39]. The emission maximum revealed via intrinsic fluorescence spectroscopy was 
located at a wavelength of λ = 327 nm for benzyl benzoate and the reference sample and at 
λ = 328 nm for sesame oil and MCT (Figure 5-5b). 2nd-derivative UV spectra of mAb1 released 
from oily suspensions as well as incubated with WFI (reference sample) were characterized by 
peak minima occurring at 271, 284 and 292 nm, while peak maxima were found at 262, 279, 
289 and 297 nm (Figure 5-5c). The application of these spectroscopic methods in the 
development of protein formulations is described in detail in section 3.2 of chapter 4. The 
effect of silicone oil on the secondary and tertiary protein structure has widely been addressed 
[17, 23, 24, 33]. Although the structure of the proteins investigated was not substantially 
affected by the presence of silicone oil, the authors agree that silicone oil might nevertheless 
impact a small population of the particular protein, the rest remaining unaltered, and that 
certain biophysical methods are not sensitive enough to detect these small amounts of silicone-
oil induced conformational changes. 
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 (a) (b) 
  
 (c) 
 
Figure 5-5: Protein structure of mAb1 in the native aqueous phase after release from sesame 
oil, benzyl benzoate and MCT PCMC suspension: (a) FT-IR spectroscopy, (b) intrinsic 
fluorescence spectroscopy, (c) 2nd-derivative UV spectroscopy; reference sample: mAb1 PCMC 
powder in WFI. 
An ELISA was conducted to verify that also the specific antigen binding affinity of the antibody 
released from the oily PCMC suspension was not affected. Figure 5-6 visualizes that, 
independent of the oily vehicle, the binding activity was completely retained after release from 
the oily PCMC suspensions, compared to the PCMC reference sample. All values were within 
the specification limits of 65-130 % of the standard reference sample. 
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Figure 5-6: Binding activity of mAb1 in the native and filtered aqueous phase after release 
from sesame oil (S), benzyl benzoate (B) and MCT (M) PCMC suspension; reference 
sample (R): mAb1 PCMC powder in WFI. 
Thus, neither significant protein loss nor any hint to conformational nor binding relevant 
changes due to protein adsorption at the oil-water interface was observed for mAb1 released 
from oily PCMC suspensions. 
3.3 Injectability of oily solvents and compatibility with primary packaging 
material 
Although the need for functionality test procedures of pre-filled syringes and auto-injector 
packaged parenteral formulations is addressed in EMA and FDA guidelines, there are only very 
little corresponding case studies during protein product development [40, 41]. For the 
evaluation of oily vehicles as suspension media for PCMCs, the viscosity and the injectability of 
sesame oil, benzyl benzoate, MCT and mixtures made of sesame oil and benzyl benzoate were 
analyzed. Moreover, pre-filled syringes were stored for 6 months at room temperature to test 
the compatibility between the oily solvents and the primary packaging material. Swelling of 
stoppers and tip caps after incubation in the oils was additionally investigated. 
3.3.1 Viscosity and injectability of oily solvents 
The viscosity of pure sesame oil was 71.8 mPas. The addition of increasing amounts of benzyl 
benzoate, having a viscosity of 10.3 mPas, successively decreased the viscosity of the mixtures 
(Table 5-4). A viscosity of 31.1 mPas was detected for pure MCT. 
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Table 5-4: Viscosity of sesame oil (S), benzyl benzoate (B), MCT and sesame oil benzyl 
benzoate mixtures (v/v) measured at  = 1000 s-1. 
 Oily solvent  Viscosity [mPas] 
 Sesame oil  71.8 ± 0.9 
 S:B 90:10  56.7 ± 0.3 
 S:B 70:30  37.4 ± 0.5 
 S:B 50:50  25.1 ± 0.2 
 S:B 30:70  16.6 ± 0.1 
 S:B 10:90  12.1 ± 0.2 
 Benzyl benzoate  10.3 ± < 0.1 
 MCT  31.1 ± 0.3 
 
Injectability tests provided force-displacement plots, exemplarily shown in Figure 5-7 for baked-
on siliconized syringes. They were characterized by an initial maximum indicating the break-
loose force of the stopper [10], followed by a permanent, slight increase representing the 
forces required to inject the oil through the needle. Amongst others, it was influenced by 
kinetic energy that needs to be imparted to the fluid and by friction forces of the stopper in the 
syringe barrel [11]. The sharp decline at approx. 29 mm depicted the end of the injectability 
testing. 
  
Figure 5-7: Force-displacement curve of sesame oil (S), benzyl benzoate (B), MCT and sesame 
oil benzyl benzoate mixtures (v/v) expelled from baked-on siliconized syringes via 23 G 1 inch 
needle; vertical lines indicate the limits used for calculation of mean force. 
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Without needle the mean force recorded for the injection of sesame oil, benzyl benzoate and 
mixtures thereof in baked-on siliconized syringes ranged from 3.3 to 3.8 N, independent of the 
amount of benzyl benzoate. 4.3 N were required in the case of MCT, as opposed to 4.5 N 
detected for syringes filled with air instead of oil. Thus, the injection force of the syringes was 
reduced in the presence of sesame oil and/or benzyl benzoate, acting as lubricant, but not in 
the presence of MCT. 
 (a) (b) 
 
Figure 5-8: Force required to expel sesame oil (S), benzyl benzoate (B), MCT (M) and sesame 
oil benzyl benzoate mixtures (v/v) from syringes through a 23 G 1 inch needle; (b) in 
dependence of viscosity measured at   = 1000 s-1; linear regression y = 0.073x+3.44 R²=0.821 
(baked-on siliconized), y = 0.063x+1.71 R²=0.995 (spray siliconized). 
For syringes equipped with a 1 inch 23 G needle significantly higher injection forces were 
detected (Figure 5-8a). The injection of pure sesame oil from baked-on siliconized syringes 
resulted in a mean force of 8.5 N. With increasing amounts of benzyl benzoate the forces 
decreased steadily down to a mixing ratio of 50:50 (v/v) because the viscosity of the oily 
mixtures continuously diminished. Further addition of benzyl benzoate did not significantly 
reduce the injection force because, in this range, the impact of the viscosity was overlaid by 
other effects, such as the gliding force of the stopper. This could also be seen in Figure 5-8b 
showing an overall linear correlation between the injection force and the viscosity of the oily 
solvents. The linear correlation corresponds to the Hagen-Poiseuille equation that describes the 
pressure drop (p1) in a fluid flowing through a cylindrical line and that can thus be applied to 
the injection via syringe (Equation 5-1). In Equation 5-1, F1 is the injection force and t the 
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injection time, while V and η describe the volume and the viscosity of the fluid, A1 is the 
internal barrel area, r1 the inner barrel radius, r2 the inner needle radius and l2 the needle 
length. 
 =  ∗  =
	



=  ∗   (5-1) 
Hence, based on viscosity data the injection force of oily vehicles could be predicted. MCT 
(6.6 N) deviated from the straight line which was attributed to a less pronounced lubricating 
effect. The deviating behavior of MCT was also reflected in a considerably steeper force-
displacement curve than for the other oils (Figure 5-7). 
Furthermore, compared to baked-on siliconized syringes, significantly lower injection forces 
were detected when spray siliconized syringes were used (Figure 5-8), because baked-on 
siliconized syringes contained approx. 0.05 mg as opposed to spray siliconized syringes with 
0.8 ± 0.2 mg silicone oil [42], confirming the results reported by Badkar at al. [31]. However, the 
use of spray siliconized syringes could substantially reduce the injection force. But it has to be 
considered that spray siliconization is associated with a higher risk of particle formation in the 
subvisible range originating from silicone oil droplets with or without precipitated protein [31]. 
3.3.2 Compatibility between oily solvents and primary packaging material 
Dexter and Shott observed diffusion of oil into the rubber matrix of syringe stoppers that 
caused the rubber to swell [10]. Swollen rubber could release higher amounts of 
leachables/extractables into the oily solvent which may affect protein stability, as e.g. reported 
by Badkar et al [31]. Therefore, the compatibility between the oils and the primary packaging 
material, namely stoppers and tip caps, was investigated. 
The incubation of stoppers with pure sesame oil, benzyl benzoate and MCT for 24-98 h at room 
temperature did not affect the stoppers´ height, as presented in Table 5-5. In contrast, 
incubated tip caps significantly increased in length which was also noticeable by the naked eye. 
Both components were made of bromobutyl rubber, but, as opposed to the tip caps, the 
stoppers were coated with a fluorocarbon film or a fluorinated polymer intended to reduce the 
interaction between rubber and drug product. This coating prevented the rubber from uptake 
of the oily vehicles. Consequently, in the development of the final application device for oily 
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PCMC suspensions, attention should be paid to inert coatings of rubber materials to ensure that 
the components in contact with the drug product do not have any detrimental effect [43]. 
Table 5-5: Stoppers` and tip caps` height [mm] after storage in sesame oil, benzyl benzoate 
and MCT for 24 h, 48 h and 98 h. 
Helvoet stoppers     
 Oily solvent  Initial value  24 h  48 h  98 h 
 Sesame oil  8.0 ± 0.1  8.0 ± < 0.1  8.0 ± 0.1  8.0 ± < 0.1 
 Benzyl benzoate  8.0 ± 0.1  8.0 ± 0.1  8.0 ± 0.1  8.0 ± < 0.1 
 MCT  8.0 ± 0.1  8.0 ± < 0.1  8.0 ± 0.1  8.0 ± < 0.1 
West stoppers     
 Sesame oil  8.2 ± 0.1  8.3 ± < 0.1  8.3 ± < 0.1  8.3 ± 0.1 
 Benzyl benzoate  8.2 ± 0.1  8.3 ± 0.1  8.3 ± 0.1  8.2 ± 0.1 
 MCT  8.2 ± 0.1  8.2 ± < 0.1  8.2 ± 0.1  8.2 ± < 0.1 
Tip caps     
 Sesame oil  16.3 ± 0.1  16.7 ± 0.1  16.8 ± 0.1  17.2 ± 0.1 
 Benzyl benzoate  16.3 ± 0.1  17.0 ± < 0.1  17.2 ± < 0.1  17.3 ± 0.1 
 MCT  16.3 ± 0.1  16.9 ± 0.1  17.3 ± 0.1  17.7 ± 0.1 
 
 (a) (b) 
  
Figure 5-9: Required force to expel sesame oil (S), benzyl benzoate (B), MCT (M) and sesame 
oil benzyl benzoate mixtures (v/v) from syringes after 3 and 6 months storage; (a) baked-on 
siliconized syringes; (b) spray siliconized syringes. 
Furthermore, incompatibility between the primary packaging material and the oily solvents 
could result in increasing injection forces. Therefore, injectability was tested after 3 and 
6 months storage of syringes at room-temperature. Independent of the composition of the oily 
vehicle, the injection forces did not significantly change over storage time for baked-on and 
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spray siliconized syringes (Figure 5-9). Thus, apart from the tip caps, the compatibility between 
the syringes and the oils was proven. 
3.4 Characterization of oily mAb1 PCMC suspensions 
For the investigation of rheology and injectability of oily mAb1 PCMC suspensions, mixtures of 
sesame oil and benzyl benzoate with mixing ratios of 30:70 and 70:30 (v/v) as well as pure MCT 
were chosen as solvents. MCT and the sesame oil benzyl benzoate mixture 70:30 (v/v) were 
selected because they had approximately the same viscosity, whereas the viscosity of the 
30:70 (v/v) mixture of sesame oil and benzyl benzoate was significantly lower (Table 5-4 in 
section 3.3.1). The influence of inner needle diameter on injectability was analyzed, too. 
Moreover, the sedimentation behavior of oily mAb1 PCMC suspensions was evaluated and 
injectability data was compared to the values of a corresponding liquid formulation. 
3.4.1 Appearance and rheology of oily mAb1 PCMC suspensions 
Macroscopically even oily mAb1 PCMC suspensions were prepared up to a solid content of 
316 mg/mL. Optical polarization microscopy revealed the presence of two particle fractions, 
birefringent needle-like crystals and fine anisotropic amorphous material (Figure 5-10). The 
crystals composed of α-glycine, as detected via XRD analysis (Figure 5-11), were already present 
in the initial PCMC powder and were not a consequence of potential recrystallization of carrier 
material in the oily suspensions. 
a  b  
Figure 5-10: Optical light microscopy of S:B 30:70 (v/v) PCMC suspension with a solid content 
of 224 mg/mL; (a) without and (b) with polarizing filters. 
Chapter 5 
147 
(a) 
 
(b) 
 
Figure 5-11: XRD analysis of mAb1 formulated as (a) PCMC powder and (b) S:B 30:70 (v/v) 
PCMC suspension with a solid content of 224 mg/mL. 
The viscosity of the oily mAb1 PCMC suspensions depended on the viscosity of the pure oily 
media. Suspensions made of sesame oil and benzyl benzoate with a mixing ratio of 30:70 (v/v) 
were significantly less viscous than those containing either a 70:30 (v/v) mixture or MCT. As 
exemplarily presented in Figure 5-12a, the rheograms recorded for the oily mAb1 PCMC 
suspensions all demonstrated shear thinning or pseudoplastic flow behavior [44]. This effect 
was more pronounced with increasing solid content and is typical of concentrated suspensions 
[45]. It is widely believed that shear thinning is caused by realignment of the particles reducing 
the energy dissipated under shear [46]. However, based on light-scattering experiments, 
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Ackerson associated shear thinning to a distortion of the liquid-like structure assumed to 
decrease the energy dissipation [47]. Moreover, shearing at 1000 and 2000 s-1 for several 
seconds resulted in continuously decreasing viscosity of the suspensions, referred to as 
thixotropy (Figure 5-12b). Microscopic inspection precluded at least substantial modification of 
suspended particles under extreme shear stress.  
 (a) (b) 
 
Figure 5-12: Rheology of S:B 30:70 (v/v) mAb1 PCMC suspension with a solid content of 
316 mg/mL; (a) viscosity in dependence of shear rate; (b) viscosity measured at   = 1000 s-1 
over time. 
According to the equation of Einstein (Equation 5-2), valid for diluted suspensions with 
spherical particles that do not influence each other and show Newtonian flow behavior, the 
viscosity of the suspension (η) depends on the viscosity of the suspension medium (η) and on 
the volume fraction of suspended particles (φ). 
η = η + η ∗ 2.5 ∗ φ (5-2) 
In contrast, oily mAb1 PCMC suspensions showed a nonlinear increase in viscosity with 
increasing volume fraction (Figure 5-13), potentially attributed to interactions between 
suspended particles [48].  
0 500 1000 1500 2000
0
1000
2000
3000
4000
5000
6000
>
>
 
 
Vi
sc
os
ity
 [m
Pa
s]
Shear rate [s-1]
0 2 4 6 8 10
0
560
580
600
620
640
660
 
 
Vi
sc
os
ity
 [m
Pa
s]
Time of shearing at 1000/s [s]
Chapter 5 
149 
 
Figure 5-13: Viscosity of oily mAb1 PCMC suspensions in dependence of the volume fraction 
of powder. 
3.4.2 Injectability of oily mAb1 PCMC suspensions  
All oily mAb1 PCMC suspensions investigated were manually and mechanically injectable 
without any clogging phenomenon. Irrespective of the oily solvent, the injection force 
augmented nonlinearly with increasing solid content of the suspensions (Figure 5-14a). Due to 
the linear relationship between viscosity and injection force (Figure 5-14b), viscosity 
measurements are well suitable to predict the injectability of the oily formulations.  
 (a) (b) 
  
Figure 5-14: Injection force for oily mAb1 PCMC suspensions; (a) in dependence of solid 
content; (b) in dependence of the viscosity measured at   = 1000 s-1, linear regression: 
y = 0.05x+4.4 R2 = 0.997 (S:B 70:30 v/v), y = 0.06x+2.1 R2 = 0.982 (S:B 30:70 v/v), y = 0.06x+3.1 
R2 = 0.982 (MCT). 
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Moreover, the influence of the inner needle diameter on the injection force for S:B 30:70 (v/v) 
mAb1 PCMC suspensions with a solid content of 224 mg/mL was studied for 20 G (670 ± 8 µm), 
23 G (416 ± 3 µm) and 25 G (328 ± 5 µm) needles. The inner needle diameter was measured 
based on SEM pictures (supplementary material). A linear relationship between the injection 
force and the fourth power of the inner needle diameter was revealed (Figure 5-15), in 
accordance to the Hagen-Poiseuille law (Equation 5-1 in section 3.3.1). Hence, the injection 
force could easily be calculated for needles with different inner needle diameter. 
 
Figure 5-15: Injection force for S:B 30:70 (v/v) mAb1 PCMC suspensions with a solid content 
of 224 mg/mL in dependence of inner needle diameter; linear regression: y = 0.31x+4.6 
R²=0.999. 
Subcutaneous injectability can easily be modulated by the choice of needle and syringe, e.g. 
referring to inner needle diameter, needle length, plunger diameter and siliconization of the 
syringe. But these parameters also influence the convenience of injection for the patient. For 
example, the use of a needle with larger diameter is associated with increased injection pain. 
General recommendations of both appropriate testing procedure and maximal acceptable 
injection force are missing in the current Pharmacopoeias and various injectability values are 
reported in literature (Table 5-6). With respect to the oily PCMC suspensions, all formulations 
were physically injectable under the skin because the maximal injection force for the 
suspensions with a solid content of 316 mg/mL and a protein concentration of approx. 
140 mg/mL was 50 N for MCT and the sesame oil benzyl benzoate mixture with a mixing ratio 
of 70:30 (v/v), as opposed to 40 N for the 30:70 (v/v) sesame oil benzyl benzoate mixture. 
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Table 5-6: Injectability values reported in literature. 
Needle Force / pressure Description Reference 
20,22,26 G > 45-50 N Difficult to inject  [49] 
20, 23 G 50 N  [50] 
16 G 
621-800 kPa Typical adult male hand grip strength for single administration [51] 
344-482 kPa Typical adult male hand grip strength for multiple administration 
18 G 1193 kPa  [52] 
 112 N 
Maximum force of the thumb of 
male students generated within 
3-5 s 
[53] 
13, 15, 
17-27 G 13 N 
Tolerable for an adult to maintain 
for 1 min [54] 
18, 20-25, 
27 G 
11-25 N Easy to inject 
[55] 26-50 N Injectable 51-100 N Injectable with some difficulty 
100-130 N Difficult to inject 
 20 N Easy to generate for a physician [56] 
 
3.4.3 Comparison of mAb1 formulated as oily PCMC suspension and liquid 
formulation 
The viscosity and injection force of oily mAb1 PCMC suspensions were compared to a liquid 
formulation of the monoclonal antibody, containing the same excipients as the PCMCs. The 
viscosity of the liquid formulation and consequently also the injection force were considerably 
smaller than the values for the oily suspensions with the same protein concentration 
(Figure 5-16). Hence, formulating mAb1 as oily PCMC suspension instead of high concentration 
liquid formulation was not beneficial with respect to injectability. In contrast, a significant 
decrease of viscosity was observed by Miller et al. for nonaqueous suspensions of lysozyme 
based on benzyl benzoate and safflower oil, compared to a high concentration liquid 
formulation of the enzyme [57]. A similar finding was described by Yang et al. for subcutaneous 
formulations of monoclonal antibodies [58]. A suspension of infliximab in 10 % ethanol and 
10 % PEG 3350 with 125 mg/mL protein had a viscosity of approx. 20 mPas, whereas the 
viscosity of a corresponding liquid formulation was significantly higher, with a value of approx. 
85 mPas [58]. Furthermore, it has to be considered that mAb1 used in the current study on oily 
PCMC suspensions showed very low viscosity values, even for high protein concentrations. For 
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example, the viscosity at a protein concentration of approx. 120 mg/mL was only about 7 mPas. 
Liu al. as well as Kanai et al. found considerable higher viscosity of approx. 50 mPas for a liquid 
120 mg/mL mAb1 formulation, which highly depended on pH and ionic strength of buffer and 
charged excipients [59, 60]. Nevertheless, the viscosity of this liquid mAb formulation was 
significantly lower than the values detected for oily mAb1 PCMC suspensions with comparable 
protein concentration. Thus, apart from limited solubility and aggregation phenomena often 
associated with high concentration protein solutions [61], formulating mAbs as oily PCMC 
suspensions could only be advantageous in the case of extremely high viscosity of the liquid 
injectable. 
 (a) (b) 
  
Figure 5-16: Comparison of mAb1 formulated as oily PCMC suspension and liquid formulation 
with respect to (a) viscosity and (b) injection force in dependence of protein concentration. 
3.4.4 Sedimentation behavior of oily mAb1 PCMC suspensions 
As part of the stability testing, the sedimentation behavior of oily mAb1 PCMC suspensions 
based on sesame oil and benzyl benzoate mixtures with mixing ratios of 70:30 and 30:70 (v/v) 
as well as on MCT was monitored in vertically stored spray siliconized glass syringes over 26 d 
(t26d) at 22 ± 3 °C. In all cases, hindered settling characterized by clear supernatants increasing 
with time occurred, exemplarily shown for MCT in Figure 5-17 (for S:B 70:30 and S:B 30:70 see 
supplementary material). With increasing solid content the volume of the clear supernatant 
decreased, independent of the choice of oily vehicle. Based on the height of supernatant the 
sedimentation rate decreased in the following order: MCT > S:B 70:30 > S:B 30:70. As no 
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compacted sediment formed during settling, the oily suspensions could be successfully 
resuspended. 
a  b  
Figure 5-17: Sedimentation behavior of MCT mAb1 PCMC suspensions at (a) t0 and (b) t26d; 
solid content from left to right: 133, 163, 194, 224, 255 and 285 mg/mL. 
4 Conclusion 
The development of oily mAb1 PCMC suspensions with sesame oil, benzyl benzoate and MCT as 
resuspension media required the design of an appropriate in vitro release model. Prolonged 
incubation time, higher temperature, the use of water as acceptor medium as well as short-
term stirring and final centrifugation ensured 100 % protein recovery after the release from oily 
mAb1 PCMC suspensions and enabled the analysis of protein integrity despite of considerable 
amounts of dispersed oil droplets in the aqueous acceptor. The analytical focus was on 
insoluble and soluble aggregates, protein secondary and tertiary structure as well as on binding 
activity of the antibody. Neither the formation of insoluble protein particles or soluble 
aggregates was detected nor did the spectroscopic methods indicate changes in the mAb´s 
secondary and tertiary structure. Specific antigen binding affinity of the antibody was 
completely retained. As the antibody could quantitatively transfer from the oily suspensions 
into the aqueous phase without measurable deleterious effect, these oleaginous media 
represent appropriate vehicles for the suspension of mAb1 coated microcrystals. 
MCT, sesame oil and benzyl benzoate as well as mixtures of the latter two could all be easily 
expelled from baked-on and spray siliconized glass syringes. The maximal mean injection force 
did not exceed 9 N. Spray siliconization of the syringes significantly reduced the injection forces 
because it resulted in a higher amount of the lubricant silicone oil present in the syringes. 
Injectability of baked-on siliconized syringes was not affected during 6 months storage at room 
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temperature. Coated stoppers were compatible with the oily solvents, as opposed to uncoated 
tip caps which swelled due to oil uptake. 
Based on MCT and mixtures of sesame oil and benzyl benzoate with a mixing ratio of 70:30 and 
30:70 (v/v), mAb1 PCMC suspensions were prepared up to a solid content of 316 mg/mL, 
corresponding to 138 mg/mL protein. The suspensions showed hindered settling, decreasing 
with increasing solid content, and could be resuspended without any residual compacted 
sediment. The rheology of the suspensions was characterized by shear thinning behavior and 
the viscosity increased nonlinearly with increasing solid content. Suspensions made of sesame 
oil and benzyl benzoate 30:70 (v/v) were significantly less viscous than MCT and S:B 30:70 (v/v) 
suspensions due to lower viscosity of the suspension medium. As a linear relationship between 
the viscosity and the injectability was revealed, the injection forces followed the same trend as 
the viscosity. All suspensions were injectable without any clogging phenomenon and the 
injection forces were in an acceptable range with a maximal mean injection force of approx. 
40 N for the 316 mg/mL mAb1 PCMC suspensions in sesame oil and benzyl benzoate 30:70 (v/v) 
and of 50 N for MCT and S:B 30:70 (v/v). Compared to the corresponding mAb1 solutions, 
formulating the antibody as oily PCMC suspension was not beneficial with respect to viscosity 
and ease of administration by injection. As the viscosity of the oily mAb1 PCMC suspensions 
was also significantly higher than viscosity values of liquid high concentration mAb formulations 
described in literature, this dosage form would only be advantageous in the case of extremely 
high viscosity of protein solutions, e.g. due to gelation. However, other challenges typically 
associated with the development of high concentration liquid formulations, including 
pronounced aggregation tendency, reduced solubility and poor overall stability, might be 
overcome by the choice of oily PCMC suspension as promising alternative dosage form for 
therapeutic proteins.  
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6 Appendix: supplementary material 
6.1 Determination of inner needle diameter via SEM 
The inner needle diameter of 20 G (670 ± 8 µm), 23 G (416 ± 3 µm) and 25 G (328 ± 5 µm) 
needles was determined via SEM, as exemplarily shown in Figure 5-18. 
 
Figure 5-18: Determination of inner diameter of a 23 G needle via SEM. 
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6.2 Sedimentation behavior of S:B 70:30 and S:B 30:70 (v/v) mAb1 PCMC 
suspensions 
a  b  
Figure 5-19: Sedimentation behavior of S:B 70:30 (v/v) mAb1 PCMC suspensions at (a) t0 and 
(b) t26d; solid content from left to right: 133, 163, 194, 224, 255 and 285 mg/mL. 
a  b  
Figure 5-20: Sedimentation behavior of S:B 30:70 (v/v) mAb1 PCMC suspensions at (a) t0 and 
(b) t26d; solid content from left to right: 133, 163, 194, 224, 255 and 285 mg/mL. 
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Chapter 6  
M e c h a n i s t i c  i n s i g h t s  i n t o  t h e  
P C M C  f o r m a t i o n  p r o c e s s  
Abstract 
Although the protein-coated microcrystals (PCMC) technology has been successfully applied to 
a wide variety of molecules, such as peptides, proteins and DNA/RNA and the development of 
high concentration PCMC suspensions as final dosage form has recently advanced, the 
mechanism of particle formation is still unclear. Based on various studies on cytokine and mAb1 
PCMCs with respect to morphology, composition and resulting stability, this chapter aimed to 
develop mechanistic insights in the PCMC formation process. The crystallinity/amorphicity of 
mAb1 PCMCs, containing trehalose, glycine, NaCl, histidine, phenylalanine and EDTA as carrier 
components, was investigated in dependence of protein load (PL) and trehalose (tre) content. A 
total amount of ≥ 85-90 % (m/m) protein and trehalose dihydrate, typically forming amorphous 
solids, was necessary to obtain a completely amorphous XRD pattern for the proteinaceous 
particles. The storage stability over 4 weeks at 40 °C/32 % RH of three amorphous powders 
with different protein loads and trehalose contents (60 % PL 30 % tre, 50 % PL 40 % tre, 
40 % PL 50 % tre) and one crystalline formulation (10 % PL 30 % tre), which comprised 
detectable amounts of crystalline α-glycine and NaCl at t0, was analyzed with respect to 
insoluble and soluble protein aggregates (protein recovery, turbidity, HP-SEC, SDS-PAGE) as well 
as morphological and carrier stability (SEM, XRD). Except for on-going NaCl crystallization 
detected for crystalline mAb1 PCMCs, only marginal differences were found between the 
formulations, all providing good overall storage stability of the antibody. Confocal laser 
scanning fluorescence microscopy clearly showed homogenous mAb1 distribution within the 
spherical particles for the amorphous mAb1 formulations. In contrast, the crystalline 
formulation was characterized by non-fluorescent rod-shaped glycine crystals with amorphous 
proteinaceous material being attached to the crystal surface. The presence of two 
corresponding particle fractions, namely carrier crystals forming the core of the particles and 
amorphous proteinaceous material on the surface, was further proven in case of cytokine 
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PCMCs by powder fractionation via Andersen cascade impactor. Thus, the supramolecular 
structure of these particles was consistent with the initial idea of PCMCs presented by Vos [1], 
in contrast to the amorphous mAb1 PCMCs which did not show these two distinct material 
fractions, but instead a homogenous particle composition which only differed in size. Cytokine 
PCMCs could further be manufactured via standard one-step precipitation as well as by two-
step precipitation in batch mode. Two-step precipitation comprised the separate production of 
carrier crystals on which the protein was precipitated in a second step. The manufacturing 
method did not affect the morphology or the protein process stability. Batch mode production 
of protein-free mAb1 PCMCs was only feasible with some limitations, but revealed the 
existence of an emulsion-like state, comprising dispersed droplets of an “excipient and protein 
rich/solvent poor” phase in a continuous “excipient and protein poor/solvent rich” phase, 
during the formation of these particles. Crystal growth at the liquid-liquid interface as well as 
inside the droplets was observed via polarization microscopy. Thus, the spinodal decomposition 
model was suggested to be appropriate to describe the formation process of these mAb1 
PCMCs. 
1 Introduction 
The protein-coated microcrystals technology represents an alternative method of protein 
stabilization in the solid state via coprecipitation of an aqueous solution of protein and carrier 
material induced by rapid mixing with a surplus of organic water-miscible solvent. The idea that 
goes back to a patent of Moore [2] has not only successfully been applied to various proteins, 
peptides and polypeptides, such as such as e.g. subtilisin Carlsberg protease [3], lipase [4, 5], 
trypsin [1, 6], BSA [6, 7], IgGs [6, 8], but also DNA and RNA [9]. König established a pilot-scale 
production process for PCMCs that enables a continuous production of up to 120 L suspension 
per hour [10]. Based on this progress, the preceding chapters of this thesis dealt with the 
development of cytokine (chapter 2) and mAb2 (chapter 3) PCMCs providing high process and 
storage stability to the protein. Additionally, organic water-miscible and oily solvents were 
evaluated as resuspension media for PCMCs allowing for subcutaneous application as high 
concentration suspensions (chapters 4 and 5). Despite these achievements, the particular 
mechanism how PCMC particles form via rapid dehydration of protein and carrier material 
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during coprecipitation is still unclear. Vos who focused on the PCMC mechanism discussed the 
classical nucleation and growth model as well as the model of spinodal decomposition to 
explain the formation of protein-coated microcrystals [1]. According to the classical nucleation 
theory, the free energy of a multicomponent system initially existing as a single phase is 
changed by modification of pressure or temperature or by homogenous mixing with a 
supplementary component. Consequently, phase separation, being energetically more 
favorable, leads to the coalescence of particles and thus to the formation of nuclei which begin 
to grow [11]. Spinodal decomposition describes the spontaneous rapid separation of a 
supersaturated, initial one-phase solution brought inside the spinodal curve, tracing the 
stability limit, by changing its composition without actual nucleation [11, 12]. Vos suggested 
that the latter model was slightly more appropriate for the description of the PCMC formation 
process [1]. But, it has to be considered that in most real systems the transition between the 
two mechanisms is gradual, as reviewed by Horn and Rieger [11].  
The current chapter that comprises various studies on cytokine and mAb1 PCMCs touching 
their morphology, composition and resulting stability aimed to gain further mechanistic insights 
into the PCMC formation process. Therefore, the influence of protein load and trehalose 
content on the morphology and storage stability of mAb1 PCMCs was investigated. 
Fractionation of cytokine and mAb1 PCMC powder via Andersen cascade impactor intended to 
specify the chemical composition of different particle populations and ultimately the 
supramolecular structure of the particles. Finally, the manufacturing of cytokine and mAb1 
PCMCs via one- and two-step precipitation as well as of protein-free particles was studied. 
2 Materials and methods 
2.1 Materials 
L-Phenylalanine, sodium bicarbonate, dimethyl sulfoxide (DMSO), phosphate buffered saline 
pH 7.4 and sodium hydroxide were purchased from Sigma-Aldrich, Steinheim, D, disodium 
EDTA dihydrate, hydrochloric acid (1 mol/L), isobutanol (Emplura®), ethanol 95-97 % (v/v), 
Brij® 35, L-2-methyl-2,4-pentanediol and water free glycerin (Emprove®) from Merck, 
Darmstadt, D. Glycine, L-histidine and L-histidine hydrochloride monohydrate were procured 
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from Ajinomoto Omnichem, Louvain-la-Neuve, B. Sodium dihydrogen phosphate dihydrate was 
delivered by Dr. Paul Lohmann, Hungen, D, sodium chloride by Akzo Nobel, Hengelo, NL, and 
trehalose dihydrate by Ferro Pfanstiehl, Waukegan, IL, USA. D/L-Valine was purchased from 
Fluka (Buchs, CH) and trisodium citrate dihydrate and citric acid monohydrate from 
Jungbunzlauer (Ladenburg, D). Sucrose was obtained from Südzucker (Mannheim, D). Sodium 
dodecyl sulfate was from Serva, Heidelberg, D. All chemicals were utilized without further 
purification. The protein bulk drug substances were provided by Boehringer Ingelheim. 
2.2 Methods 
2.2.1 Preparation of protein solutions 
The mAb1 bulk drug substance was composed of 20 mg/mL human IgG2 monoclonal antibody, 
0.68 mg/mL L-histidine, 3.27 mg/mL L-histidine hydrochloride monohydrate, 0.1 mg/mL 
disodium EDTA dihydrate, 84.0 mg/mL trehalose dihydrate and 0.1 % polysorbate 80. The 
buffer of the bulk drug substance was exchanged via ultra- and diafiltration resulting in a 
protein solution that consisted of 75.1 mg/mL protein, 0.2 mg/mL L-histidine, 0.8 mg/mL 
L-histidine hydrochloride monohydrate, 0.03 mg/mL disodium EDTA dihydrate and approx. 
0.4 mg/ml polysorbate 80 (crossflow buffer exchange and concentration unit, Boehringer 
Ingelheim, Biberach/Riss, D; membrane cassette Sartocon Slice, Hydrosart, 30 kd, Sartorius, 
Göttingen, D; Quattroflow 150 S membrane pump, Quattroflow Fluid Systems, Hardegsen, D). 
The cytokine bulk drug substance contained 1.5 mg/mL hydrophobic cytokine, 50 mM sodium 
acetate trihydrate, 1 mM disodium EDTA dihydrate and 0.1 % sodium dodecyl sulfate (SDS). 
After ultra- and diafiltration (membrane cassette Sartocon Slice, Hydrosart, 5 kd, Sartorius, 
Göttingen, D) the protein solution comprised 18.0 mg/mL protein, 22 mM citrate and approx. 
1.2 % SDS. 
The surfactants polysorbate 80 or SDS were present in the final protein solutions because they 
cannot be removed via ultra-/diafiltration, as similarly reported by Mahler at al. for 
polysorbate 20 [13]. 
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2.2.2 PCMC production process 
The PCMC production process is divided into four main steps: preparation of protein-carrier 
solution, precipitation, concentration/solvent exchange, and drying. 
2.2.2.1 Preparation of protein-carrier solutions 
For the preparation of the protein-carrier solution, the carrier material was dissolved in water 
and the solution pH value was adjusted to 5.5 prior to the addition of the protein solution. 
The composition of the protein-carrier solutions for the study on mAb1 PCMCs with varying 
protein load (PL) and trehalose (tre) content are presented in Table 6-1 and Table 6-2. 
Furthermore, a formulation with 40 % protein and 50 % trehalose was produced (Table 6-3) and 
additionally used for the fractionation via cascade impactor. Variation of protein load or 
trehalose content led to different relative amounts of the remaining carrier components 
(glycine, phenylalanine, sodium chloride, histidine hydrochloride monohydrate, histidine, 
trehalose dihydrate and Di-Na-EDTA dihydrate) to ensure a constant solid content of the 
protein-carrier solutions of 100 mg/mL. Depending on the protein load, the 
polysorbate 80 concentration ranged from approx. 0.05 to approx. 0.3 mg/mL. 
Table 6-4 shows the composition of the protein-carrier solution for the production of cytokine 
PCMCs with a solid content of 45 mg/mL. 
Table 6-1: Composition of protein-carrier solutions with constant protein load (PL) of 50 % 
and varying trehalose (tre) content [% w/w]. 
Excipient 50 % PL, no tre 
50 % PL, 
25 % tre 
50 % PL, 
30 % tre 
50 % PL, 
35 % tre 
50 % PL, 
40 % tre 
mAb1 50.0 50.0 50.0 50.0 50.0 
L-Histidine HCl monohydrate 5.0 2.5 2.0 1.5 1.0 
L-Histidine 1.0 0.5 0.4 0.3 0.2 
NaCl 10.0 5.0 3.9 3.0 2.0 
Glycine 30.4 15.2 11.9 9.1 6.05 
L-Phenylalanine 3.4 1.7 1.3 1.0 0.7 
Trehalose dihydrate -- 25.0 30.4 35.0 40.0 
Di-Na-EDTA dihydrate 0.2 0.1 0.1 0.1 0.05 
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Table 6-2: Composition of protein-carrier solutions with constant trehalose (tre) content of 
30 % and varying protein load (PL) [% w/w]. 
Excipient 10 % PL 30 % tre 
45 % PL 
30 % tre 
50 % PL, 
30 % tre 
55 % PL, 
30 % tre 
60 % PL, 
30 % tre 
mAb1 10.0 45.0 50.0 55.0 60.0 
L-Histidine HCl monohydrate 6.0 2.5 2.0 1.5 1.0 
L-Histidine 1.2 0.5 0.4 0.3 0.2 
NaCl 12.0 5.0 3.9 2.9 1.9 
Glycine 36.2 14.9 11.9 8.8 5.8 
L-Phenylalanine 4.0 1.6 1.3 1.0 0.6 
Trehalose dihydrate 30.4 30.4 30.4 30.4 30.4 
Di-Na-EDTA dihydrate 0.2 0.1 0.1 0.1 0.1 
 
Table 6-3: Composition of protein-carrier solution with protein load (PL) of 40 % and 50 % 
trehalose (tre) [% w/w]. 
Excipient 40 % PL 50 % tre 
mAb1 40.0 
L-Histidine HCl monohydrate 1.0 
L-Histidine 0.2 
NaCl 2.0 
Glycine 6.0 
L-Phenylalanine 0.7 
Trehalose dihydrate 50.0 
Di-Na-EDTA dihydrate 0.1 
 
Table 6-4: Composition of the protein-carrier solution of cytokine PCMCs [% w/w]. 
Excipient Cytokine PCMCs 
Trisodium citrate dihydrate 8.6 
Citric acid monohydrate 1.2 
Cytokine 10.0 
DL-Valine 79.2 
Sucrose 1.0 
 
2.2.2.2 Continuous precipitation of mAb1 and cytokine PCMCs 
The continuous precipitation was carried out as described in detail by König [10]. Briefly, two 
equal streams of precipitating agent were mixed with one stream of protein-carrier solution in 
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a small double jet impingement mixer of an inner diameter of 1.5 mm (Boehringer Ingelheim, 
Biberach/Riss, D). The mixing ratio of the precipitating agent saturated with all carrier 
components, isobutanol for mAb1 PCMCs and a 1:1 mixture of isopropanol and 
2-methyl-2,4-pentanediol based on volume for cytokine PCMCs, and the protein-carrier 
solution was set to 95 : 5 (v/v). The modular mixing platform from Ehrfeld (Bayer Technology, 
Wendelsheim, D) encompassed three micro gear pumps (HNP pumps mzr 11507 and 7255, 
Hydraulik Nord Fluidtechnik, Parchim, D), pressure sensors and temperature sensors to monitor 
the precipitation step. The total flow rate of 1000 mL/min was controlled by the software 
LabView (National Instruments, Munich, D) and Coriflow mass flow meters (Bronkhorst, Kamen, 
D). The final suspension volume after precipitation was 1 L for cytokine PCMCs, 2 L for mAb1 
PCMCs and 0.5 L for the suspensions containing Alexa® 488 labeled mAb1. 
2.2.2.3 Batch mode preparation of cytokine and mAb1 PCMCs via one-step and two-
step precipitation 
One-step precipitation of cytokine and mAb1 PCMCs in batch mode was performed, according 
to Khosravani et al. and Kreiner and Parker [4, 14]. Briefly, 25.0 mL of the protein-carrier 
solution were added dropwise within approx. 3 min into 475 mL precipitating agent under 
stirring at 500 rpm (Mini MR standard IKAMAG®, IKA, Staufen, D). The precipitating agent was a 
1:1 (v/v) mixture of isopropanol and 2-methyl-2,4-pentanediol saturated with all carrier 
components for cytokine PCMCs and pure saturated isobutanol for mAb1 PCMCs. 
The preparation of PCMCs via two-step precipitation included two separate batch mode 
precipitation processes. First, 50.0 mL carrier solution were precipitated into 950 mL 
precipitating agent, as described above. After 18 h of sedimentation the supernatant was 
decanted and replaced by fresh precipitating agent. This procedure was repeated after another 
12 h of sedimentation. Subsequently, 23.7 mL protein solution, comprising 101 mg cytokine or 
mAb1 in water, were added dropwise within approx. 3 min into 450 ml of the previously 
prepared carrier suspensions under stirring.  
2.2.2.4 Concentration/solvent exchange 
For concentration of mAb1 PCMC suspensions, the supernatant was decanted 18 h after the 
precipitating step. The supernatant was replaced with fresh saturated isobutanol. After 24 h of 
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sedimentation the sediment, i.e. the concentrated suspension, was used for the supercritical 
drying process. 
In the case of cytokine PCMCs, after 18 h of sedimentation, the suspension was filtered off at 
600 mbar (Durapore Membrane Filter 0.45 µm HV 47 mm, Millipore, Schwalbach, D), the filter 
cake was washed twice with 50 mL saturated isopropanol and finally resuspended in 50 mL 
saturated isopropanol. 
2.2.2.5 Supercritical drying 
Supercritical drying (Thar SFE-500, Thar Technologies, Pittsburgh, PA, USA) was performed with 
carbon dioxide at 100 bar, 45 °C and a flow rate of 25 g/min. Finally, the pressure was 
decreased by 3 bar/min. After drying of 240 mL concentrated mAb1 PCMC suspension within 
90 min, vacuum drying was conducted at 30 mbar and 40 °C for 2 h (APT.line™ VDL, Binder, 
Tuttlingen, D; diaphragm membrane pump MZ 2C, Vacuubrand, Wertheim, D). 
For cytokine PCMCs, the resuspended filter cake was dried via supercritical drying process for 
81 min. Subsequent vacuum drying was not carried out. 
2.2.3 Binding of Alexa® 488 dye to mAb1 
Protein bulk drug substance without polysorbate 80 was dialyzed into PBS pH 7.4 within 24 h at 
2-8 °C (Slide-A-Lyzer® Dialysis Cassette G2, 20,000 MWCO, 0.5 mL, Thermo Scientific, Rockford, 
IL, USA). After dialysis, the protein concentration was determined via UV spectroscopy, as 
described in detail in section 2.2.7. Alexa® 488 dye (Alexa® Fluor 488 Carboxylic Acid, 
Invitrogen, Darmstadt, D) was dissolved in DMSO to reach a concentration of 2 mg/mL. For 
coupling, 2 ml protein solution with 1 mg/mL protein was added to 200 µl 1 M sodium 
bicarbonate solution and 10 µl Alexa® 488 dye solution. After incubation for 1 h at 22 ± 3 °C on 
a horizontal shaker with 200 rpm, the sample was purified via PD-10 column (SephadexTM G-
25M, GE, Buckinghamshire, UK). Equilibration of the column and sample elution was performed 
with a histidine buffer containing 0.68 mg/mL L-histidine, 3.27 mg/mL L-histidine hydrochloride 
monohydrate, 0.1 mg/mL Di-Na-EDTA dihydrate and 56.0 mg/mL trehalose dihydrate. 
Fractions 4-8 out of 10-12 fractions of 500 µl were collected, combined and dialyzed into 
histidine buffer within 24 h at 2-8 °C protected from light (Slide-A-Lyzer® Dialysis Cassette G2, 
Chapter 6 
169 
20,000 MWCO, 0.5 mL, Thermo Scientific, Rockford, IL, USA). The degree of labeling after 
dialysis was determined via UV measurement at 280 and 495 nm (Equation 6-1 and 6-2) [15]. 
 =  !"#.∗ $%.&	'  (6-1) 
()((	+,	-./(-01 =  $%∗2345∗6   (6-2) 
For the preparation of the protein-carrier solutions the ratio of labeled to unlabeled mAb1 was 
1:500. 
2.2.4 Accelerated short-term storage stability study 
For the stability study, 100 mg of the PCMC powders (10 % PL 30 % tre, 60 % PL 30 % tre, 
50 % PL 40 % tre and 40 % PL 50 % tre) were filled into 2 R glass vials (Fiolax®, Schott, 
Mühlheim, D) and stored unstoppered at 40 °C for 4 weeks in a desiccator over saturated MgCl2 
solution providing relative humidity of approx. 32 % [16]. Analysis of the PCMC powder (protein 
content, turbidity, HP-SEC, SDS-PAGE) was performed after one and four weeks of storage. 
Investigations via x-ray diffractometry, scanning electron microscopy and Karl-Fischer titration 
were limited to t4wk. 
2.2.5 Powder fractionation via cascade impactor 
Fractionation of PCMC powders was performed via Andersen Cascade Impactor (eight stage 
non-viable sample series 20-800, Thermo Andersen, Smyrna, GA, USA) at a flow rate of 
39 L/min (corresponding to a pressure drop of 4 kPa with the HandiHaler®), as described in 
detail by Claus et al. [17]. Within 6.15 s a total air volume of 4 L passed through the device and 
the PCMC powder encapsulated into polyethylene capsules was inserted into the induction port 
of the cascade impactor. The baffle plates were uncoated to allow easy harvesting of the 
powder suitable for further analysis via HPLC. On the contrary, the fixation of SEM patches 
(Leitfähige Haftaufkleber Ø 12 mm, Plano, Wetzlar, D) for morphological analysis of the powder 
required the coating of the plates with a mixture made of 83 % glycerin, 14 % ethanol 
95-97 % (v/v) and 3 % Brij® 35. 
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2.2.6 X-ray powder diffraction (XRD) 
The crystallinity of mAb1 PCMCs was analyzed with XRD in transmission mode from 
3 °- 40 ° 2 Θ, 0.5 ° steps and 20 s/step based on 1.5406 Å CuKα-radiation at 40 kV and 
40 mA (Stoe, Darmstadt, D). Samples were fixed in the sample holder between two Ultraphan 
foils (cellulose diacetate) with a thickness of 0.014 mm (Stoe, Darmstadt, D). 
2.2.7 Protein content via UV measurement 
MAb1 PCMC powder was dissolved in deionized water to give a concentration of approx. 
0.4 mg/mL and ensure absorption within the linear range of the spectrometer (0.3 to 0.8 AU). 
30 min after reconstitution, absorption in Halfmicro Plastibrand® cuvettes (Brand, Wertheim, D) 
was measured at 279 nm based on an extinction coefficient of 1.43 with a Lambda 20 
spectrometer (PerkinElmer, Rodgau-Jügesheim, D) and deionized water serving as blank (n=3). 
30 mg of cytokine PCMC powder were dissolved in 11.5 mM NaCl pH 2 and filtered through a 
0.45 µm syringe filter (Rotilabo-Spritzenfilter steril 0.45 µm PVDF, Carl Roth, Karlsruhe, D) 
30 min after reconstitution. UV measurement was carried out at 280 nm, corrected against 
buffer, based on an extinction coefficient of 1.70 (n=3) [18, 19]. 
2.2.8 Turbidimetry 
After dissolution of mAb1 PCMC powder with deionized water, turbidity was measured at a 
protein concentration of 1 mg/mL by 90 ° light scattering at λ = 633 nm 30 min after 
reconstitution (UH turbidimeter, Boehringer Ingelheim, self-construction) and expressed in 
formazine nephelometric units (FNU) (n=3). 
2.2.9 High performance size exclusion chromatography (HP-SEC) 
30 min after reconstitution of mAb1 PCMC powder in deionized water, the solution was filtered 
through a 0.45 µm syringe filter (Rotilabo-Spritzenfilter steril 0.45 µm PVDF, Carl Roth, 
Karlsruhe, D) and 25 µl samples of 2.0 mg/mL protein were injected in duplicate. Soluble 
protein aggregates, monomers and fragments were separated on an Äkta micro (GE Healthcare, 
Uppsala, S) with a TSKGel G3000 SWXL column (7.8 mm ID x 30.0 cm L, Tosoh, Stuttgart, D), 
equipped with a 40 x 6.0 mm TSKgel SWXL Guardcol precolumn, using filtered (0.22 µm) and 
degassed mobile phase of 60 mM sodium chloride and 5 mM sodium dihydrogen phosphate 
pH 7.0 in deionized water at 1.0 mL/min flow rate and UV detection at 280 nm. Aggregation 
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and fragmentation in percent was calculated based on the ratio of the area under the curve 
(AUC) of soluble aggregates and fragments to the total AUC of aggregates, monomer and 
fragments (n=2). Furthermore, changes in the AUC were considered.  
According to Hawe and Friess, for HP-SEC analysis of cytokine PCMCs a TSKgel G3000SW 
column (7.8 mm ID x 60.0 cm L) and a TSKgel SWXL Guardcol precolumn (Tosoh Bioscience, 
Stuttgart, D) were used on an Äkta micro with 200 mM sodium dihydrogen phosphate and 
0.1 % SDS [18]. 25 µl samples of 0.6 mg/mL protein were injected in duplicate and protein 
elution was monitored via UV-detection at 210 nm (n=2). 
2.2.10 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE of mAb1 PCMC powders was conducted at 200 V with Power Ease 500 and XCell Sure 
Lock in combination with 12 % Bis-Tris gels (NuPAGE®, 1 mm, 15 wells, Invitrogen, Darmstadt, 
D) and NuPAGE® MOPS SDS running buffer. Samples were mixed 8:2 with NuPAGE® LDS sample 
buffer, and 7:2:1 with NuPAGE® LDS sample buffer and 0.5 M dithiothreitol for the reducing 
SDS-PAGE. After heating up to 95 °C for 5 min, 5 µl of the samples and the marker (Precision 
Plus Protein Standard, Bio-Rad, Hercules, CA, USA), representing 1 µg protein, were loaded to 
each well. Furthermore, 2 ng BSA were loaded to one well for the purpose of sensitivity control. 
The gels were stained with SilverXpress® Silver Staining Kit. All equipment was from Invitrogen 
(Darmstadt, D). 
2.2.11 Particle morphology via scanning electron microscopy (SEM) 
Particle morphology of PCMC powder was analyzed by the use of a scanning electron 
microscope (Model Tescan Vega II SBH, Tescan, Brno, CZ). Samples were prepared on an 
aluminum stub and coated with gold/palladium (Model Cressington 108auto/SE Cool Sputter 
Coater, Cressington, Watford, GB). 
2.2.12 Water content via Karl-Fischer titration 
For water content quantification, two aliquots of 100 mg mAb1 PCMC powder per sample were 
filled into 2R vials and flanged either immediately after the drying process or after storage for 
4 weeks at 40 °C/32 % RH. After dissolution in methanol (Mallinckrodt Baker, Phillipsburg, NY, 
USA), titration was performed using Hydranal® Coulomat-AG reagent (Fluka, Buchs, CH) and a 
756 KF-Coulometer (Methrom, Sofingen, CH) for endpoint detection (n=2). 
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2.2.13 Confocal laser scanning fluorescence microscopy (CLSFM) 
CLSFM of mAb1 PCMCs containing Alexa® 488 labeled protein was performed via inverted 
fluorescence microscope (Leica DM IRBE) equipped with a confocal scanner (Leica TCS SP2), a 
multiline argon laser with an excitation wavelength of 488 nm and oil immersion objectives 
(Leica HC PL APO 10x 0.4 IMM and HC PL APO 10x 0.7 IMM/CORR). Leica Confocal Software, 
version 2.61, was used for taking and evaluation of pictures. All equipment was from Leica 
(Heidelberg, D). 
2.2.14 Quantification of the cytokine by reverse-phase high performance liquid 
chromatography (RP-HPLC) 
The amount of cytokine after powder fractionation via cascade impactor was analyzed by RP-
HPLC (Alliance 2695, Waters, Milford, MA, USA) with a Zorbax 300SB-CN column (4.6 x 150 mm, 
Agilent, Böblingen, D) as stationary phase at 40 °C, as developed by BI. The mobile phase was 
composed of phase A (100 % water with 0.1 % trifluoroacetic acid (TFA)) and phase B (84 % 
acetonitrile, 16 % water, 0.084 % TFA). The volume fraction of phase B was increased from 40 % 
to 55 % (9 min), 60 % (15 min) and 80 % (20 min) and finally reduced back to 40 % (21 min). 
Cytokine PCMC powder was reconstituted in 11.5 mM NaCl pH 2 within 15 min. A duplicate of 
samples with 0.04-0.25 mg/mL protein was injected at a flow rate of 0.7 mL/min and detected 
at 214 nm (UV). Based on the AUC, the cytokine content was calculated using the linear 
calibration curve (n=2). 
2.2.15 Quantification of valine by gas chromatography (GC) 
For quantification of valine in cytokine PCMCs via BI internal method, the powder was dissolved 
in 1 mL NaCl/Na2CO3 buffer (62 mmol/L and 28 mmol/L, respectively) and valine was 
derivatized via EZ: faast ™ kit (GC-FID Physiological, Amino Acid Analysis Kit, Phenomenex, 
Torrance, CA, USA) (n=2). An Agilent 6890N Network GC equipped with a ZB-AAA column 
(10 m x 0.25 mm, 0.25 µm film thickness, Phenomenex, Torrance, CA, USA) and a flame-
ionization detector was used at a column flow of 1.5 mL He/min. The column oven temperature 
was raised by 38 °C/min from 110 to 320 °C and the FID detector temperature was 320 °C. A 
duplicate of 2 µl samples was injected at 250 °C and a split level of 1:15 (n=2). L-Norleucine 
(Sigma-Aldrich, Steinheim, D) was used as internal standard amino acid. 
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2.2.16 Quantification of trehalose by high performance liquid chromatography 
(HPLC) 
Lower molecular substances, such as trehalose and the amino acids, were separated from 
protein via centrifugation (Heraeus® Biofuge® primo, Carl Roth, Karlsruhe, D). The filtration 
units (Amicon® Ultra-0.5 Ultracel-10k, Millipore, Schwalbach, D) were rinsed with 0.5 mL 0.1 N 
NaOH and subsequently equilibrated with dissolved PCMCs containing 2 mg/mL mAb1 in 
deionized water at 12000 g for 10 min. 0.5 mL samples of dissolved PCMCs with 2 mg/mL 
protein were subsequently separated at 12000 g for 10 min. The filtrate was checked for 
protein residues via UV absorption and analyzed (2 x 40 µl) by HPLC using a Rezex RCM 
Monosaccharide Ca2+ 300 x 7.80 mm column with guard column (SecurityGuard Cartridges 
Carbo-Ca 4 x 3.0 mm, Phenomenex, Torrance, CA, USA) at 85 °C. Filtered HPLC-water 
(Chromasolv® plus, Sigma-Aldrich, Steinheim, D) was used for elution at a flow rate of 
0.6 mL/min. Detection was performed via changes in refractive index (RI). The trehalose RI 
signal between 5.5 and 6.9 mL was integrated and trehalose content was calculated using the 
linear calibration curve for concentrations from 0.25 to 0.8 mg/mL (n=3). 
2.2.17 Bioactivity assay 
The bioassay of cytokine PCMCs was based on lung cancer indicator cells A549 [20]. Briefly, 
preincubated with different concentrations of the cytokine, the cells were infected with 
encephalomyocarditis virus and thus a cytopathic effect was evoked leading to cell lysis. The 
number of viable cells was analyzed by an MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. The concentration of the cytokine that led to the lysis of 
50 % of the cells (ED50) was referred to cytokine standard. The biological activity of the samples 
was determined based on three independent batches of each sample. Each batch consisted of 
two plates with the sample in triplicates. 
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3 Results and discussion 
3.1 Investigation of mAb1 PCMCs with varying protein load and trehalose 
content 
To investigate the role of the crystallizing carrier components of mAb1 PCMCs as well as of the 
amorphous excipient fraction and to gain insight into the supramolecular structure of the 
particles, first, the crystallinity of mAb1 PCMCs was studied in dependence of protein load (10-
60 %) and trehalose level (0-40 %). Four formulations were subsequently chosen and stored at 
40 °C/32 % RH for 4 weeks to study the influence of the composition on protein storage 
stability with respect to aggregation (protein content, turbidity, HP-SEC and SDS-PAGE) and on 
carrier and morphology stability (XRD and SEM). Confocal laser scanning microscopy was 
performed to analyze the localization of the protein within the microcrystals. 
3.1.1 Crystallinity of mAb1 PCMCs in dependence of protein load and trehalose 
content 
For mAb1 PCMCs that contained 50 % protein and trehalose ranging from 0-40 %, the 
crystallinity/amorphicity of the microcrystals depended on the level of the disaccharide. In the 
absence of trehalose, mainly crystalline α-glycine and NaCl were detected via XRD (Figure 6-1a). 
Furthermore, peaks associated with β-glycine were identified in the spectrum. Increasing 
amounts of trehalose reduced the crystallization tendency of both NaCl and glycine. In the 
sample prepared with 50 % mAb1 and 25 % trehalose crystalline signals were limited to 
α-glycine and were clearly less pronounced than in the sample without trehalose. The degree of 
crystallinity of α-glycine further decreased in the presence of 30 % trehalose. Higher amounts 
of the disaccharide led to completely amorphous PCMCs. Hence, an increasing amount of 
trehalose prevented NaCl and glycine from crystallization during the manufacturing of the 
particles. As discussed in detail in chapter 3, trehalose played a key role in the stabilization of 
mAb2 formulated as PCMCs via formation of a glassy matrix. In accordance with the current 
findings on mAb1 PCMCs, the absence of trehalose resulted in the crystallization of α-glycine. 
These at least partially crystalline mAb2 PCMCs provided less stabilization against aggregation 
of the monoclonal antibody during production as well as storage, compared to completely 
amorphous formulations. As opposed to the corresponding mAb1 formulation, no crystalline 
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signal was observed in the XRD spectrum for mAb2 PCMCs with a protein load of 50 % and a 
trehalose level of 30 % (see chapter 3 section 3.1.1). This PCMC composition thus represented 
the borderline between partially crystalline and predominantly amorphous mAb microcrystals. 
Moreover, it has to be considered that the mAb1 and mAb2 bulk drug substances slightly 
differed in the EDTA concentration and the polysorbate amount and type. Inhibition of glycine 
crystallization in the presence of trehalose was also observed during lyophilization by 
Chatterjee et al. [21]. In that case, the prevention of glycine crystallization required a mass ratio 
of glycine to trehalose dihydrate below 1. For mAb1 PCMCs, the mass ratio of glycine to 
trehalose dihydrate was 1.2 for the formulation containing crystalline glycine and 0.12-0.19 for 
the amorphous ones, being in line with the results of Chatterjee et al. 
With respect to the mAb1 PCMC formulations with a constant trehalose content of 30 % and 
varying protein load in the range of 10-60 %, the degree of crystallinity decreased with 
increasing protein load (Figure 6-1b). The spectrum of the sample that comprised 10 % protein 
and 30 % trehalose showed peaks that were attributed to crystalline α-glycine and NaCl. The 
use of 45, 50 and 55 % mAb1 resulted in PCMC powder that only contained crystalline 
α-glycine, at decreasing levels, whereas all the other components were amorphous. MAb1 
PCMCs composed of 60 % protein and 30 % trehalose did not manifest any crystalline signal in 
the XRD spectrum and were thus assumed to be completely amorphous. Hence, increasing 
amounts of monoclonal antibody impeded crystallization of NaCl and glycine, which 
corresponds to literature [22-25]. However, it also has to be taken into consideration that, in 
parallel with the augmenting level of mAb1 in the formulations, the amount of the potentially 
crystallizing components NaCl and glycine decreased and gradually approached the detection 
limit of the analytical technique. The additional formulation containing 40 % mAb1 and 50 % 
trehalose was also amorphous in XRD. In summary, the sum of trehalose dihydrate and mAb1, 
typically forming amorphous solids, was essential for the overall physical state of the mAb1 
PCMC formulations. 
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 (a) 
 
 (b) 
 
Figure 6-1: XRD analysis of mAb1 PCMCs with (a) varying trehalose content and (b) varying 
protein load; spectrum assignment: (a) I: NaCl, II: α-glycine; III: β-glycine; IV: 50 % PL no tre; 
V: 50 % PL 25 % tre; VI: 50 % PL 30 % tre; VII: 50 % PL 35 % tre; VIII: 50 % PL 40 % tre; 
(b) I: NaCl, II: α-glycine; III: 10 % PL 30 % tre; IV: 45 % PL 30 % tre, V: 50 % PL 30 % tre; 
VI: 55 % PL 30 % tre; VII: 60 % PL 30 % tre; arbitrary offset for better comparison. 
3.1.2 Accelerated short-term stability study 
For 4 weeks storage at 40 °C/32 % RH, one crystalline (10 % PL 30 % tre) and three amorphous 
mAb1 PCMC formulations (60 % PL 30 % tre, 50 % PL 40 % tre, 40 % PL 50 % tre) were chosen. 
The study aimed to investigate whether a crystalline or a completely amorphous matrix could 
provide best storage stability of the monoclonal antibody. With respect to the overall 
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crystalline formulation, the question was if the amount of amorphous excipient fraction was 
sufficient for adequate protein stabilization. Referring to the amorphous formulations, the 
impact of trehalose content and protein load, and thus of the molar ratio of amorphous 
excipient to protein, was further investigated. 
Karl-Fischer titration revealed that the initial water content of the crystalline formulation 
(10 % PL 30 % tre) with a value of 1.7 % was significantly lower than for the amorphous 
formulations which ranged from 2.5 to 3.6 % (Table 6-5). After 4 weeks of storage, the water 
content of the amorphous formulations amounted to approx. 6 %, as opposed to 3.8 % 
detected for the crystalline formulation. Thus, the amorphous powders were more hygroscopic 
than the crystalline one, being consistent with literature [23, 26]. Ahlneck and Zografi found 
that in combinations of amorphous and crystalline material, absorption of water vapor 
preferentially occurred into the amorphous structure [27], thus rendering a higher water 
content and greater plasticizing effect in the amorphous fraction. Hygroscopicity of amorphous 
spray-dried and lyophilized powders bearing the risk of recrystallization and consequently 
instability during storage was also described for protein formulations, e.g. by Hawe and Friess 
[23] as well as by Hino et al. [28]. 
Table 6-5: Water content [% m/m] of mAb1 PCMCs with varying protein load and trehalose 
content stored at 40 °C/32 % RH for 4 weeks. 
Formulation t0 t4wk 
10 % PL 30 % tre 1.7 ± 0.08 3.8 ± 0.02 
60 % PL 30 % tre 3.6 ± 0.24 6.1 ± 0.04 
50 % PL 40 % tre 3.1 ± 0.19 6.0 ± < 0.01 
40 % PL 50 % tre 2.5 ± 0.04 6.0 ± 0.05 
 
Turbidity measurement is frequently applied in the formulation development and purification 
of therapeutic proteins to detect insoluble protein aggregates [29, 30]. Independent of protein 
load and trehalose content, it revealed very low and constant turbidity values ranging from 0.4 
to 1.7 FNU for the amorphous formulations (60 % PL 30 % tre, 50 % PL 40 % tre, 
40 % PL 50 % tre) (Figure 6-2a). In contrast, the turbidity of the crystalline mAb1 PCMC sample 
(10 % PL 30 % tre) was higher with 3.0-6.5 FNU and a slight, but statistically significant increase 
was found within 4 weeks of storage (p < 0.05). Hence, the protection against insoluble 
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proteinaceous particle formation throughout the PCMC production process as well as storage 
was better in an amorphous carrier matrix than in a crystalline one. This difference between 
the PCMC formulations selected for the accelerated short-term stability study was too low to 
be reflected in the protein content that did not change significantly within 4 weeks of storage, 
irrespective of the PCMC composition (Figure 6-2b).  
 (a) (b) 
  
Figure 6-2: Turbidity (a) and protein content (b) of mAb1 PCMCs with varying protein load 
and trehalose content stored at 40 °C/32 % RH for 4 weeks. 
Soluble protein particles are most commonly assessed via HP-SEC [31, 32]. After 4 weeks 
storage, all mAb1 PCMC formulations showed a faint decrease of the monomer content 
(Figure 6-3) and only minor differences were found between the formulations. The smallest 
decline, by only 0.5 %, was detected for the crystalline formulation (30 % PL 10 % tre), whereas 
this formulation displayed the smallest initial monomer level of all formulations analyzed. The 
amorphous formulations with a protein load of 60 and 50 % lost 2.3 and 2.4 % of the initial 
monomer level, respectively, whereas the monomer content of the amorphous formulation 
containing 40 % mAb1 was only reduced by 0.9 %. The latter formulation also had the highest 
initial monomer content, compared to the other mAb1 PCMC formulations. This outcome 
indicated that a protein load of 60 and 50 % was probably too high to be optimally stabilized via 
PCMC technology, which is consistent with the findings on mAb2 PCMCs discussed in chapter 3. 
Independent of the formulation, the decrease of the monomer content was ascribed to the 
formation of soluble protein aggregates because fragmentation of mAb1 formulated as PCMCs 
was not observed during the accelerated short-term stability study. Moreover, irrespective of 
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the formulation, the AUC in HP-SEC did not change significantly over time. Thus, all samples 
were free of considerable amounts of large protein particles typically prone to accumulate in 
the precolumn or at the column top [32]. 
 
Figure 6-3: Monomer content of mAb1 PCMCs with varying protein load and trehalose 
content stored at 40 °C/32 % RH for 4 weeks. 
SDS-PAGE, representing an orthogonal method for the analysis of soluble protein aggregates 
[31], confirmed the HP-SEC results with an obvious increase in aggregates for all mAb1 PCMC 
formulations investigated (Figure 6-4). The broad aggregate band above 250 kDa under non-
reducing conditions (gel a) was more pronounced in lanes V, VIII, XI and XIV compared to all 
other lanes. Likewise, the bands at about 100 kDa, 75 kDa and 37 kDa under reducing 
conditions (gel b) were slightly darker in those lanes. But generally, as silver stained bands 
cannot be quantified reliably, interpretation should mainly be restricted to qualitative 
evaluation [31]. A faint extra band above 250 kDa indicating mAb1 aggregation with prolonged 
storage time was detected for all amorphous formulations (lanes VIII, XI and XIV) at t4wk. For the 
crystalline formulation (10 % PL, 30 % tre), this band was already present at t0 and t1wk, in 
accordance with the higher initial aggregate level detected via HP-SEC. Additional faint bands 
found above 10 kDa in the lanes IV, V, VIII, XI and XIV under non-reducing as well as reducing 
conditions were attributed to mAb1 fragments formed during storage of the PCMC powders. 
Fragments were not detected during HP-SEC analysis and therefore fragment levels were 
assumed to be very low (< 0.1 %). No further differences between the samples with varying 
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protein load and trehalose content were observed within 4 weeks of storage. Non-reducible 
aggregates were not detected because no aggregate band persisted under reducing conditions. 
In summary, SDS-PAGE indicated only negligible formation of covalent soluble aggregates. 
(a) 
 
(b) 
 
Figure 6-4: SDS-PAGE of mAb1 PCMCs with varying protein load and trehalose content stored 
at 40 °C/32 % RH for 4 weeks; (a) non-reducing and (b) reducing conditions; lane assignment: 
I: BSA control; II: Precision Plus Protein Standard; III-V: reconstituted mAb1 PCMC samples 
with 10 % PL 30 % tre ; VI-VIII: reconstituted mAb1 PCMC samples with 60 % PL 30 % tre ; 
IX-XI: reconstituted mAb1 PCMC samples with 50 % PL 40 % tre ; XII-XIV: reconstituted mAb1 
PCMC samples with 40 % PL 50 % tre; XV: Precision Plus Protein Standard. 
Overall, only minor differences were revealed between the 4 formulations with respect to 
protein storage stability. The turbidity of the crystalline sample (10 % PL 30 % tre) was slightly 
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higher than of the amorphous ones (60 % PL 30 % tre, 50 % PL 40 % tre, 40 % PL 50 % tre) and 
increased with prolonged storage time. However, the formation of soluble protein particles 
analyzed via HP-SEC was slightly less pronounced in the presence of an at least partially 
crystalline carrier matrix, compared to completely amorphous particles. Thus, based on these 
results of the accelerated short-term stability study, the physical state of the mAb1 PCMCs had 
no tremendous effect on the degree of stabilization of the monoclonal antibody during storage 
and all formulations investigated provided good protein stability. The amorphous state in 
comparison to the crystalline state is defined by a lack of long-range order of molecular packing 
or well-defined molecular conformation if the constituent molecules are conformationally 
flexible as it is the case for proteins [33, 34]. In general, amorphous solids are supposed to be 
less stable physically and chemically [34]. Nevertheless, the effect of the physical state of the 
solid on the stabilization of proteins is ambiguously discussed in literature. Crystalline glucose 
oxidase and lipase [35] as well as lysozyme [36] and amylase [37] were reported to be more 
stable than their amorphous counterparts. However, Pikal and Rigsbee who studied the 
stability of pure insulin in crystalline and amorphous solids revealed a greater stability for the 
amorphous form, although the mechanism involved could not successfully be clarified [38, 39]. 
Nevertheless, one aims to achieve a fully amorphous product during freeze-drying processes as 
successful interaction between excipient and protein is thought to be more likely if both 
interaction partners are within the same amorphous phase [40, 41]. Therefore, crystallization is 
inhibited by the addition of ‘impurities’ such as other excipients as well as by the protein it-self 
[34, 42]. 
Furthermore, the molar ratio of trehalose dihydrate to protein, being approx. 
200 (60 % PL 30 % tre), 320 (50 % PL 40 % tre) and 500 (40 % PL 50 % tre), influenced the 
storage stability of the amorphous mAb1 PCMC formulations. As the decrease of the monomer 
content was less pronounced for mAb1 PCMCs with 40 % PL and 50 % tre, the literature 
recommendation of a molar sugar to protein ratio of ≥ 360 for adequate protein stabilization in 
lyophilisates [43-45] could be successfully applied to these microcrystals. 
Apart from protein stability, the carrier and its morphology stability need to be investigated 
during PCMC storage studies because they are often associated with each other, as described in 
Mechanistic insights into the PCMC formation process 
182 
chapter 2 section 4.3.2. Referring to the mAb1 microcrystals with varying protein load and 
trehalose content, carrier and morphology stability was assessed via XRD and SEM. X-ray 
spectra of all amorphous samples (60 % PL 30 % tre, 50 % PL 40 % tre, 40 % PL 50 % tre) 
recorded after 4 weeks of storage did not differ from the initial pattern (Figure 6-5a). This 
indicated the absence of recrystallization processes of the amorphous carrier components. For 
the crystalline sample containing 10 % mAb1 and 30 % trehalose, the signals at 27.2 ° and 31.6 ° 
2 theta that were attributed to NaCl increased within 4 weeks storage (Figure 6-5b). Thus, NaCl 
further crystallized under the storage conditions selected for the accelerated short-term 
stability study. Excipient crystallization during storage of solid protein formulations was 
reported to cause protein destabilization, e.g. by Kreilgaard et al. as well as by Izutsu et al. [46, 
47]. The authors speculated, amongst others, that the maintenance of an amorphous protein-
excipient phase allowing for extensive molecular interactions between these two formulation 
components was essential for long-term storage stability. However, sucrose crystallization 
taking place during storage of partially collapsed freeze-dried cakes of LDH did not significantly 
reduce the activity of the protein since a sucrose amount sufficient for LDH stabilization 
remained in the amorphous state [48]. This explanation could also be applied to the recent 
findings on mAb1 PCMCs. Despite continuing NaCl crystallization during the accelerated short-
term stability study, the integrity of the antibody was not affected. As NaCl represented only 
12 % of the total solid in the protein powder, the other components forming a glassy matrix, 
such as trehalose, were suggested to provide sufficient protein storage stability. 
Ongoing NaCl crystallization of mAb1 PCMCs with 10 % PL and 30 % trehalose was not 
noticeable in SEM (Figure 6-6a and b). The pictures taken at t4wk did not differ from those of the 
initial PCMC powder and showed rod-shaped crystals partially coated with a less compact 
crumbly material. In accordance with the observations made on cytokine-coated microcrystals, 
described in detail in chapter 2, the latter powder fraction was assumed to be made of 
amorphous carrier components, mainly trehalose and antibody. The stabilization mechanism of 
the disaccharide as well as its use in solid protein formulations is discussed in detail in 
section 3.1.1. The rod-shape of PCMCs that contained glycine as main carrier component was 
also reported by König [6] and is consistent with the description of glycine crystals by Lahav and 
Leiserowitz [49]. The amorphous mAb1 PCMC formulations (Figure 6-6c-h) were characterized 
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by spherical particles similar to those obtained after spray-drying [24, 50, 51]. Moreover, SEM 
pictures did not provide any indication of excipient recrystallization or collapse either, proving 
high excipient and morphology stability of the amorphous PCMCs. Though, it has to be taken 
into consideration that the mAb1 PCMCs were not exposed to high moisture levels during 
storage.  
 (a) 
 
 (b) 
 
Figure 6-5: XRD of mAb1 PCMCs with varying protein load and trehalose content stored at 
40 °C/32 % RH for 4 weeks; (a) spectrum assignment: I: 60 % PL 30 % tre; II: 50 % PL 40 % tre; 
II: 40 % PL 50 % tre; black: t0, grey: t4wk; (b) spectrum assignment: I: NaCl, II: α-glycine; 
III: 10 % PL 30 % tre t0;  10 % PL 30 % tre t4wk. 
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a  b  
c  d  
e  f  
g  h  
Figure 6-6: SEM pictures of mAb1 PCMCs with varying protein load and trehalose content at t0 
(left) and stored at 40 °C/32 % RH for 4 weeks (right); a)/b) 10 % PL 30 % tre; 
c)/d) 60 % PL 30 % tre; e)/f) 50 % PL 40 % tre; g)/h) 40 % PL 50 % tre. 
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3.1.3 Confocal laser scanning fluorescence microscopy of mAb1 PCMC powders 
Confocal laser scanning fluorescence microscopy of mAb1 PCMC formulations selected for the 
accelerated short-term stability study was applied to investigate the protein distribution within 
these particles. Scanning through different layers of the microcrystals, this technique allowed 
also assessing the interior structure of the particles, as opposed to SEM. Widely, CLSFM has 
successfully been used in numerous applications of cellular biology, as reviewed by Földes-Papp 
et al. as well as by Halbhuber and König [52, 53]. Furthermore, there is considerable interest in 
the use of this technique in pharmacologic and therapeutic areas. 
In accordance with the SEM analysis of the powders (section 3.1.2), the morphology of the 
crystalline microcrystals (10 % PL 30 % tre) detected via CLSFM differed from the microscopic 
appearance of the amorphous formulations (60 % PL 30 % tre, 50 % PL 40 % tre and 
40 % PL 50 % tre). In the crystalline mAb1 PCMC powder, the silhouettes of large rod-shaped 
crystals were clearly visible (Figure 6-7). These structures also observed in SEM and associated 
with glycine crystals were further characterized by low fluorescence intensity, indicating that 
they were essentially free of labeled protein. Besides these crystalline structures, material 
attached to the glycine crystal surface without distinct outlines exhibiting high fluorescence 
intensity was observed. The fluorescence intensity of this material increased when scanning 
from the outside to the inside of the particles. Thus, labeled protein was present throughout all 
layers of this material. 
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a  b  
c  d  
Figure 6-7: CLSFM of mAb1 PCMCs with 10 % protein load and 30 % trehalose; the lower and 
right sections represent the cross-sections of the particles; fluorescence intensity: blue < cyan 
< green < yellow < brown. 
These morphological observations were consistent with the general idea of the PCMC 
technology including a crystalline core of carrier and amorphous protein coated onto the 
surface of these crystals, as presented in Figure 6-8 modified from Vos [1]. The author´s theory 
was derived from several experiments on PCMCs, including atomic force microscopy (AFM), 
zeta potential measurements and dynamic light scattering (DLS) as analytical techniques. AFM 
analysis revealed the presence of protein clusters on the crystal surface, showing clear step-
contours, for valine subtilisin Carlsberg PCMCs. Zeta potential measurements of uncoated and 
coated microcrystal particles further revealed a shift of the particles´ surface charge when 
protein was coprecipitated with the carrier material. Moreover, Ostwald ripening was detected 
via DLS for uncoated microcrystals, as opposed to particles coated with protein. The complete 
Chapter 6 
187 
inhibition of this phenomenon in the presence of albumin was associated with the formation of 
a protein coating on the excipient surface. During the desorption experiment albumin valine 
PCMCs were resuspended in a saturated aqueous valine solution, impeding the dissolution of 
the microcrystals. The vast majority of the protein was afterwards recovered in the 
supernatant. With respect to the cytokine PCMCs, the amorphous fraction attached to the 
crystal surface was further assumed to be not only composed of pure protein, but additionally 
of carrier excipients tending towards the formation of an amorphous structure, such as 
trehalose (see section 3.1.1).  
 
Figure 6-8: Formation of PCMCs modified from Vos [1]; protein (yellow spheres) and excipient 
(blue cubes) are preblended/dissolved in water and coprecipitated into non-solvent, resulting 
in the self-assembly of PCMCs with protein located on the surface of the excipient crystals. 
Independent of the exact composition of the particles, the CLSFM appearance of all amorphous 
mAb1 PCMC formulations, exemplarily shown in Figure 6-9 for the sample containing 60 % 
protein and 30 % trehalose, was similar. Being in line with the XRD and SEM results 
(section 3.1.1 and 3.1.2), the amorphous powders were free of any crystalline structures and 
were composed of one homogenous particle fraction. Within these particles the labeled 
antibody was evenly distributed as indicated by the fluorescence intensity changing from 
blue/green over yellow and brown back to blue/green while scanning through the PCMCs. The 
cross-section further revealed a spherical shape of the single particles forming larger powder 
agglomerates, as also observed via SEM analysis. 
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a  b  
c  d  
e  f  
Figure 6-9: CLSFM of mAb1 PCMCs with 60 % protein load and 30 % trehalose; the lower and 
right sections represent the cross-sections of the particles; fluorescence intensity: blue < cyan 
< green < yellow < brown. 
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Hence, the structure of these particles did neither correspond to the conception of Vos 
presented in Figure 6-8 nor to the term “protein-coated microcrystals”, because carrier 
excipients and protein did not form two morphologically and chemically different fractions, but 
amorphous, uniform spherical particles. Therefore, the idea offered in Figure 6-10 seemed to 
be more suitable for the graphical description of these particles. 
 
Figure 6-10: Proposed formation process of mAb1 PCMCs; the coprecipitation of protein 
(yellow spheres) and excipient (blue cubes) results in the self-assembly of homogeneous, 
amorphous “PCMCs”. 
3.2 Fractionation of cytokine PCMCs and mAb1 PCMCs via cascade impactor 
SEM analysis of crystalline cytokine PCMCs with 10 % protein load (chapter 2 section 3.2), and 
amorphous mAb1 PCMCs with a protein level of 40-60 % and 50-30 % trehalose (section 3.1.2 
of the current chapter), suggested fundamentally different morphologies of these particles. The 
former, which contained valine as main carrier component as well as citrate/citric acid and 
sucrose, were composed of two particle fractions, a compact crystalline one forming rosettes 
and another less compact crumbly one (Figure 6-11a). Some of the less compact crumbly 
material was coated on the surface of the compact crystalline fraction, another part existed 
separate from the crystals. Amorphous mAb1 PCMCs, with trehalose, glycine, NaCl, histidine 
and phenylalanine as carrier excipients, however, were characterized by homogenous spherical 
material (Figure 6-11b). For more detailed characterization of the powders, an attempt was 
made to separate different size fractions of the powders via Andersen Cascade Impactor. 
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c  d  
e  f  
g  h  
Figure 6-11 : Cytokine PCMCs (left) and mAb1 PCMs (40 % PL 50 % tre) (right) separated via 
Andersen Cascade Impactor; picture alignment: a)/b) initial PCMC powder, powder harvested 
from c)/d) stage 0, e)/f) stage 3, g)/h) stage 5. 
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The cytokine PCMC powder collected from plate 0 of the cascade impactor resembled the initial 
powder inserted into the device (Figure 6-11c). The powder harvested from plate 1, however, 
only contained few intact rosette-shaped crystals. Furthermore, platelets representing 
fragments of the rosettes were visible and considerably more crumbly material was present, 
compared to the initial powder. The number of rosettes further decreased from plate 1 to 
plate 2. Powder deposited on plate 3, 4 and 5 was free from larger crystals, whereas the 
amount of crumbly material increased (Figure 6-11e). Plates 6 and 7 only contained very little 
amounts of powder insufficient for SEM analysis. Thus, the cascade impactor successfully 
divided the cytokine PCMCs into these two particle fractions based on a smaller aerodynamic 
diameter of the crumbly material compared to the large valine crystals. 
In case of mAb1 PCMC powder with a protein load of 40 % and 50 % trehalose, the material 
deposited on plate 0 of the cascade impactor was composed of many spherical particles 
different in size (Figure 6-11d). It seemed as if the amount of larger particles was slightly 
increased at the expense of smaller ones, compared to the initial mAb1 PCMCs (Figure 6-11b 
and d). With increasing plate number the quantity of larger particles decreased and the average 
particle size decreased (Figure 6-11f and h). 
The composition of the powder fractions gained via cascade impactor was analyzed with 
respect to the protein content, i.e. cytokine and mAb1, and the content of valine and trehalose 
dihydrate representing the main carrier components of the PCMCs selected. For the cytokine 
PCMCs, the protein content increased with increasing plate number, whereas the amount of 
valine in the powder fractions decreased (Figure 6-12a). This increase of the cytokine content 
with increasing plate number corresponded to an augmented level of fluffy and crumbly 
material. Hence, the cytokine was primarily located in this particle fraction, as opposed to the 
crystalline material, being in line with the hypothesis presented in chapter 2 section 4.1. Since 
proteins and peptides in the solid state usually exist in the amorphous form [22], this particle 
fraction was further assumed to be amorphous, being consistent with its loose microscopic 
appearance. As sucrose and citrate, representing additional carrier components of the cytokine 
formulation besides valine, are prone to form amorphous solids [24, 54-57], the loose and 
crumbly material certainly does not only incorporate the hydrophobic cytokine, but at least 
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some parts of those carriers (see chapter 2 section 4.1). This could also explain the high process 
and storage stability of the cytokine PCMCs because interactions between excipients and 
proteins are supposed to be most successful if both partners exist in the same amorphous 
phase (see section 3.1.2). On the contrary, the crystalline rosette-shaped powder fraction 
essentially consisted of the main carrier component valine. Consequently, the morphology and 
composition of these cytokine PCMCs was well in accordance with the original idea of this 
technology [1, 2, 58]. 
 (a) (b) 
  
Figure 6-12: Composition of (a) cytokine PCMC and (b) mAb1 PCMC (40 % PL 50 % tre) 
fractions separated via Andersen Cascade Impactor with respect to protein content, valine 
content and trehalose dihydrate content in dependence of the plate (P) number; the amount 
of powder collected from plates 4-7 (cytokine PCMCs) and 6+7 (mAb1 PCMCs), respectively, 
was too small to be analyzed. 
The powder fractions of mAb1 PCMCs collected from plate 0 to plate 5 neither differed in the 
protein nor in the trehalose content (Figure 6-12b). Thus, in accordance with the SEM pictures, 
these PCMCs did not include one protein-rich fraction and one fraction that was dominated by 
the presence of carrier material, unlike cytokine PCMCs. Instead, mAb1 PCMCs were proposed 
to comprise a mixed phase homogenously unifying mAb1 and carrier excipients as spherical 
particles of different size. Hence, the powder did not correspond to the PCMCs` definition. 
Therefore, a new name seems to be required to adequately describe these particles originating 
from formulation variations of the initial PCMC technology. The term “coprecipitated 
amorphous protein particles” (CAPPs) would only be applicable to predominantly amorphous 
PCMC formulations, as opposed to “solvent precipitated protein powder” (SP3s) which does 
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not specify the overall physical state of the precipitated protein carrier particles. However, the 
latter is evocative of the well-known ethanol protein precipitation used for plasma 
fractionation for decades, which was first described in detail by Cohn et al [59]. Finally, as the 
morphology of the amorphous mAb1 formulations was similar to typical spray-dried protein 
formulations, as discussed in section 3.1.2, a new term is not mandatory. 
3.3 Preparation of cytokine and mAb1 PCMCs via one-step and two-step 
precipitation in batch mode 
In this study cytokine and mAb1 PCMCs, intended to be prepared via one-step and two-step 
precipitation, were compared with respect to particle morphology (SEM) and protein process 
stability (HP-SEC, bioassay). The one-step precipitation represented a simultaneous 
coprecipitation of carrier material and protein, usually applied for the manufacturing of PCMCs. 
On the contrary, the two-step precipitation process consisted of separate precipitation of pure 
crystalline excipients, followed by subsequent protein precipitation on these carrier particles. 
3.3.1 Precipitation of protein-free carrier solutions 
Precipitation of pure carrier material of the cytokine PCMC formulation resulted in the 
formation of rosette-shaped crystals (Figure 6-13), being consistent with the crystal shape 
observed in the corresponding cytokine formulation (chapter 2 section 4.1). Likewise, the 
precipitation was slightly decelerated and the product was not yet turbid at the outlet of the 
mixer, but turbidity immediately built up in the container used for harvesting. Thus, the 
presence of the protein was not prerequisite for the precipitation process. 
a  b  
Figure 6-13: SEM of separately precipitated carrier crystals of cytokine PCMCs. 
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a  b  
c  d  
Figure 6-14: Polarization microscopy of separately precipitated carrier material of 
corresponding mAb1 PCMCs; a) immediately, b) approx. 2 min, c) approx. 3 min and 
d) approx. 5 min after precipitation. 
As opposed to cytokine-free valine PCMCs, the precipitation of pure carrier material of the 
standard mAb1 formulation was not possible. The dropwise addition of the aqueous carrier 
solution to the precipitating agent immediately caused turbidity associated with particle 
formation, but the product could not be harvested. Macroscopically droplets deposited and 
finally stuck to the bottom of the device despite continuous stirring. Microscopic investigation 
of the supernatant revealed the presence of dispersed droplets in a continuous phase 
(Figure 6-14). The droplets contained birefringent crystals mainly aligned at the liquid-liquid 
interphase, but also inside. The crystalline structures significantly grew within a few minutes 
after precipitation. These observations were evocative of the ouzo effect derived from the 
alcoholic beverage and described in detail by Vitale and Katz who studied the formation of 
liquid droplet dispersions by homogenous liquid-liquid nucleation [12]. This physical effect that 
occurs in liquid systems comprising three or more components describes the formation of 
dispersed oil droplets in water in consequence of the rapid addition of water to a solution of oil 
dissolved in a solvent. As the oil supersaturates, it then nucleates into small relatively stable 
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droplets. In his review on recent developments and applications of the ouzo effect, Botet 
further specified that the ouzo region only represents a particular part of the area between the 
binodal and spinodal line (Figure 6-15) [60]. 
 
Figure 6-15: Ternary phase diagrams with ouzo region at constant temperature and pressure 
according to Botet [60]; the ouzo effect occurs when a three-component solution is rapidly 
brought into the ouzo region in the metastable area between the binodal (miscibility-limit 
curve) and spinodal (stability-limit curve) curves by the addition of solvent. 
However, as opposed to the PCMC precipitation, the ouzo effect occurs spontaneously without 
the use of mechanical agitation, surfactants or dispersing agents and corresponding emulsions 
appeared to be stable for months [12, 60]. Therefore, according to Vos [1], spinodal 
decomposition representing the rapid separation of an initial one-phase solution brought inside 
the spinodal curve by changing its compositions [12] seemed to be more suitable for 
characterizing the PCMC formation process. As the large surplus of organic solvent strips out 
the water molecules, protein and excipient partition into small, dense precursor droplets 
resembling oils or melts of excipient and protein. These droplets coalesce and the protein is 
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transported to the outer periphery of the droplet. As soon as the oily excipient core reaches 
saturation, nucleation and growth of the crystalline core is highly favorable and solid PCMCs 
form. In a secondary process, the excluded protein assembles at the surface of the excipient 
core to form a continuous network, being attached via hydrogen bonding and van der Waals 
interactions. Vos´ hypothesis was derived from DLS and simultaneous laser obscuration 
measurements of in-situ prepared PCMC samples [1]. The observation that the particle 
formation process was typically completed after approx. 100 s in combination with calculations 
on the time taken for dense pre-cursor particles to aggregate by shear forces as well as by 
Brownian motion was in line with the spinodal decomposition model. The particle formation 
process by nucleation and growth, however, was expected to take in the order of minutes, not 
seconds, and in that case particles were assumed to exhibit significantly more Ostwald ripening 
effects. Therefore, spinodal decomposition appeared to be more appropriate for the 
description of the PCMC formation process. 
The recent observation of dispersed droplets containing crystallizing excipients, mainly at the 
liquid-liquid interface, after the precipitation of a mAb1 carrier solution was well in line with 
the spinodal decomposition model. Therefore, the rapid introduction of excessive solvent was 
proposed to result in the formation of two phases, one “excipient and 
protein rich/solvent poor” phase and one “excipient and protein poor/solvent rich” phase, via 
spinodal decomposition (Figure 6-16). Diffusion of water molecules out of the inner “excipient 
and protein rich/solvent poor” phase in the continuous second phase and of solvent in the 
opposite direction was suggested to lead to supersaturation of excipients and protein finally 
resulting in precipitation. At this stage excipient crystallization could be avoided by the choice 
of formulation composition, as discussed in previous sections of this chapter (section 3.1.2) as 
well as in chapter 3 (sections 3.1.1 and 3.2.1). The amount of protein and excipients tending 
towards the formation of amorphous solids significantly influences the overall physical state of 
the particles formed via coprecipitation. At last, the continuous phase is removed via 
supercritical fluid extraction. The overall spherical particle form revealed for amorphous mAb1 
PCMC formulations via SEM (chapter 3 and 6) supported the hypothesis of spinodal 
decomposition. Based on confocal laser scanning fluorescence microscopy (section 3.1.3) 
proposing homogenous distribution of the protein within the amorphous mAb1 PCMCs, the 
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protein is not expected to be transported to the periphery of the droplets during the particle 
formation process, as opposed to the conception of Vos [1]. 
 
Figure 6-16: Particle formation process proposed for amorphous mAb PCMCs via spinodal 
decomposition model; color assignment: green: homogenous phase of aqueous protein-
carrier solution and solvent immediately after addition of the solvent; light green: “excipient 
and protein poor/solvent rich” phase; dark green: “excipient and protein rich/solvent poor” 
phase; yellow: precipitated protein; blue: precipitated carrier material. 
Probably, this proposed particle formation process was only applicable for amorphous mAb 
PCMC formulations and not for cytokine-coated microcrystals, as discussed in the following 
section, because an emulsion-like intermediate was not detected during the production of both 
proteinaceous and protein-free cytokine PCMC formulations. 
3.3.2 Precipitation of cytokine on separately prepared carrier crystals in 
comparison to standard one-step precipitation 
As protein-free particles corresponding to standard mAb1 formulation could not be produced, 
this study was limited to cytokine PCMCs. The cytokine PCMCs manufactured via two-step 
precipitation did not morphologically differ from those particles produced via coprecipitation of 
carrier material and protein (Figure 6-17). Moreover, no significant differences between the 
PCMCs produced via one-step and two-step precipitation were revealed with regard to protein 
content, monomer content, AUC in HP-SEC and biological activity (Table 6-6). The results were 
comparable to the values found for the bulk drug substance of the cytokine. Hence, irrespective 
of the type of preparation, the PCMC technology provided good overall process stability to the 
cytokine. 
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a  b  
c  d  
Figure 6-17: Cytokine PCMCs produced via a)/b) one-step and c)/d) two-step precipitation. 
These observations suggested that the so-called one-step precipitation might be subdivided 
into two separate processes, the parallel precipitation of crystalline “carrier rich/protein poor” 
material and amorphous “carrier poor/protein rich” solid subsequently attaching to the surface 
of the crystalline structures in a second step, thus leading to the formation of protein-coated 
microcrystals. If the cytokine was involved into the early precipitation step of the carrier 
material, one-step precipitation and two-step precipitation would probably affect the particle 
morphology as well as the protein process stability. A secondary protein coating step was also 
proposed by Vos based on his DLS and laser obscuration measurements [1]. The author 
hypothesized that the carrier crystals primarily formed via spinodal decomposition (see above). 
However, no observations supporting the latter hypothesis were made during the current study 
on cytokine PCMCs, as opposed to mAb1 PCMCs. Therefore, it is also possible that the 
formation of carrier crystals was based on the classical nucleation and growth model. However, 
in most real systems the transition of the two mechanisms is known to be gradual [11]. Thus, 
further detailed investigations on the PCMC formation process are indispensable to answer this 
question. According to Horn and Rieger, to understand the stages through which the formation 
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of colloidal particles pass it is necessary to experimentally record the particle formation process 
by time resolution from the timepoint when supersaturation is achieved [11]. As this procedure 
is not trivial at all, the description of the particle formation process is often still limited to a 
retrospective derivation from the particle structure formed. Correspondingly, there are no 
doubts that mechanistic differences exist in the formation of cytokine PCMCs, on the one hand, 
and mAb1 PCMCs, on the other hand, as also reflected by their supramolecular structure. 
Table 6-6: Protein process stability of cytokine PCMCs produced via one-step and two-step 
precipitation with respect to protein content, monomer content (HP-SEC), AUC in HP-SEC and 
biological activity; cytokine bulk drug substance contained 98.9 ± < 0.1 % monomer and 
resulted in an AUC of 315 ± 1 mAU*mL. 
 One-step precipitation 
Two-step 
precipitation 
Protein content [%] 12.7 ± 0.1 11.7 ± < 0.1 
Monomer content [%] 98.8 ± 0.1 98.6 ± 0.1 
AUC in SEC [mAU*mL] 296 ± 16 293 ± 3 
Biological activity [IU/mg protein] (2.2 ± 0.4) x 107 (2.4 ± 0.3) x 107 
 
3.3.3 Precipitation of cytokine in the absence of carrier material 
This study aimed to investigate whether the cytokine could be successfully precipitated via 
standard PCMC process from a pure aqueous protein solution that did not contain any carrier 
material. When a mixture made of 2-methyl-2,4-pentanediol and isopropanol (1:1 v/v), 
saturated with all carrier components, was used as precipitating agent, the precipitation 
process resulted in the formation of a gel that could neither be further processed nor analyzed. 
Gel formation due to protein aggregation has been reported several times, as reviewed by 
Wang [61]. For example, Renard et al. studied the gelation and aggregation properties of 
β-lactoglobulin in ethanol/water solutions [62]. In the presence of pure saturated isopropanol, 
as opposed to unsaturated solvent, cytokine precipitation was detected, but the small amount 
of powder harvested did not allow for analysis of protein integrity. Thus, the saturation of 
isopropanol with all carrier excipients was prerequisite for the precipitation of the protein. 
After saturation of the solvent, residual carrier crystals were removed via filtration through a 
0.22 µm membrane filter (Stericup-GV, 47mm, PVDF, Sartorius, Göttingen, D). However, small 
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carrier particles passing the filter were assumed to act as heterogeneous nuclei indispensable 
for the precipitation of the cytokine. 
4 Conclusion 
Based on various studies on cytokine and mAb1 PCMCs focusing on the morphology, 
composition and stability of the particles, this chapter aimed to gain mechanistic insights into 
the PCMC formation process. The initial PCMC conception presented by Vos comprised a 
crystalline particle core made of carrier excipients that was coated by a protein layer. Confocal 
laser scanning fluorescence microscopy revealed such a supramolecular structure for crystalline 
mAb1 PCMCs containing 10 % antibody and 30 % trehalose. An equivalent assembly was also 
proposed for cytokine PCMCs with a protein load of 10 % that could successfully be separated 
into a crystalline rosette-shaped carrier fraction and a less dense amorphous fraction 
dominated by protein via Andersen Cascade Impactor in combination with SEM analysis. 
Furthermore, cytokine PCMCs could be manufactured via standard one-step precipitation, but 
also via two-step precipitation describing the protein precipitation on previously prepared 
carrier crystals. The precipitation type neither affected the morphology nor the protein process 
stability of the cytokine PCMCs. In contrast, two-step precipitation was not possible for 
amorphous mAb1 PCMCs because the carrier could not be processed in the absence of protein 
in batch mode. However, the presence of an emulsion-like state of the protein-free mAb1 
PCMC formulation was detected in this study via polarization microscopy. Transferred to 
proteinaceous mAb1 PCMCs, the inner dispersed phase was assumed to be made of much 
carrier material and protein but a small amount of solvent, as opposed to the outer continuous 
“excipient and protein poor/solvent rich” phase. Crystal growth was observed at the boundary 
and inside the dispersed droplets. Hence, the spinodal decomposition model seemed to be 
suitable to describe the mAb1 PCMC formation mechanism. After addition of a surplus of 
organic water-miscible solvent to the aqueous protein-carrier solution, phase separation of the 
homogenous phase was proposed to occur via spinodal decomposition resulting in one 
continuous “excipient and protein poor/solvent rich” and one dispersed “excipient and protein 
rich/solvent poor” phase. Diffusion of the solvent from the outer into the inner phase and from 
water in the opposite direction probably leads to supersaturation and finally precipitation of 
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protein and carriers in the inner phase. Spherical particles containing homogenously distributed 
protein and carrier material were suggested to form in this way, while the outer “excipient and 
protein poor/solvent rich” is removed via supercritical fluid extraction. This formation process 
was also in line with the particle morphology and supramolecular structure of mAb1 PCMCs 
representing uniform spherical particles of different size in which the protein was 
homogenously distributed instead of being bound to the surface. Thus, these particles could 
only be fractionated by size via Andersen Cascade Impactor. 
The question whether this particle formation process might also be applied to cytokine PCMCs 
and crystalline mAb1 formulations could not be answered yet because an emulsion-like state 
was not observed in these cases. Therefore, additional mechanistic investigations are necessary 
to clarify the PCMC formation mechanism. Depending on the sum of protein and trehalose 
dihydrate in the formulation, both typically forming amorphous solids, crystalline or amorphous 
particles were formed. A completely amorphous state of mAb1 PCMCs could be achieved in the 
case of ≥ 85-90 % (m/m) mAb1 and trehalose dihydrate. Despite the structural differences 
between crystalline and amorphous mAb1 PCMC formulations, only marginal differences with 
respect to protein storage stability, namely turbidity values and monomer content, were 
revealed after storage at 40 °C/32 % RH for 4 weeks. All formulations provided good overall 
stability to the antibody. Hence, in all cases, the amount of amorphous excipient fraction was 
sufficient for adequate protein stabilization. 
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Chapter 7  
F i n a l  s u m m a r y  
The focus of the thesis was on pharmaceutical applications of the protein-coated microcrystals 
(PCMC) technology. As described in detail in chapter 1, the PCMCs represent an alternative 
method for the stabilization of protein in the solid state via coprecipitation of protein and 
carrier material. Apart from mechanistic investigations, the thesis included formulation 
considerations of cytokine and mAb2 PCMCs as well as the evaluation of concentrated PCMC 
suspensions for s.c. administration as final dosage form. 
Chapter 2 aimed to develop a stable HSA-free formulation of a hydrophobic cytokine. A 
formulation screening that focused on protein process stability as well as on PCMC formation 
and particle structure was conducted to optimize the PCMC composition with respect to amino 
acid, sugar and salt. As only minor differences were revealed between the formulations during 
this study, a promising one comprising valine and sucrose as carriers was selected for detailed 
investigation of protein bioactivity and long-term stability over one year at 5 ± 3 °C and 
22 ± 3 °C. These cytokine PCMCs completely retained their bioactivity during the PCMC 
production process. The amount of aggregated species monitored via HP-SEC and SDS-PAGE as 
well as the oxidation level of the protein only augmented slightly over storage time in 
dependence of the temperature. Stored at 5 ± 3 °C, the PCMCs provided high overall stability to 
the cytokine over one year. In comparison to long-term stability studies of marketed lyophilized 
cytokine formulations, the stability as PCMCs was slightly superior. 
Similarly to the preceding section of the thesis, chapter 3 dealt with the formulation of a 
therapeutic monoclonal antibody (mAb2). The formulation screening aimed to reduce the 
number of carrier excipients and thus investigated the influence of each carrier component, 
namely sodium chloride, glycine, histidine, phenylalanine and trehalose, on the protein process 
stability. Apart from positive effects on the manufacturability of PCMCs, the use of sodium 
chloride inhibited the formation of considerable amounts of insoluble protein aggregates. 
Glycine, histidine and trehalose elicited positive effects on the monomer content. Trehalose 
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further prevented glycine from crystallization and thus ensured the formation of a homogenous 
amorphous product. Phenylalanine had no positive effects on the PCMC product quality and 
was thus eliminated in the lead formulation to reduce the complexity of the system. Based on 
an accelerated short-term stability study conducted at 40 °C over 4-8 weeks, an optimum 
protein loading of approx. 50-62.5 % was revealed for the lead formulation. Higher protein load 
led to increased amounts of soluble protein particles detected via HP-SEC and SDS-PAGE, but 
no alterations of tertiary protein structure were noticeable in 2nd-derivative UV and intrinsic 
fluorescence spectra. Thus, mAb2 formulated as PCMCs provided good overall storage stability, 
not only compared to corresponding liquid formulations that were prone to both aggregation 
and fragmentation phenomena. 
The development of PCMC suspensions for subcutaneous administration required 
physiologically acceptable solvents that show good protein compatibility and that do not, at 
least substantially, dissolve the PCMC powder prior to application. Besides organic water-
miscible solvents, namely glycerol, NMP, propylene glycol and PEG 400 (chapter 4), oily 
vehicles, sesame oil, benzyl benzoate and MCT (chapter 5), were studied for the resuspension 
of mAb1 PCMC powder. Among the organic water-miscible solvents, glycerol and PEG 400 were 
found to be overall compatible with mAb1 PCMCs with respect to protein aggregation 
(turbidimetry, HP-SEC), protein structure (FT-IR, intrinsic fluorescence and 2nd-derivative UV 
spectroscopy) and specific binding capacity of the antibody, irrespective of the solvent content 
ranging from 10 to 100 % (v/v). Macroscopically acceptable suspensions were formed in the 
presence of ≥ 50 % solvent. In the case of propylene glycol, at least 90 % solvent was necessary 
for the formation of a suspension. However, these high propylene glycol concentrations 
induced the formation of considerable amounts of insoluble and soluble protein aggregates and 
perturbation of secondary and tertiary protein structure. For NMP, a PCMC suspension was 
obtained in the presence of the pure solvent leading to a significant level of aggregated 
antibody. Reduction of the solvent concentration either led to complete dissolution of the 
PCMC powder (90 and 70 % NMP) or protein instability in terms of aggregate formation or/and 
conformational changes (≤ 50 % NMP). Consequently, glycerol and PEG 400 are suggested to be 
used for further development of PCMC suspensions in water-miscible organic solvents for 
subcutaneous delivery. 
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Besides the analysis of the compatibility between protein and solvent, the evaluation of the oily 
components as resuspension media included the development of an appropriate in vitro 
release model, the investigation of protein integrity after release from oily suspensions, the 
compatibility between the oily solvents and primary packaging material as well as the 
characterization of rheology and injectability of the suspensions. A 24 h incubation at 40 °C in 
water with integrated short-term stirring and final centrifugation at 100 g for 30 min ensured 
100 % recovery of mAb1. Irrespective of the choice of oily solvent, the integrity of mAb1 was 
completely retained with respect to aggregation, secondary and tertiary protein structure and 
specific antigen binding affinity after release from oily PCMC suspensions. The injection forces 
for the oily solvents that depended on the siliconization process of the glass syringes were not 
impacted by 6 months storage at 22 ± 3 °C proving compatibility with the primary packaging 
material. The maximal solid content achieved for oily suspensions based on MCT and 70:30 and 
30:70 (v/v) mixtures of sesame oil and benzyl benzoate was 316 mg/mL, corresponding to 
138 mg/mL protein. In dependence of the viscosity of the pure oils, the viscosity of the 
suspensions, showing shear thinning behavior, augmented with increasing solid content. The 
relationship between viscosity and injectability of the suspensions was found to be linear. 
Maximal injection forces were approx. 40 N for a 30:70 (v/v) sesame oil benzyl benzoate 
suspension with a solid content of 316 mg/mL, opposed to 50 N for the inverse mixture and 
MCT. Thus, the formulation of mAb1 as oily PCMC suspension was feasible, but it was not 
beneficial with respect to viscosity and injectability compared to a corresponding mAb1 
solution.  
Based on various studies on cytokine and mAb1 PCMCs with respect to morphology, 
composition and resulting stability, chapter 6 aimed to gain mechanistic insights in the PCMC 
formation process. The crystallinity/amorphicity of mAb1 PCMCs depended on the protein load 
(PL) and trehalose (tre) content of the formulation. A combination of either a protein load of 
50 % with a trehalose content of ≥ 35 % or a trehalose content of 30 % with a protein load of 
≥ 60 % were required to obtain completely amorphous mAb1 PCMCs according to the XRD 
spectra. The storage stability over 4 weeks at 40 °C/32 % RH of three amorphous formulations 
(60 % PL 30 % tre, 50 % PL 40 % tre, 40 % PL 50 % tre) and one crystalline powder 
(10 % PL 30 % tre) was analyzed with respect to insoluble and soluble protein aggregates 
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(protein recovery, turbidity, HP-SEC, SDS-PAGE) as well as morphological and carrier stability 
(SEM, XRD). Apart from ongoing NaCl crystallization detected for crystalline mAb1 PCMCs, no 
crucial differences were found between the formulations all providing good overall storage 
stability to the antibody. Homogenous mAb1 distribution within the spherical particles for the 
amorphous mAb1 formulations, as opposed to the crystalline one, was detected via confocal 
laser scanning fluorescence microscopy. The crystalline formulation was characterized by non-
fluorescent rod-shaped glycine crystals with amorphous proteinaceous material deposited on 
the crystal surface. Powder fractionation via Andersen cascade impactor confirmed the 
presence of corresponding particle fractions in cytokine PCMCs, namely crystalline carriers 
forming the core of the particles and amorphous proteinaceous material being attached on the 
surface. The overall structure of these particles was hence in line with the initial idea of PCMCs, 
unlike amorphous mAb1 PCMCs that could only be separated depending on the size of the 
spherical, homogenously composed particles. The manufacturing of cytokine PCMCs was 
further feasible via standard one-step precipitation as well as by two-step precipitation in batch 
mode. Two-step precipitation included the separate production of carrier crystals on which the 
protein was coated in a second step. The production method did not influence the morphology 
or the protein process stability. Batch mode production of protein-free mAb1 PCMCs was only 
feasible with some limitations. The existence of an emulsion-like state characterized by 
dispersed droplets of an “excipient and protein rich/solvent poor” phase in a continuous 
“excipient and protein poor/solvent rich” phase was observed during the formation of these 
particles. Crystal growth at the liquid-liquid interface as well as inside the droplets was 
detected via polarization microscopy. Hence, the spinodal decomposition model was suggested 
to be appropriate to describe the formation process of these mAb1 PCMCs. Overall, the 
physical state, morphology and supramolecular structure of the PCMCs that were found to 
strongly depend on the formulation composition including protein type (cytokine vs. mAb1) and 
load as well as choice and amount of carrier excipients, suggested that the formation 
mechanisms of these particles differed to some extent. 
Thus, although further investigations on the PCMC formation process are still necessary to 
explain the self-assembly of the particles in detail, the studies provided an extensive 
characterization of cytokine and mAb PCMCs, not only with respect to formulation 
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considerations but also regarding mechanistic questions. Organic water-miscible as well as oily 
solvents were shown to be compatible with mAb1 PCMCs allowing for subcutaneous 
administration as PCMC suspension. This final dosage form, especially in combination with a 
dual chamber device enabling resuspension immediately before administration, could be an 
alternative to liquid protein formulations in the case of reduced solubility or poor overall 
stability. 
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List of abbreviations 
AFM atomic force microscopy 
Arg arginine 
Asp aspartic acid 
AUC area under the curve 
BI Boehringer Ingelheim 
BSA bovine serum albumin 
CD circular dichroism 
CLSFM confocal laser scanning fluorescence microscopy 
CO2 carbon dioxide 
CSP cell surface protein 
DLS dynamic light scattering 
DMSO dimethyl sulfoxide 
DSC differential scanning calorimetry 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunoassay 
EMA European Medicines Agency 
FDA US Food and Drug Administration 
FNU formazine nephelometric units 
FT-IR fourier transform infrared spectroscopy 
GC gas chromatography 
Glu glutamic acid 
Gly glycine 
HCl hydrochloride, hydrochloride acid 
His histidine 
HP-SEC high pressure size exclusion chromatography 
HSA human serum albumin 
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ID inner diameter 
IFN interferon 
Ig immunoglobulin 
IgG immunoglobulin class G 
IgG1 immunoglobulin G subclass 1 
IgG2 immunoglobulin G subclass 2 
kDa kilodalton 
K2SO4 potassium sulfate 
L length 
mAb monoclonal antibody 
MCT medium-chain triglycerides 
MFI microflow-imaging 
MOPS 3-(N-morpholino)-1-propanesulfonic acid 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
Na2CO3 sodium carbonate 
NaCl sodium chloride 
NaHCO3 sodium bicarbonate 
NaOH sodium hydroxide 
NMP N-methyl-pyrrolidone 
NTU nephelometric turbidity unit 
PBS phosphate buffered saline 
PCMC protein-coated microcrystals 
PEG polyethylene glycol 
Ph.Eur. European Pharmacopoeia 
Phe phenylalanine 
pI isoelectric point 
PL protein load 
rpm rounds per minute 
RH relative humidity 
RI refractive index 
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RP-HPLC reversed phase high pressure liquid chromatography 
s.c. subcutaneous 
SCF supercritical fluid 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM scanning electron microscopy 
Suc sucrose 
TFA trifluoroacetic acid 
Tg glass transition temperature 
Tre trehalose 
UV ultraviolet 
Val valine 
VIS visible 
WFI water for injection 
XRD x-ray powder diffraction 
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